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ABSTRACT 
 
Locally advanced breast cancer (LABC) represents 15% of all non-metastatic 
breast cancers, with an overall poor prognosis, despite current guidelines that 
recommend neoadjuvant chemotherapy followed by surgery and adjuvant 
radiation. Therefore, a novel treatment paradigm using concurrent neoadjuvant 
chemoradiotherapy was proposed. A clinical trial was designed, where 32 LABC 
patients were treated with q3 weekly 5-fluorouracil, epirubicin and 
cyclophosphamide for three cycles, followed by weekly docetaxel for 9 weeks 
with concurrent regional radiation (45+5.4Gy) for the first 6 weeks. Patients 
subsequently underwent modified radical mastectomies. Pathological complete 
responses (pCR) and 3 year overall survival rates were compared to a matched 
concurrent control cohort. The concurrent chemoradiation cohort saw a 
significant increase in pCR rate and a trend toward 15% improvement in overall 
survival that failed to reach statistical significance. This regimen was not without 
toxicity, and 25% of patients experienced grade 3 or greater dermatitis and 25% 
experienced grade 3 or greater pneumonitis, resulting in one death. Tumour 
biomarker, plasma osteopontin, prior to chemotherapy was found to significantly 
predict for overall survival. In conclusion, LABC is an aggressive subset of breast 
cancer for which novel regimens must continue to be developed, taking 
advantage of the improved response to treatment with radiosensitivity seen in 
	 iii 
this concurrent chemoradiation regimen, but using alternative radiosensitizing 
agents to minimize toxicity.  
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CHAPTER 1 
 
General Introduction and Literature Review 
 
 
 
 
 
 
Portions of this chapter were adapted from a published manuscript in which M. 
Brackstone was a co-author: Mandilaras V, Bourginam N, Spayne J, Dent R, 
Aranaout A, Boileau FJ, Brackstone M, Meterissian S, Clemons M. Current 
Oncology 2015, vol. 22(1): 25–32. Reproduced with permission. 
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CHAPTER 1: GENERAL INTRODUCTION AND LITERATURE REVIEW 
 
1.1 BREAST CANCER 
Breast cancer is the most common non-cutaneous cancer diagnosis for 
women in Canada, with an anticipated 24,400 Canadian women diagnosed in 
2014, and 5,000 women dying of the disease [1]. Although newer treatments 
have improved both overall survival and progression-free survival for early and 
metastatic cancer patients respectively [2], there remains a subgroup of women 
with Locally Advanced Breast Cancer (LABC) who do poorly.  
 
1.2 PATHOPHYSIOLOGY OF CANCER  
Cancer is a multi-step process that occurs because of an interaction 
between an environmental factor(s) and a host that is genetically susceptible 
[3,4]. Cell division is a physiological process that occurs in almost every tissue 
type in the body. Under normal circumstances, the balance between proliferation 
and programmed cell death (usually in the form of apoptosis) is maintained by 
regulation of both of these processes, to ensure the integrity of tissues and 
organs. Any alteration by mutation of the genes responsible for the control of 
either of these leads to cancer. Cancer cells, therefore, behave as cells that have 
lost the control over their growth rate, spreading to other tissue types and 
invading other areas of the body, as well as interfering with their function. This 
can lead to death if not treated or removed.  
	 3 
DNA damage is considered to be the primary cause of any cancer. Normal 
damage to DNA is common, but inherent repair machinery is available and able 
to fix it. Thus, a deficiency in DNA repair would cause more DNA damage to 
accumulate and increase the risk of cancer. There are two main types of genes 
that regulate cancerous cell growth and differentiation: oncogenes (normal genes 
that regulate cellular growth are called proto-oncogenes, while mutation of these 
genes results in constitutive activation; these genes are then called oncogenes, 
which are either present in inappropriately high numbers, or altered, to then 
exhibit new tumour promoting properties as a result of their alteration) and 
tumour suppressor genes (genes that inhibit cell division or survival of cancer 
cells; mutations in these genes result in a loss of function and resultant cancer 
[3,4]. 
Breast cancer refers to several types of neoplasm arising from breast 
tissue. The most common one is adenocarcinoma, originating from the epithelial 
cells lining the terminal duct lobular unit. Over 80% of breast adenocarcinomas 
are derived from the epithelial cells lining the ducts specifically, termed mammary 
ductal carcinoma. Carcinoma in situ (DCIS) is proliferation of cancer cells within 
the duct itself but without invasion through the myoepithelial and basement 
membrane lining of the ducts; invasive carcinoma (IDC) is composed of cancer 
cells that have invaded through the myoepithelial lining of the ducts into the 
surrounding stromal tissue of the breast. Lymphovascular space invasion is 
usually associated with a more aggressive phenotype. Although DCIS is believed 
to be a non-obligate precursor of IDC in most instances, approximately 40% of 
	 4 
DCIS will progress to IDC if left untreated, evidenced by DCIS and IDC having 
very similar gene expression patterns, although both display intra-tumoural 
heterogeneity [5]. The drivers of invasion, or epithelial-to-mesenchymal transition, 
remain unknown, but epigenetic (DNA methylation) or histone modification 
events have been implicated [5]. The breast microenvironment, as well as 
genetic and epigenetic factors have been also implicated in driving tumour 
progression from invasive to metastatic breast cancer. 
 
1.2.1 Risk Factors for Developing Breast Cancer 
There are many risk factors associated with the development of this 
disease; these include gender (females are more prone than males), age (the 
risk of developing breast cancer increases with age, particularly after 
menopause), reproductive history (risk increases with higher number of ovulatory 
cycles and nulliparity), lactation (lactational changes related to breast feeding 
reduces risk of developing breast cancer), exposure history (ionizing radiation 
exposure, alcohol intake and hormone replacement therapy all increase the risk 
of having breast cancer), height and weight (taller women and those of higher 
BMI have a higher chance of developing breast cancer), family history and 
Breast Related Cancer (BRCA-1/BRCA-2) gene mutation (these significantly 
increase the chance of breast cancer) [6,7]. 
A number of inherited tumour suppressor gene mutations can lead to 
breast cancer, the most common of which are within the BRCA1 and BRCA2 
genes. BRCA gene mutations significantly increase the risk of breast cancer 
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development from a 1 in 9 risk for average women to 65% lifetime risk for BRCA 
gene mutation carriers [8]. BRCA genes are DNA repair genes, responsible for 
identifying and repairing erroneous double-stranded DNA breaks. BRCA gene 
mutation carriers have inherited a defective copy of this gene from one parent 
and therefore rely on the other functioning inherited copy. A secondary somatic 
mutation in this gene leads to cancer development, consistent with the 2-hit 
hypothesis [9]. As a result, these gene mutation carriers develop breast and/or 
ovarian cancer (tissues where BRCA proteins are most responsible for DNA 
damage repair) at an earlier age than is seen in women who develop somatic 
mutations in each of their normal genes as a result of exposure or other unknown 
factors. Mutation carriers can develop cancer in their early 20s, are much more 
likely to be pre-menopausal at diagnosis, and develop more aggressive cancers 
(typically estrogen negative in 80% of cases) [10]. 
Hormones appear to have an important influence over the development of 
breast cancer, particularly estrogen and progesterone. Estrogen and 
progesterone are steroidal sex hormones that are produced by the ovaries in 
premenopausal women, whereas in postmenopausal women, they are derived 
from the conversion of androgens to estrogen by aromatase in the adrenal 
glands and to a lesser degree in peripheral tissues such as adipose tissue [11]. 
Progesterone is derived from pregnenolone that is itself derived from cholesterol 
[11]. Circulating estrogen (estradiol or its weaker counterpart, estriol) promotes 
the upregulation of progesterone receptors, particularly in breast tissue [11]. Both 
estrogen and progesterone have a number of roles, including female sexual 
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development, maintenance of sex characteristics and fertility. Two different types 
of estrogen receptors (ER) exist: alpha (α) and beta (β) (ERα and ERβ 
respectively). Various tissues express ER (breast, ovaries and the endometrium 
express ERα, while the kidneys, brain, lungs and several other organs express 
ERβ). The role of ERβ in carcinogenesis remains controversial, whereas, a clear 
link between ERα protein and breast cancer has been established [12]. Both ER 
subtypes carry a DNA binding domain and exist in the nucleus and the 
cytosol.  When estradiol enters the cell, it binds the ER, and the complex 
migrates into the nucleus, where it functions as a transcriptional activator and 
promoter of cell growth.  Most breast cancers (at least 80%) are ER positive 
and/or PR positive, meaning that these cancer cells proliferate in the presence of 
circulating estradiol, and are, therefore, inhibited by ER antagonists or aromatase 
inhibitors [11]. 
 
1.2.2 Prognostic Factors or Markers 
A number of tumour and patient factors determine the risk of recurrence or 
death from recurrence of breast cancer [13]. These include tumour stage 
(outlined below, in section 1.4.1), menopausal status (worse prognosis with pre-
menopausal status), tumour grade (worse prognosis with higher grade), and 
histological subtype (some breast cancer subtypes exhibit more favourable 
prognoses as a function of slower tumour growth and lower risk of developing 
metastases; favourable types include mucinous, medullary and tubular 
carcinomas) [14]. 
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Another poor prognostic factor is HER2/neu (HER2) status. HER2 is a 
receptor that belongs to the human epidermal growth factor receptor (HER) 
family of proto-oncogenes including epidermal growth factor receptor (EGFR, 
HER1), one of four plasma membrane-bound receptor tyrosine kinases. HER 
family proteins have an extracellular ligand binding domain, a transmembrane 
domain and an intracellular domain that can bind and activate signaling 
molecules through its tyrosine kinase as a result of, or independent of, ligand 
binding [15]. HER2 can heterodimerize or homodimerize for activation and is, 
therefore, the preferred partner in dimerizing of the HER family receptors. Its 
constitutive activation by dimerization results in it functioning as an oncogene by 
autophosphorylating tyrosine residues, thus activating those signaling pathways 
[15]. Up to 30% of all breast cancers are comprised of tumour cells that 
overexpress HER2, and this overexpression allows for homodimerization and 
activation of HER2, promoting oncogenic features such as rapid tumour growth 
as well as an increased risk of locoregional and distant recurrence after surgery. 
As a result, HER2 overexpression is an independent poor prognostic marker and 
these breast cancers are associated with worse survival than HER2 normal 
tumours. 
Overall, the integration of ER, PR and HER2 status, as well as 
proliferation markers such as Ki67, allow for the prognostication of tumours 
based on a rough molecular subtype [16,17]. The molecular classification was 
first described as a genomic DNA classification of tumours into 5 main subtypes, 
roughly defined by the following: Luminal A (low grade, ER positive, HER2 
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negative); Luminal B (ER positive, Ki67 high, usually high grade, HER2 positive 
or negative); HER2 positive (typically ER negative and HER2 positive); Triple 
negative (ER negative, PR negative and HER 
2 negative) and Basal-like (high grade, poorly differentiated) [16]. Since 
then, a number of other classification systems have been reported, some using 
DNA expression patterns, others using mRNA expression, others still with 
molecular phenotype as a surrogate for gene expression profiling. This 
differentiation remains the most clinically relevant prognostic marker for breast 
cancer. 
 
1.3 CLASSIFICATION 
Breast cancers can be classified and substratified using a number of 
clinically relevant features. The purpose of classification is to select the best 
therapy and treatment algorithms, as well as to prognosticate. The major 
classification features include histopathological type, the grade of the tumour, the 
stage of the tumour, and the molecular (ER/PR/HER2) subtype (a surrogate for 
gene expression profile classification).  
Histopathological classification involves the differentiation between in situ 
and invasive breast cancers, as well as their histologic type and grade. 
Histological features roughly stratify the invasive cancers as either no special 
type (infiltrating ductal) or special type (medullary, mucinous, lobular, tubular, 
cribriform), although there are also other more rare forms (e.g. metaplastic, 
apocrine, adenosquamous, etc.) [18]. Tumours showing mixed ‘no special type’ 
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and ‘special type’ features usually behave and are classed as a ‘no special type’ 
tumour of the same histologic type and grade. 
 Grading focuses on the differentiation of the breast cancer cells compared 
to that of the normal breast cells. As the cell division becomes uncontrolled, 
nuclei become less uniform and cell arrangement more disorganized. The grade 
of an invasive carcinoma is assessed using the Scarff-Bloom-Richardson grading 
system, which involves three criteria: tubule formation (the percentage of tumour 
made up of tubular structures (1 point for >75% tubules; 2 points for 10-75% 
tubules and 3 points for <10% tubules)); nuclear pleomorphism (the degree of 
change in the shape and size of the cells’ nuclei (1 point for small and uniform 
nuclei; 2 points for medium to large nuclei but they remain consistent in shape); 
and 3 points for large and varied nuclei)); and mitotic count (number of cells 
under microscope that are actively dividing (1 point for slow mitotic rate; 2 points 
for medium mitotic rate and 3 points for rapid mitotic rate)) [19]. Thus every 
tumour is graded out of a possible 9 points. This is then further collapsed into a 
score for grade out of three (grade 1=1-5 points; grade 2=6-7; grade 3=8-9 
points). These could also be described as well differentiated (low-grade), 
moderately differentiated (intermediate-grade) and poorly differentiated (high-
grade) as the cells progressively lose the features and arrangement of normal 
breast cells. The poorer the differentiation is (or the higher the grade), the worse 
the prognosis for the patient [19]. 
 Staging of breast cancer is based on the size where it originally started, 
and the locations to which it has travelled. The tumour, lymph nodes, metastasis 
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(TNM) staging system from the American Joint Committee on Cancer is used 
(see section 1.4.1 on Staging) [20]. 
 Receptor status (ER, PR, HER2) is also a clinically-relevant classification 
stage, given that it determines treatment with hormonal therapy (selective 
estrogen receptor modulator, for premenopausal women to function as an ER 
antagonist (such as anastrazole, letrozole or aromasin drugs) breast cells 
including cancer cells, or an aromatase inhibitor (to block the conversion of 
steroidal molecules into estrogen for postmenopausal women to virtually 
eliminate any estrogen which could otherwise bind to ERs in cancer cells). HER2 
overexpressing tumours are treated with a targeted monoclonal antibody called 
trastuzumab following chemotherapy, with other anti-HER2 targeted therapies 
currently under investigation. 
 
1.4 DIAGNOSIS 
Patients present with cancer in one of two ways: a palpable breast mass 
or change in breast appearance, or an abnormality such as a mass or 
microcalcifications seen on screening mammogram. Appropriate diagnostic 
imaging for any suspicious finding requires both a mammogram and an 
ultrasound [21]. If the finding persists on imaging, then an image-guided core 
needle biopsy is performed. If the clinical finding persists but the mammogram 
and ultrasound are negative, a surgical consultation is obtained to determine 
whether this is an abnormal finding requiring an excisional biopsy procedure, or 
whether further imaging (such as magnetic resonance imaging (MRI)) would be 
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warranted for the few cancers which present as mammogram and/or ultrasound 
occult [21]. 
Once a biopsy is done using image guidance, the specimen is processed 
by the pathology team, using formalin fixation and paraffin embedding for 
microscopic examination, with hematoxylin and eosin staining. The pathologist 
determines whether the cancer is in situ or invasive, and if invasive, its histologic 
type and grade, as described above. Immunohistochemical staining is done to 
determine whether the cancer cells are ER and/or PR positive and whether the 
cells are HER2 overexpressing [22]. If the tumour is HER2 equivocal by 
immunohistochemistry, testing for the HER2 gene may be performed by 
fluorescent in situ hybridization (FISH), to determine whether or not the HER2 
gene is amplified. 
 Distant staging investigations (searching for distant metastases using 
imaging tests) are not recommended for early breast cancers; however, as the 
risk of distant metastases rises, then staging investigations are recommended 
prior to any systemic therapies. These standardly include a computerized 
tomography (CT) scan of the chest, abdomen and pelvis, and a full body bone 
scan. Imaging of the brain is not indicated in the absence of symptoms, as the 
yield for detecting metastases is otherwise low [21]. 
 
1.4.1 Staging 
 There are two different staging methods that can be applied to breast 
cancer. These are the Roman numeral staging system, as well as TNM staging, 
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which is most clinically utilized [20]. The TNM staging system can be collapsed 
into the Roman numeral staging system for ease of use prognostically. 
The TNM system [20] is used for staging breast cancer in order to roughly 
prognosticate survival and determine need for adjuvant therapies based on 
statistical likelihood of distant recurrence.   
Tumour: tumour classification (TX, T0, Tis, T1, T2, T3 or T4) depends on 
the cancer site. TX refers to an inability to assess that site; Tis refers to ductal in 
situ carcinoma, lobular in situ carcinoma or Paget’s disease of the nipple; T1 
represents tumours up to 2cm in size; T2 represents tumours more than 2cm but 
less than 5cm; T3 represents tumours 5cm or greater; T4 represents tumours 
invading surrounding structures including chest wall, skin, both or infiltrating 
dermal lymphatics resulting in a clinical diagnosis of inflammatory breast cancer.  
Lymph Node: lymph node involvement with cancer (NX, N0, N1, N2 or 
N3) depends on the number and location of the involved lymph nodes, whether 
axillary lymph nodes, the infra or supraclavicular lymph nodes, or the internal 
mammary lymph nodes are affected. The axilla is designated as having three 
levels: lateral, deep and medial to the pectoralis muscle. In the axilla, NX 
designation means the lymph nodes have not been assessed; N0 signifies no 
lymph node metastases; N1 means 1-3 lymph nodes are involved with cancer 
(either microscopic or macroscopic nodal involvement); N2 means 4-9 nodes are 
involved and N3 means 10 or more nodes are involved. Clinically, all nodal 
basins are examined and any positive nodes identified clinically are classed 
based on their location: N1 means palpable but mobile axillary nodes; N2 
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represents matted nodes in the axilla or infraclavicular or internal mammary 
nodes; N3 represents nodes found in the supraclavicular nodal basin. 
Metastases: The clinically relevant classification for distant metastases 
for breast cancer are M0 and M1, which refers to distant detectable metastases 
or absence thereof. The most likely areas for breast cancer cells to harbour 
clinically visible or relevant metastases are bone, lung, liver and brain.  
Roman numeral staging involves assigning a number to describe the 
progression of cancer. The following stages are recognized: 
• Stage 0: carcinoma in situ. 
• Stage I: T1 tumours that are lymph node negative. 
• Stage II: tumours up to T2 in size, with up to N1 nodal metastases, or T3 
in size but no nodal metastases. This is the most common stage at 
diagnosis for breast cancer, and typically involves the addition of systemic 
therapies such as chemotherapy, and hormonal or antibody-based 
therapies if indicated. Distant staging is indicated from this stage forward. 
• Stage III: This stage is considered locally advanced. These cancers are all 
lymph node positive (N1-N3) or invading surrounding structures (T4). The 
patients all benefit from systemic therapy and are usually given 
neoadjuvant chemotherapy prior to surgery, in order to cytoreduce the 
tumour burden and increase the likelihood of successful resectability. 
• Stage IV: cancer has metastasized to other organs or throughout the 
body. Management of stage IV cancers is palliative, and treatments are 
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aimed at lengthening quality of life and reducing negative symptoms of the 
disease. 
 
1.4.2 LABC 
 Locally advanced breast cancer (LABC) is a mix of neglected and 
aggressive cancers [23]. In developing nations, most patients present with LABC, 
but it appears that the majority of these are neglected due to patient, societal and 
care access factors, allowing the tumour to grow and advance in stage. LABC in 
North America can present as a neglected cancer in patients with denial and/or 
fear of the diagnosis, but more commonly represents an aggressive subset of 
breast cancer which can present as a large burden of disease that arises within a 
year from an otherwise normal screening mammogram (called an interval 
cancer). Neglected tumours tend to be seen in older patients, with the tumours 
displaying lower grade, and are more commonly ER positive, while interval LABC 
cancers tend to present in younger patients, with the tumours displaying high 
grade features and ER negativity. LABC is most commonly defined as stage IIB 
(T3N0) and Stage IIIA/B/C from the TNM classification (AJCC 2009) [20,24-26]; 
clinically, these tumours being greater than 5cm in size and/or extend beyond the 
breast tissue into the surrounding skin or muscle, with/without matted axillary 
lymph nodes (N2), internal mammary nodes or ipsilateral supraclavicular lymph 
node involvement  (N3). LABC represents approximately 10-15% of all breast 
cancer cases, and the overall survival has historically been estimated at 30-42% 
at 5 years [27] a significant portion of whom will be living with metastatic disease. 
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However, a small subset of women receiving neoadjuvant chemotherapy who 
achieve a complete pathological response, or pCR, (defined as no residual 
invasive breast cancer pathologically following neoadjuvant treatment) to 
treatment are projected to have a vastly improved 5 year disease free survival 
rate of 87% [27] with 5 year overall survival rates of 89% to 90% [28]. As such, 
pCR rates have become the surrogate measure for favorable long-term 
outcomes in trials involving neoadjuvant treatment [29], particularly since the 
efficacy of systemic therapy can only readily be evaluated with the tumour in vivo.  
Historically, pCR was defined as no residual invasive breast cancer within 
the breast [30], but has since been more commonly used to denote the absence 
of residual invasive breast cancer either within the breast or axillary nodes [31]. 
More recently, it has also been demonstrated that pCR is significantly associated 
with tumour subtype (also termed intrinsic subtype, roughly classified by a 
combination of estrogen receptor (ER) or progesterone receptor (PR) positivity, 
tumour grade and epidermal growth factor receptor HER2 over-
expression/amplification as described above), based on a meta-analysis of 30 
trials [32]. A review of 7 German neoadjuvant trials also showed that pCR rates 
rose with increasing number of chemotherapy cycles, increasing anthracycline 
dose, cumulative taxane dose and capecitabine-containing regimens [33]. The 
most significant predictor of response to neoadjuvant chemotherapy (as 
measured by pCR) was found to be molecular subtype status [33]. Based on this, 
pCR is being increasingly considered a suitable surrogate for all tumour subtypes 
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except Luminal A (clinical proxy for genotypic classification of Luminal A is made 
using ER positive, HER2 negative, absence of high grade) [34].  
 
1.5 THERAPEUTIC APPROACH TO LABC 
1.5.1 Systemic Chemotherapy 
 Systemic chemotherapy can be delivered in two main regimens: 
neoadjuvant (prior to surgery) and adjuvant (following surgery). Multiple 
chemotherapeutic agents may be used in combination. Determining the 
appropriate regimen depends on the character of the tumour (i.e. its hormonal 
status), lymph node status, and the age/health of the patient. Many regimens 
have been clinically evaluated and proposed, but for the majority of breast 
cancers, the regimens typically contain an anthracycline and a taxane, as these 
have demonstrated superior survival to regimens not containing these classes of 
drugs [26]. Six international randomized controlled trials (RCTs) that have 
compared neoadjuvant versus adjuvant chemotherapy have included patients 
diagnosed with breast cancer from stages T1-T4 [35-40]. All failed to 
demonstrate a survival advantage with neoadjuvant chemotherapy, although an 
individual level pooled analysis of the LABC subset of these trials is currently 
underway (Brackstone, unpublished). For more detailed discussion regarding 
specific regimens, see the neoadjuvant chemotherapy section below. Tumours 
that are HER2 overexpressing benefit from the addition of trastuzumab to reduce 
recurrence and improve survival. Its use was validated in the adjuvant setting 
concurrently with the taxane component of chemotherapy [26]. As a 
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monotherapy, it is less efficacious in improving survival, therefore is not delivered 
to patients not also receiving cytotoxic chemotherapy [41]. Since trastuzumab is 
a monoclonal antibody-targeted therapy, it is delivered intravenously, with an 
initial loading dose of 18mg/m2, followed by a maintenance dose of 9mg/m2 every 
3 weeks for 18 doses (one year) [26]. Therefore, it overlaps with the 
administration of adjuvant radiation. It was tried as a concurrent regimen with 
anthracyclines, but this was found not only not to improve pCR rates, but also an 
increase in cardiac toxicity (in the metastatic setting) [41]; therefore, most 
regimens are designed to deliver the antracyclines first, followed by taxane with 
trastuzumab and radiation.  
 The most common regimens used to treat breast cancer include: AC-T 
(anthracycline and cyclophosphamide IV, q3 weekly x 4 or dose-dense as q2 
weekly x 4) followed by taxane (paclitaxel or docetaxel, either q3 weekly x 4 or q-
weekly x 9-12); FEC-D (5-fluorouracil, epirubicin and cyclophosphamide IV q3 
weekly x 3) followed by docetaxel IV q3 weekly x 3. The dosages and more 
specific details regarding these regimens can be found below (Section 1.6). 
Systemic hormonal therapy is recommended for all ER and/or PR positive 
breast cancers where there is a significant risk of distant relapse, balanced 
against the toxicity profile of these agents for each individual patient. Current 
recommendations support the use of a selective estrogen receptor modulator for 
10 years in premenopausal patients, and an aromatase inhibitor for 5 years (10 
year versus 5 year RCT, NCIC-MA17R, results still pending). 
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1.5.2 Surgery 
The goal of surgery is to remove all of the cancerous tissue (tumour), plus 
some of the margins. The extent of surgery is dictated by the staging and the 
type of tumour, and may include lumpectomy (removal of the lump) or 
mastectomy (removal of the whole breast). Most early breast cancers (stage I 
and II) consist of small primary breast cancers that are, therefore, easily 
resectable by lumpectomy (termed ‘breast conserving surgery’), whereas stage 
III advanced cancers tend to occupy a larger portion of the breast and, therefore, 
require a mastectomy for successful removal of the entire involved area. 
Standard practice requires the surgeon to establish margins clear of cancer, 
indicating that the cancer has been completely excised. If the removed tissue 
does not have clear margins, further operations to remove more tissue may be 
necessary. Therefore, in an effort to minimize the risk of margin positivity while 
reducing the amount of normal breast tissue that needs to be resected, 
neoadjuvant chemotherapy has increasingly been used to downsize the primary 
breast cancer, in order to render operable breast cancers amenable to breast 
conserving surgery [40]. These tumours would otherwise require a mastectomy 
for complete removal if chemotherapy were to be delivered in the adjuvant 
setting.  
For larger breast cancers that remain extensive despite neoadjuvant 
chemotherapy, or which are multicentric in nature (separate tumours distributed 
throughout different quadrants of the breast), a mastectomy remains the 
standard of care. This involves removing the glandular breast tissue from the 
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pectoralis fascia, resecting overlying skin and nipple-areolar complex and 
achieving primary skin closure over the chest. A drain is left beneath these large 
skin flaps, as seromas tend to accumulate over the ensuing 1-2 weeks, until the 
wound heals. 
During the operation, the lymph nodes in the axilla must be sampled or 
removed entirely, in order to stage the patient for regional metastases. Until the 
early 2000s, the standard of care for staging the axilla involved resection of all 
axillary lymph nodes in the level I and II zones, resulting in reduced arm mobility, 
dysesthaesias of the upper arm and a 10-20% risk of permanent lymphoedema 
of the arm (lymphatic drainage was severely affected by the removal of so many 
lymph nodes, resulting in a swollen upper extremity). More recently, the 
technique of sentinel lymph node (SLN) dissection has become popular, as it 
requires the removal of far fewer lymph nodes (i.e. fewer side effects) [26,42]. 
The SLN dissection involves resection of the first tier of axillary lymph nodes that 
drain the breast, mapped functionally using dual tracer modality (blue dye 
injected into breast parenchyma preoperatively and technetium 99-m (99-mTc) 
radiocolloid bound to sulphur protein injected intradermally preoperatively). SLN 
mapping can spare 65-70% of patients with breast cancer from having a 
complete lymph node dissection, for what could turn out to be a negative nodal 
basin, but is indicated for early breast cancers felt clinically to be lymph node 
negative. In LABC, the vast majority of these patients are lymph node positive 
(either clinically or pathologically) and, therefore, the standard of care remains an 
axillary lymph node dissection [26], although this is a rapidly evolving field. 
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Removal of the breast with the axillary lymph nodes is called a modified radical 
mastectomy (radical mastectomy refers to removal of the breast, axillary lymph 
nodes and pectoralis muscle, a surgical technique that is no longer performed). 
 Patients with Stage IV breast cancer are deemed incurable and, therefore, 
goals of care are shifted to extension of quality life years. As a result, there is 
great debate whether the patient should undergo surgery to remove the primary 
cancer if it has already metastasized, particularly if the primary tumour appears 
to be well-controlled by the systemic therapies being given to control the distant 
disease. This is being addressed by a current clinical trial, the results of which 
remain outstanding (NCIC MAC14). Certainly there is a tendency to treat distant 
disease with monotherapies rather than combined regimens of chemotherapies 
and hormonal therapies, in an effort to maximize the duration of treatment 
response from each. 
 
1.5.3 Radiation Therapy 
Radiation therapy (RT) is used to reduce the risk of locoregional 
recurrence, and is almost always delivered in the adjuvant setting to the surgical 
field. It is the standard of care for reducing by more than 50% the risk of local 
recurrence in the breast following lumpectomy, or following mastectomy for 
lymph node positive breast cancers [43]. 
 RT involves the delivery of high-energy X-rays that target the tumour, or 
post-surgery tumour site. It can be delivered in the form of external beam 
radiotherapy (linear accelerator), or brachytherapy (radiation source is placed 
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directly at the treatment site, which for breast remains largely confined to select 
subspecialty cancer centers or through clinical trials). This high energy therapy 
results in double-stranded DNA breaks for rapidly dividing cells, felt to target any 
residual cancer cells which might be present in the surrounding normal tissues or 
pre-invasive cancer cells at risk of progressing to invasive and resulting in a local 
recurrence.  
 RT delivered by tangents (or 2-field) refers to radiation to the breast alone, 
although the radiation beams do overlap and, therefore, treat approximately 80% 
of the lower axilla. Four-field or regional radiation refers to additional fields or 
radiation to the upper axilla (level III nodes, clavicular and internal mammary 
nodal basins). 
The dose of radiation must be strong enough to be cytotoxic to 
proliferating cancer cells, but tolerable by surrounding normal cells, since all 
tissue types are susceptible to this damage. Therefore, the radiation delivery is 
planned using a 3-dimensional conformal CT scan where radiation oncologists 
and physicists calculate dosage to deliver even radiation to the area in question 
while constraining doses to critical structures. Damage is then minimized by 
delivering the treatment over many fractions at a low dose per fraction (typically 
2Gy per fraction). 
 For LABC, the standard post-mastectomy dosage of 50Gy in 25 fractions 
is typically delivered, plus a boost of up to 9Gy in 5 fractions to regional nodes or 
surgical site for margin positivity or heavy nodal involvement [26]. Radiation is 
standardly delivered 5 days per week, excluding weekends, for administrative 
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convenience rather than for therapeutic reasons. It remains controversial whether 
patients who have achieved a pCR with neoadjuvant chemotherapy still require 
regional radiation after surgery, given the vastly improved survival rates in this 
subset, but at present it remains the standard recommendation [26]. 
 
1.6  NEOADJUVANT TREATMENT 
1.6.1 Neoadjuvant Chemotherapy 
Regardless of differential sensitivities between breast cancer subtypes, 
and despite an absence of survival benefit, neoadjuvant chemotherapy has 
become a standard of care for locally advanced breast cancer. The NSABP-18 
trial was the first large randomized study to demonstrate the efficacy of 
neoadjuvant chemotherapy.  In the study, 1523 patients with T1-3, N0-1 were 
randomized to four cycles of AC (adriamycin 60mg/m2 and cyclophosphamide 
600mg/m2) intravenously every 3 weeks either pre- or post- operatively [44].  
There was a significant improvement in clinical complete response (cCR), 
pathologic complete response (pCR) and the rate of breast conserving surgery 
with neoadjuvant treatment, but no difference in disease-free (DFS) or overall 
survival (OS) across the study population.  However, in analyzing the 13% of 
patients who achieved a pCR, there was a significant improvement in DFS 
(p=0.014), distant DFS (p=0.0004) and a trend to OS (p=0.06) when compared to 
patients who did not achieve a pCR.  At sixteen years of follow-up, these patients 
continued to show a significant improvement in DFS (Hazard Ratio (HR) 0.47, 
p<0.0001) with OS (HR 0.32, p<0.0001) now reaching statistical significance [45]. 
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The correlation between improved survival from locally advanced breast cancer 
and pCR has been identified in other studies, mainly using anthracyclines [46-48].  
In order to improve survival from breast cancer, novel cytotoxic agents 
such as taxanes were evaluated.  Docetaxel is a microtubule-stabilizing agent 
that induces cell-cycle arrest and apoptosis [49,50].  It has demonstrated 
response rates up to 50% in anthracycline-resistant metastatic breast cancer [51-
53], and superior survival when used first-line in randomized studies in the 
metastatic setting [54,55].  Docetaxel is most commonly given intravenously 
every 3 weeks.  However, a randomized phase III study in the metastatic setting 
compared docetaxel 100mg/m2 every 3 weeks, to 35mg/m2 weekly for 3 of every 
4 weeks [56].  Although response rates were lower on the weekly arm, there was 
no difference in progression-free survival (5.7 months vs 5.5 months; p=0.46) or 
OS (18.3 months versus 18.6 months; p=0.34).  There were higher rates of 
clinically significant toxicity in the q 3-weekly arm, (88.1% versus 55.9%; 
p=0.0001). 
Based on its activity in the metastatic setting, docetaxel has been tested in 
randomized trials in early stage breast cancer, and demonstrated superior 
survival when added to anthracycline-based regimens compared to the regimens 
alone [57,58]. FEC-D, (fluorouracil 500mg/m2 IV, epirubicin 100mg/m2, 
cyclophosphamide 500mg/m2 IV every 3 weeks x 3 cycles, followed by docetaxel 
100mg/m2 IV every 3 weeks x3) is currently one of the more commonly employed 
regimens in the adjuvant post-operative setting.  In the PACS-01 study, this 
regimen was compared to 6 cycles of FEC in 1999 women with node-positive 
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operable breast cancer.  With a median follow-up of 60 months, there was a 
trend toward improvement in DFS (73.2% versus 78.4% p=0.12) and overall 
survival (86.7% versus 90.7%, p=0.17) favouring the docetaxel arm [57].  Toxicity 
was considered favourable, with more grade 3 and 4 neutropenia in the FEC arm 
(33.6% versus 28.1%, p=0.008), as well as higher use of colony-stimulating 
factors to maintain blood counts (27% versus 22%, p=0.01).  There was a slightly 
higher incidence of febrile neutropenia in cycle number 4 with docetaxel 
compared to FEC (1.0% versus 4.6%, p=0.005), as well as significantly more 
edema and nail changes with the docetaxel. Similar improvements in DFS and 
OS were also found in the Breast Cancer International Study Group 001 which 
compared 6 cycles of TAC (docetaxel 75mg/m2, adriamycin 50mg/m2, 
cyclophosphamide 500mg/m2 IV every 3 weeks) to FAC (5-FU 500mg/m2, 
adriamycin 50mg/m2, cyclophosphamide 500mg/m2 IV every 3 weeks) in a 
similar population of women [58]. 
Several nonrandomized studies of docetaxel have also shown activity in 
the locally advanced setting either as a single agent, concurrent, or sequentially 
with other agents [59-63].  In order to determine whether the addition of 
docetaxel improves outcomes in the pre-operative setting, several randomized 
studies have been conducted.  The largest, the NSABP-27, randomized 2411 
women with T1c – T3 N0-N1 disease to receive 4 cycles of adriamycin and 
cyclophosphamide (AC) pre-operatively, versus 4 cycles of AC followed by 4 
cycles of docetaxel preoperatively, or 4 cycles of AC preoperatively followed by 
surgery and 4 cycles of post-operative docetaxel.  Compared to preoperative AC 
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alone, the addition of docetaxel significantly improved cCR (40.1% versus 63.6%; 
p<0.001), pCR (13.7% versus 26.1%; p<0.001) and proportion of patients with 
negative nodes (50.8% versus 58.2%; p<0.001) [64].  With 8.5 years of follow-up, 
across all 3 groups, there was no difference in DFS or OS (2).  However, in the 
patients achieving a pCR, there was a significant improvement in DFS (HR=0.49, 
p<0.0001) and OS (HR=0.36, p<0.0001).  
The Aberdeen Breast Group also tested the efficacy of the addition of 
docetaxel to an anthracycline-based regimen in the preoperative setting [65]. 
One hundred and forty-five women with newly diagnosed T3, T4 or TxN2 disease 
received 4 cycles of CVAP (cyclophosphamide 1,000mg/m2, doxorubicin 
50mg/m2, vincristine 1.5mg/m2 and prednisone 40mg).  Those who achieved a 
pCR or cCR were then randomized to either 4 more cycles of CVAP or 4 cycles 
of docetaxel (100mg/m2).  Those who did not respond to the initial 4 cycles of 
chemotherapy were treated with docetaxel in a nonrandomized fashion.  
Intention-to-treat analysis demonstrated a higher clinical cCR (94% versus 66%, 
p=0.03) and pCR (31% versus 16%, p=0.04) with the addition of docetaxel 
compared to 4 more cycles of CVAP.  At 38 months median follow-up, docetaxel 
significantly improved DFS (90% versus 77%, p=0.03) and OS (97% versus 84%, 
p=0.05) [66].  A third study, the GEPARDUO, compared AC for 4 cycles followed 
by docetaxel for 4 cycles (AC-DOC) to dose-dense doxorubicin 50mg/m2 plus 
docetaxel 75mg/m2 every 14 days for 4 cycles, with filgastrim support (ADOC) 
preoperatively in 913 women with T1-3 N0-2 breast cancer [67].  All endpoints, 
including pCR (22.4% versus 11%) and breast-conserving surgery rates (75% 
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versus 66%) were significantly improved with the sequential AC-T over the dose-
dense arm [67].  Survival endpoints have not yet been reported.  Based on these 
findings, the use of taxanes in the neoadjuvant setting has been recommended 
for non-metastatic advanced breast cancer [68]. For HER2 overexpressing 
tumours, the GerparQuattro trial (combining trastuzumab with anthracycline-
based neoadjuvant chemotherapy regimens) demonstrated a significant increase 
in pCR with the addition of trastuzumab and recommended it also be initiated in 
the neoadjuvant setting [69]. 
In spite of the improved outcomes with neoadjuvant use of chemotherapy, 
the gains are modest in terms of impact on overall survival.  Furthermore, the 
only patient groups experiencing a survival advantage are those who achieve a 
pathologic complete response, which represent a small proportion of women 
treated with a neoadjuvant approach (historically 10% in our institution as well as 
in our provincial consortium database, unpublished data). 
 
1.6.2 Concurrent Chemo-Radiotherapy (CCRT) 
Concurrent chemoradiation is an increasing form of effective therapy for a 
variety of cancers. The mechanisms by which various chemotherapeutic agents 
interact with radiation effects to produce supra-additive or synergistic effects (i.e. 
treatment response that is more than additive with what would have been seen 
with either treatment alone) differ widely [70]. There remains no one universal 
mechanism to explain the interaction between these drugs and radiation effects. 
Rather, the molecular class of drugs determines the mechanism of 
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radiosensitization; this can include modification of DNA damage by radiation, 
interference with DNA repair processes, cytokinetic cooperation, inhibition of 
proliferation, enhancing apoptosis, inhibition of angiogenesis, modifying hypoxia, 
and interference with signal transduction pathways [70]. 
Some classes of drugs exhibit biological cooperation, where the 
chemotherapy targets disease in one area, while radiation targets disease in 
another area. Others exhibit kinetic cooperation, meaning that both the 
chemotherapy and radiation modulate cell cycle and proliferation mechanisms 
[70]. 
A common feature of radiosensitizing drugs is that the interaction is dose 
and time dependent rather than tumour cell specific. For example, cisplatin must 
be present prior to radiation to produce any radiosensitizing effects [70]. Wilson 
and colleagues speculated that the presence of cisplatin molecules in the tissues 
receiving radiation inhibits sub-lethal damage repair from occurring after 
radiation-induced DNA damage [70]. 5-fluorouracil, on the other hand, inhibits 
DNA synthesis. It is not currently known what the specific mechanism is by which 
taxanes (docetaxel and paclitaxel) produce a supra-additive effect when present 
during radiation. 
For breast cancer, radiation is recommended in patients who undergo 
breast conserving surgery for early disease, as well as for patients with advanced 
or lymph node positive disease. The recommended timing for the delivery of 
radiation for breast cancer is in the adjuvant setting; however, there is evidence 
to suggest that neoadjuvant radiation may improve patient outcome and should 
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be considered. The Stockholm Breast Cancer Trial, conducted between 1971-
1976, randomized 960 early breast cancer patients to neoadjuvant radiation, 
adjuvant radiation (both delivered as 4500Gy in 25 fractions, 4-field) or surgery 
only (modified radical mastectomy for all patients) [71]. No systemic therapy was 
given. The study demonstrated a significant improvement in survival among 
patients treated in the preoperative setting, suggesting a potential benefit from 
receiving radiation therapy with the tumour in vivo. Although this study was 
completed a long time ago in what might be considered another era of care, it is 
a pure investigation, in the sense that it was a RCT where no other treatments 
were delivered (hormonal or systemic chemotherapy), thereby allowing the 
effects of the radiation to be evaluated alone in terms of impact on recurrence 
and survival. 
In other cancers diagnosed elsewhere in the body, a combined modality 
approach of local neoadjuvant radiation given concurrently with radiosensitizing 
chemotherapy has been employed, in order to improve outcomes (both the 
locoregional control and overall survival). This has become the standard of care 
for the treatment of head and neck, rectum, lung, cervix and other cancer sites. 
Furthermore, a significant improvement in pCR as a surrogate for DFS with 
preoperative chemo/radiotherapy has also been reported [72]. The concurrent 
approach has demonstrated improvements in organ preservation and survival 
over radiation alone in multiple randomized trials [73-76]. 
Several randomized trials have demonstrated improved local control and 
survival in non-small cell lung cancer with the use of concurrent versus 
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sequential chemoradiation, most commonly with platinum-based chemotherapy 
[77-80].  Multiple small studies have been done in this patient population adding 
docetaxel as the radiosensitizer [81-86].  Doses have varied from 20mg/m2 - 
40mg/m2 weekly as a single agent, or in combination with cisplatin. The studies 
showed the feasibility of adding docetaxel, for favorable response rates and 
survival, with manageable toxicity. 
Limited published data exist for the use of neoadjuvant chemo-
radiotherapy in locally advanced breast cancer.  The most common reported use 
of concurrent chemo-radiotherapy is in the metastatic setting or in locally 
advanced (inoperable) or inflammatory breast cancer patients who progress on 
first line anthracycline-based chemotherapy [87-90], all of these using 5-FU or 
capecitabine as the radiosensitizing agent. These trials all occurred prior to 
standard incorporation of taxane into breast chemotherapy regimens. 
Among early stage II breast cancer patients, the sandwich approach to 
neaodjuvant chemotherapy was evaluated, with radiation delivered between 
cycles 1,2 and 3,4 [91] in 14 patients. The regimen was considered feasible, with 
a 7% pCR rate but no survival outcome data. For similar early breast cancer 
patients treated in the adjuvant setting, sequential was later found to be similar to 
concurrent chemo-radiotherapy (ARCOSEIN trial) in terms of overall and 
disease-free survival, with the caveat of having used older, less effective 
chemotherapy regimens [92]. Of note, among the higher risk patients (node 
positive), there was an improved relapse-free survival.  
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In high-risk breast cancer patients (LABC), a few studies were undertaken 
to explore the potential use of concurrent neoadjuvant chemoradiotherapy.  The 
largest trial was a retrospective review of 1,117 LABC patients treated in South 
India from 1990-1999 [93], who were treated with cyclophosphamide, 
methotrexate and 5-fluorouracil (CMF) versus 5-fluorouracil, epirubicin and 
cyclophosphamide (FEC) chemotherapy, with 60Co delivered as 40Gy in 20 
fractions, followed by surgery and oophorectomy. A pCR rate of 34% was 
obtained with acceptable toxicity.  
Prospectively, similar smaller trials were undertaken using CMF [94] and 
50Gy in 25 fractions to breast, where a pCR rate of 44% was reported in 73 
LABC patients but no survival data was available. Again, sandwich techniques 
were explored, where radiation was delivered halfway through neoadjuvant 
chemotherapy cycles in LABC patients, but did not seem to improve outcomes 
[95,96].  
Data supporting sequential treatment derives mostly from studies in early 
stage breast cancer. From pooled data of 10 retrospective studies, delaying 
radiotherapy in favour of chemotherapy increased the risk of local relapse from 
6% to 16% [97]. Furthermore, radiotherapy given more than 8 weeks after 
surgery has been shown to double the local recurrence rate [97]. The only 
prospective trial designed to answer this question in early breast cancer 
demonstrated that patients treated initially with radiotherapy had higher rates of 
distant relapse; in contrast, patients treated with initial chemotherapy had higher 
rates of local relapse [98]. These differences were no longer apparent at 10 
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years of follow-up [99]. A major limitation of these sequential studies is the fact 
that the systemic treatments used are not comparable to modern chemotherapy 
regimens (which typically include taxanes, or targeted agents like trastuzumab). 
It is, therefore, possible that the differences in local relapse rates seen in the 
above studies may over-estimate the clinical reality today. 
A number of cytotoxic chemotherapy drugs have been demonstrated to 
have radiosensitizing features (through molecular mechanisms not fully 
understood) as assessed through improved clinical outcomes with increased 
locoregional toxicity, most notably fluoropyrimidines [93,95], mitoxantrones [100], 
taxanes (docetaxel and paclitaxel) [101,102] and platinum [87] drugs. 
Concurrent chemotherapy with radiation has the potential to offer patients 
the combined benefits of improved local and distant disease control. In early 
breast cancer, CMF-based concurrent adjuvant chemo-radiotherapy has been 
studied in several trials. Although this treatment had an acceptable toxicity profile, 
and shortened overall treatment time, clinical benefit in terms of overall or 
disease free survival was not consistently shown [103-106].  Anthracycline-based 
CCRT has been associated with serious skin toxicity, including recall reactions 
and cardiac toxicities. Mitoxantrone (12mg/m2) in combination with 
cyclophosphamide (500mg/m2) and fluorouracil (500mg/m2) every 21 days for 6 
cycles (CNF) and radiotherapy starting during the first cycle of CNF was shown 
in the multicentre randomized Arcosein trial, to improve local control in lymph 
node positive subgroup patients compared to sequential CNF and radiotherapy 
[92,107]. Unfortunately, concurrent CNF and RT compared to sequential CNF 
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and RT failed to show any benefit in 5-year DFS and OS. Similar results were 
seen in a French multicentre trial comparing concomitant CNF and radiotherapy 
to CEF (cyclophosphamide, epirubicin, and fluorouracil) and sequential RT [100]. 
A benefit in local control and decrease in local recurrence rate by 2.8 fold was 
seen in the concurrent CNF and RT arm, compared to the sequential CEF and 
RT arm, with no significance difference in OS and DFS. Unfortunately 
mitoxantrone has been associated with high rates of leukemic transformation and, 
therefore, is now rarely used.  
In exploring the role of CCRT in breast cancer, using pCR as a surrogate 
for increase in survival has its limitations. The correlation of pCR achieved with 
systemic therapy and survival has been well established. This may be due to the 
ability of systemic therapy to sterilize micrometatstases if capable of achieving a 
complete response in the primary tumour and lymph nodes. Therefore, in this 
setting pCR would be a reflection of the effect of the treatment on all cancer cells, 
including disseminated disease. The value of achieving pCR with CCRT is not 
known. In fact, if one views radiation therapy, in a minimalist fashion, as a 
locoregional treatment, then achieving a pCR might not reflect the systemic 
benefit. However, some authors have proposed an anti-tumour systemic effect of 
local breast radiation [108]. 
 
1.6.3 Neoadjuvants: Taxanes as Radiosensitizers? 
Anthracycline and taxanes are the backbone of most modern breast 
chemotherapy regimens in North America. Since anthracycline-based CCRT has 
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been associated with serious skin and cardiac toxicity, there has been an interest 
in evaluating taxane chemotherapy use as a radiosensitizer in the neoadjuvant 
setting currently with neoadjuvant radiation [109]. One retrospective review of 44 
patients receiving concurrent chemoradiation with taxanes for stage I – IV breast 
cancer as a second line regimen was reported [110].  The majority had stage IIIA 
disease (31%).  Seven patients had received prior radiation for breast cancer. 
Twenty-nine patients received concurrent paclitaxel and 15 received concurrent 
docetaxel, given on a q3 weekly schedule for the majority. Treatment was 
generally well tolerated with no grade 4 toxicities.  Nine patients (20%) 
experienced grade 3 skin toxicity (moist desquamation), leading to a delay in 
chemotherapy in 11% of patients, until radiation was completed. Only one patient 
experienced long-term toxicity with retraction and fibrosis of the breast.  Overall, 
this study demonstrated the safety and feasibility or concurrent chemoradiation 
with taxanes in locally advanced breast cancer.  Response rates and survival 
outcomes were not reported. 
A second study reported on 44 women with stage IIB to III locally 
advanced breast cancer who received twice weekly intravenous paclitaxel 30 
mg/m2 for 8 – 10 weeks concurrent with radiation to total dose of 45Gy to the 
breast plus 14Gy in 7 fractions boost, followed by surgery [101].  For those who 
responded to the initial chemoradiation, post-operative doxorubicin/paclitaxel was 
given for 4 cycles, with 4 cycles of doxorubicin/cyclophosphamide given post-
operatively to non-responders.  No grade 4 toxicities were observed in the 
preoperative chemoradiation phase.  In the postoperative phase, the only grade 
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4 toxicity was leucopenia (10%).  Ninety percent of patients received the 
prescribed concurrent treatment.  Three patients (7%) experienced grade 3 skin 
toxicity; other grade 3 toxicities noted in the preoperative treatment were 
hypersensitivity to the paclitaxel, fatigue, stomatitis, and dyspnea limited to one 
case each.  Dose reductions in chemotherapy occurred in 20% of patients:  3 for 
grade 3 neuropathy, 3 for grade 3 neutropenia, one for grade 3 stomatitis, and 1 
for grade 3 esophagitis.  No cases of radiation pneumonitis were reported. Post-
mastectomy complications occurred in 6 patients (14%).  These included 4 
infections with delayed healing, one tram flap necrosis requiring revision and one 
mastitis.  A clinical response was achieved in 91% of patients, with 11% CR and 
80% PR.  Sixteen percent of patients achieved a pCR, with 18% a pPR.  There 
was no association between total dose of preoperative chemotherapy and pCR.  
Overall survival with a median follow-up of 32 months is 93.9%.  
A third phase I/II study in 33 inoperable LABC and metastatic patients 
evaluated infusional paclitaxel with or without vinorelbine and concurrent 60-
70Gy radiation. A 50% rate of grade 3 dermatitis was reported, with a pCR in the 
LABC subset of 46% [111]. 
Two studies have also been published in abstract form only.  One reported 
on 112 patients with stage IIB – IIIB breast cancer who received 4 cycles of 
neoadjuvant FAC or AC given every 3 weeks followed by chemoradiation with 
mitomycin C 5mg weekly, 5-FU weekly, or cisplatin 30mg, gemcitabine 100mg 
weekly; 60Gy was delivered, but the fractionation schedule was not reported.  
This was followed by surgery, and 2 additional courses of postoperative 
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chemotherapy [112].  The pCR rate was 42% in breast, and 29.5% in breast and 
axillary nodes.  No relationship between pCR and RFS was found.  The only 
grade 3 toxicity reported was skin toxicity in 22.4%.  The second study reported 
on 23 patients receiving 50.4Gy over 6 weeks, with paclitaxel 175mg/m2 day 1, 
and 5-FU 1000mg/m2/day continuous infusion day 1-3 for 3 cycles every 3 weeks 
[113].  This was followed by 3 cycles of FEC every 3 weeks, then surgery. Grade 
3 toxicities included 39% radiation dermatitis. The clinical complete response rate 
was 82.6%, with a pCR rate of 52.2% and an overall 2-year survival rate of 
80.7%. 
In addition to the perceived improved response to chemoradiation when 
delivered in the neoadjuvant setting, it may be that radiation planning with the 
disease in vivo may improve dose delivery, with minimization of unwanted 
dosage to critical structures, although that has not been studied. 
 
1.7 THESIS RATIONALE 
Locally advanced breast cancer remains a significant clinical challenge 
with inferior survival in spite of improved systemic treatments.  The cumulative 
data across tumour sites demonstrates a clear association between pCR and 
improved survival.  Neoadjuvant therapy, when used in LABC, does not yield the 
high response rates that are seen and frequently cited in patients with operable 
tumours. Although pCR rates may be impressive in triple negative and HER2-
positive patients, for those who achieve less than a pCR, poor outcomes are 
likely. Taxanes have improved OS in the metastatic and adjuvant setting, as well 
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as pCR rates and survival in the neoadjuvant setting; however, the pCR rates still 
remain disappointingly low. Concurrent administration of taxanes and radiation 
have demonstrated improved outcomes including survival across different tumour 
sites. In LABC, the concurrent approach has been shown to be feasible with 
manageable toxicity.  The current standard treatment for locally advanced breast 
cancer is preoperative chemotherapy with an anthracycline and a taxane.  
However, the ideal regimen and number of cycles remain under debate.  Given 
the improvement in local control, pCR and survival in other tumour sites the 
current study is aiming to determine whether a concurrent approach will improve 
pCR in locally advanced breast cancer. 
 
1.7.1 Hypothesis 
Our hypothesis was that concurrent neoadjuvant chemotherapy with 
regional radiation would improve the pCR rate from the current provincial rate of 
10-15%, when compared to matched LABC patients undergoing standard of care 
(neoadjuvant systemic chemotherapy followed by surgery and adjuvant regional 
radiation). The goal was to use current standard full regimen chemotherapy 
(FEC-D) in order to avoid compromising on systemic efficacy for distant relapse 
with dose reductions, avoiding sandwich techniques which were felt only to 
create dose delays in the chemotherapy delivery, while delivering standard 
adjuvant doses of regional radiation in the neoadjuvant setting for radiosensitivity, 
while maintaining locoregional control in these high risk patients. The regimen 
was modified to include weekly docetaxel instead of q3 weekly (for which funding 
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for and approval of this modified regimen was secured from Ontario’s Ministry of 
Health, Health Canada and Cancer Care Ontario), in order to provide maximal 
overlap of radiosensitizing chemotherapy during radiation and to minimize 
potential toxicity from the heightened effects of docetaxel as a result of the 
concurrent radiation. 
The secondary hypothesis was that response to concurrent chemotherapy 
and radiation could be predicted by biological markers, such as imaging changes 
seen on serial cross-sectional imaging, serial measurements of tissue RNA 
concentration and integrity, and potentially predicted ex vivo using a 3D in vitro 
invasion assay. The findings of the secondary hypothesis are described in 
Appendix IV; they remain preliminary and hypothesis-generating at present. 
 
1.7.2 Outline of this Thesis 
We undertook a prospective Phase II Clinical Trial to test the effectiveness 
of the new protocol, concurrent radiation during the weekly docetaxel portion of 
neoadjuvant FEC-wD chemotherapy. As demonstrated in Chapter 2, we found 
that the neoadjuvant chemoradiation therapy significantly improved the pCR 
rates when compared to standardly treated LABC patients, with a trend toward 
improved disease-free and overall survival. 
This regimen was not without toxicity, and the increase in pneumonitis 
seen as a result of combining docetaxel with radiation is evaluated and reported 
in Chapter 3. 
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Finally, we undertook to evaluate how effective the plasma levels of 
biomarker osteopontin (OPN) would be, as a predictor of pCR or overall survival 
with our novel neoadjuvant chemoradiotherapy protocol. This study and its 
findings are described in Chapter 4. 
 Overall conclusions and recommendations for future directions are 
outlined in Chapter 5. 
 The appendix chapters contain the full clinical trial protocol, the current 
LABC guidelines (written by Muriel Brackstone for Cancer Care of Ontario), and 
the preliminary findings of the biological correlative trials (secondary hypotheses). 
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CHAPTER 2: CLINICAL TRIAL EVALUATION OF CONCURRENT 
NEOADJUVANT CHEMOTHERAPY AND RADIOTHERAPY IN 
LOCALLY ADVANCED BREAST CANCER. 
 
2.1 INTRODUCTION 
Breast cancer is the most common non-cutaneous cancer diagnosis for 
women in Canada, with an anticipated 24,400 Canadian women diagnosed in 
2014, and 5,000 women dying of the disease [1]. Although newer treatments 
have improved both overall survival and progression-free survival for early and 
metastatic cancer patients respectively [2], there remains a subgroup of women 
with Locally Advanced Breast Cancer (LABC) who do poorly. 
LABC is most commonly defined as stage IIB (T3N0) and Stage IIIA/B/C 
from the TMN classification [3]. Clinically these tumours are greater than 5 cm in 
size and/or extend beyond the breast tissue into the surrounding skin or muscle, 
with/without matted axillary lymph nodes (N2), internal mammary nodes (N3) or 
ipsilateral supraclavicular lymph node involvement [3]. LABC represents 
approximately 10-15% of all breast cancer cases, and the overall survival has 
historically been estimated at 30-42% at 5 years [4] a significant portion of whom 
will be living with metastatic disease. However, a small subset of women 
receiving neoadjuvant chemotherapy who achieve a complete pathological 
response, or pCR, (defined as no residual invasive breast cancer following neo-
adjuvant treatment) to treatment are projected to have a vastly improved 5 year 
disease free survival rate of 87% [4], with 5 year overall survival rates of 89% [4] 
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and 90% [5]. As such, pCR rates have become the surrogate measure for 
favorable long-term outcomes in trials involving neoadjuvant treatment [6], 
particularly since the efficacy of systemic therapy can only readily be evaluated 
with the tumour in vivo. Neoadjuvant, or pre-operative chemotherapy has 
become a standard of care for locally advanced inoperable breast cancer or 
operable LABC where breast-conserving surgery is being contemplated [7, 8].  
A number of cytotoxic chemotherapy drugs have been shown in other 
disease sites to have radiosensitizing features, as assessed through improved 
clinical outcomes with increased locoregional toxicity, although the molecular 
mechanisms are not fully understood. Of these, the most notable are 
fluoropyrimidines [9, 10], mitoxantrones [11], taxanes (docetaxel and paclitaxel) 
[12, 13] and platinum [14] drugs. However, limited published data exists for the 
use of neoadjuvant chemo/radiotherapy in LABC.  The most common reported 
use of radiotherapy concurrent with radiosensitizing chemotherapy is in the 
metastatic setting, locally advanced (inoperable) or inflammatory breast cancer 
patients who progress on first line anthracycline-based chemotherapy [14-17], 
where 5-fluorouracil (5-FU) or capecitabine were used as the radiosensitizing 
agent. 
Our hypothesis was that concurrent neoadjuvant radiosensitizing 
chemotherapy with regional radiation would improve the pCR rate from the 
current provincial rate of 10-15%. The goal was to use current standard full 
regimen chemotherapy in order to avoid compromising on systemic efficacy for 
distant relapse with dose reductions, avoiding sandwich techniques which could 
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create dose delays in the chemotherapy delivery, while delivering standard 
adjuvant doses of regional radiation to provide optimal locoregional control in 
these high risk patients. 
 
2.2 METHODS 
2.2.1 Rationale 
At the time that the clinical trial was created, the only Ontario health care 
funded chemotherapy regimen for breast cancer in the neoadjuvant setting was 
AC-T (doxorubicin 60mg/m2 and cyclophosphamide 600mg/m2 IV q3 weekly x 4 
cycles, followed by paclitaxel 175mg/m2 IV q3 weekly x 4 cycles). The choice of 
FEC (5-fluorouracil 500mg/m2, epirubicin 100mg/m2 and cyclophosphamide 
500mg/m2 IV q3 weekly x 3 cycles) and docetaxel was based on the superior 
survival in high risk patients in the PACS-01 study [18].  Furthermore, epirubicin 
is associated with a lower risk of cardiotoxicity than doxorubicin, which must be 
considered in light of the concurrent radiation [19, 20].  Weekly docetaxel is as 
effective as docetaxel given every 3 weeks in the metastatic setting [21], but is 
associated with less toxicity; in particular, less myelosuppression, which should 
reduce the chances of having to reduce or eliminate cycles of chemotherapy. 
Therefore, FEC-D (5-fluorouracil 500mg/m2, epirubicin 100mg/m2 and 
cyclophosphamide 500mg/m2 IV q3 weekly x 3 cycles, then docetaxel 100mg/m2 
IV q3 weekly x 3 cycles) was selected. 
The weekly docetaxel regimen (35mg/m2) was selected in order to provide 
constant radiosensitizing potential during chemotherapy [21, 22]. Special 
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permission was obtained from Cancer Care Ontario to have this regimen funded 
through Ministry of Health for this trial only. Standard regional intensity-
modulated radiotherapy (IMRT) (45Gy in 25 fractions plus or minus boost for 
gross residual disease) was selected in order to provide optimal regional therapy 
for these patients at high risk of locoregional and distant relapse. Permission was 
obtained from Health Canada for use of these chemotherapy and radiation 
regimens concurrently in the neoadjuvant setting. This study was approved by 
Western University’s Health Subjects Research Ethics Board (Appendix I). 
 
2.2.2 Patient Description 
Thirty-two patients presenting to the London Regional Cancer Program 
with non-inflammatory LABC were offered participation in this single-arm 
prospective Phase II clinical trial. Patients were deemed eligible if they had 
biopsy-proven LABC (defined as any T3 or T4 tumour stage or any N2 or N3 
nodal stage by American Joint Committee on Cancer [23] staging). Patients were 
all female, at least 18 years of age and able to give informed consent, with a 
negative serum pregnancy test, no prior history of invasive cancer and adequate 
renal, hepatic, pulmonary and cardiac function. The clinical trial schedule is 
outlined in the trial calendar (Table 2.1). Patients were staged using CT 
chest/abdomen/pelvis and bone scan to rule out metastases (protocol details in 
Appendix III).  
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Table 2.1. LABC clinical trial calendar. 
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2.2.3 Treatment Regimen 
Patients were treated with 3 cycles of FEC (intravenous 5-fluororuracil 
500mg/m2, epirubicin 100mg/m2 and cyclophosphamide 500mg/m2) q3 weekly, 
followed by docetaxel weekly x 9 weeks (dose adjusted to 35mg/m2) (Figure 2.1). 
On the evening prior to docetaxel chemotherapy, dexamethasone 8mg oral was 
taken by each patient. Concurrent radiation therapy was started during the first 
day of docetaxel.  Radiation therapy consisted of external beam IMRT therapy for 
a total dose of 45Gy in 25 fractions over 5 weeks. A reduced volume boost of 
5.4Gy in 3 fractions to 9Gy in 5 fractions was given to residual gross disease in 
the breast and/or regional lymph nodes.  All treatment planning was performed 
on the Phillips Pinnacle workstation, and radiation treatment was delivered on 
megavoltage machines using 6MV energy or greater. Chemotherapy with 
radiation was followed by modified radical mastectomy (including standard level I 
and II axillary node dissection) 5 weeks after the last dose of docetaxel, allowing 
8 weeks of radiation recovery preoperatively. 
Adverse events from chemotherapy and radiation therapy as well as 
grading of any developed toxicity were assessed by the oncologist as per the 
National Cancer Institute [24]. Patient tolerability was assessed every 3 patients, 
and any grade 4 or higher toxicities or any treatment delays were reviewed by an 
independent data safety monitoring committee (IDSMC).  Mid-study, the protocol 
was modified to include a normal pulmonary function test and non-smoker status 
after the first three patients with pneumonitis were reviewed by the IDSMC. 
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Figure 2.1. Schema for LABC clinical trial. 
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Women with HER2/neu positive breast cancer received one year of 
trastuzumab, initiated in the neoadjuvant setting concurrently with docetaxel as 
per standard of care, given the absence of evidence to support increased 
cardiotoxicity even when administered concurrently with radiation or taxanes [25, 
26]. Monitoring for cardiac toxicity from trastuzumab included a wall motion study 
performed every 3 months while on therapy.  Dose modification was made as per 
international and institutional guidelines for trastuzumab-associated cardiac 
dysfunction [27]. Women with estrogen receptor positive breast cancer received 
postoperative endocrine therapy according to their menopausal status. 
 
2.2.4 Assessment of Pathological Response 
Pathological response was subcategorized as follows [28]: pCR – 
pathological complete response (no residual invasive breast cancer in the breast 
tissue or axila); pSPR – pathological significant partial response (<10 foci of 
microscopic invasive tumour within breast); pPR – pathological partial response 
(<30% of original invasive breast tumour volume remaining); SD – stable disease 
(30-80% of original invasive breast tumour volume remaining); NR – no response 
(81-120% of original invasive breast tumour volume remaining). 
Molecular subtype was categorized using tumour phenotype as a surrogate for 
genotypic classification as follows: 
• Luminal A: Estrogen receptor (ER) and/or Progesterone receptor (PR) 
positive, epidermal growth factor receptor erb2 (HER2) negative, NOT 
high grade  
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• Luminal B: ER and/or PR positive, high grade only (HER2 positive or 
negative) 
• HER2+: ER and PR negative, HER2 positive 
• Basal:  ER and PR negative, HER2 negative 
The proliferation marker Ki67 is not measured at our institution. 
 
2.2.5 Statistical Analysis 
This study was designed to accrue 52 patients, based on a sample size 
calculation powered to detect a doubling of pCR rate (26% to 52%) from 
published clinical trials of neoadjuvant chemotherapy [8], but was closed 
prematurely after a treatment-related death, with 32 patients accrued, at the 
recommendation of the IDSMC. The treatment cohort (n=32) was compared to a 
concurrent control cohort of LABC patients off-study treated at the same 
institution, all of whom received neoadjuvant chemotherapy (FEC-D or AC-D), 
modified radical mastectomy and equivalent locoregional radiation delivered in 
the adjuvant setting (50Gy in 25 fractions using IMRT). Patients were matched 
1:N by stage, age, and molecular subtype using greedy matching by propensity 
score +/- 0.1 to minimize selection bias. Cox regression analysis was employed 
using a robust sandwich estimator for paired comparison of pCR rates between 
the concurrent chemoradiation cohort and the control cohort. Cox proportional 
hazards analysis was used to compare disease-free and overall survival between 
the two cohorts. SAS 9.3 was used for all statistical analyses (SAS Institute Inc., 
Cary NC). 
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2.3 RESULTS 
Of the 32 patients accrued to the study, one patient progressed during the 
FEC portion of the treatment and was taken off study in favor of second line 
chemotherapy. Another patient with inoperable bilateral LABC received bilateral 
regional radiotherapy during the docetaxel/radiation portion of the study and 
developed pneumonitis-induced acute respiratory distress syndrome shortly after 
completion of radiation. This patient did not go on to surgery and died shortly 
thereafter. From 30 remaining patients who all completed neoadjuvant therapy 
and surgery, 27 were successfully matched to 81 concurrent control patients 
using propensity score greedy matching to minimize selection bias, since 
statistical power was optimized with a 1:3 matching.  
No statistically significant difference in patient age, pre-treatment tumour 
size, pre-treatment nodal status or molecular subtype was found using Cox 
regression analysis (Table 2.2). A statistically significant difference in post-
chemotherapy tumour size was seen (mean residual tumour size in concurrent 
chemoradiation cohort was 13.16mm versus 31.12mm in control cohort, p<0.001) 
(Table 2.3). 
The overall pCR rate was significantly higher in the concurrent 
chemoradiation cohort (22.6% versus 14.9% in control cohort, p=0.019) (Table 
2.3). The number of patients in each molecular subtype group was too small to 
permit statistical comparisons of pCR rates by molecular subtype. None of the 
concurrent  chemoradiation  cohort  patients  who  achieved  a  pCR  have  had a  
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Table 2.2. Patient demographics comparing LABC neoadjuvant 
concurrent chemotherapy and radiotherapy study patients to 
matched control cohort. 
 
 
 
Variable 
LABC Chemotherapy 
Matched Cohort (3:1) 
(n=81) 
Chemoradiation LABC 
Study 
(n=27) 
 
Mean age at registration 
(years) 
 
 
51.2 
 
49.3 
 
Baseline mean tumour 
size (mm) – pre-treatment 
(baseline ultrasound) 
 
 
 
42.0 
 
 
43.2 
 
Baseline clinical node (%) 
N0 
N1-N3c 
NX 
 
 
 
10.1% 
65.9% 
24.0% 
 
 
28.1% 
68.8% 
3.1% 
 
Luminal subgroup – N (%) 
Luminal A 
Luminal B 
HER2+ 
Basal 
 
 
 
29 (34.9) 
33 (39.8) 
8 (9.6) 
13 (15.7) 
 
 
 9 (33.3) 
10 (37.0) 
 3 (11.1) 
 5 (18.5) 
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Table 2.3. Clinical response to neoadjuvant therapy (primary 
chemotherapy for LABC chemotherapy matched cohort versus 
concurrent chemotherapy with radiotherapy for LABC study 
patients). *p<0.05 
 
 
 
Variable 
LABC Chemotherapy 
Matched Cohort (3:1) 
(n=81) 
Chemoradiation 
LABC Study 
(n=27) 
 
Mean tumour size (mm) – post-
treatment (pathology) 
 
 
 
31.12 
 
 
13.16 
 
Lymph nodes positive (%) post-
treatment 
 
 
 
60.9 
 
 
53.3 
 
Luminal subgroup with pCR (%) 
Luminal A 
Luminal B 
HER2+ 
Basal 
 
 
 
6.0 
13.9 
30.3 
18.0 
 
 
0 (33.3) 
10 (37.0) 
3 (11.1) 
5 (18.5) 
 
TOTAL with pCR (%) 
 
 
14.9 
 
22.6* 
 
Follow-up – distant recurrence (%) 
 
 
18.9 
 
20.0 
 
  
	 60 
Table 2.4. Treatment related toxicity rates between LABC neoadjuvant 
concurrent chemotherapy with radiotherapy and matched 
control cohort. 
 
 
 
Toxicity * 
LABC Chemotherapy 
Matched Cohort (3:1) 
(n=81) 
Chemoradiation 
LABC Study 
(n=27) 
 
Dermatitis 
 
 
0 (0%) 
 
6 (22%) 
 
Pneumonitis 
 
 
1 (1%) 
 
5 (19%) 
 
Cardiomyopathy 
 
 
2 (2%) 
 
0 (0%) 
 
Neuropathy/Arthralgia 
 
 
3 (4%) 
 
0 (0%) 
 
Febrile Neutropenia 
 
 
8 (10%) 
 
 
0 (0%) 
 
The numbers were too small for statistical comparison between groups. 
 
* Only class 3 or higher toxicities causing treatment delays or interruptions were used; as most 
radiation pneumonitis occurs at the end of treatment (hence it rarely interrupts treatment), it is, 
therefore, likely that the effect is under-represented in the adjuvant treatment control cohort. 
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recurrence, while 36% of patients who did not achieve a pCR recurred and died 
of their disease within 36 months of treatment. 
Although there was no significant difference in disease-free (DFS) or 
overall survival (OS) between the treatment groups due to premature study 
termination and resultant smaller sample size, there was a trend at 36 months in 
DFS for the concurrent chemoradiation cohort of 79% versus 64% for the control 
cohort (Figure 2.2). The Hazard Ratio (HR) for DFS in the concurrent 
chemoradiation cohort was 0.51 (95% CI=0.16-1.4; p=0.185). A similar trend was 
also seen for OS, where the OS for the concurrent chemoradiation cohort was 
84% versus 69% in the matched control cohort (Figure 2.3). The HR for OS was 
0.46 in favor of the concurrent chemoradiation cohort (95% CI=0.16-1.4; 
p=0.161). 
 
 
2.4 DISCUSSION 
 This study demonstrated that the addition of neoadjuvant radiation to 
anthracycline and taxane-based chemotherapy significantly improved the pCR 
rate in LABC patients, with a trend of 15% higher overall survival at 3 years as 
well as disease-free survival that failed to reach statistical significance based on 
sample size. 
 Since the trial was initiated, other trials using concurrent neoadjuvant 
chemotherapy with radiation for breast cancer have been published. Follow-up 
data  from  Formenti’s  2003  trial  [12]  was  subsequently  published  [29], 
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Figure 2.2. Disease free survival (DFS) comparing concurrent 
chemoradiation cohort to matched control cohort. 
  HR, hazard ratio; Chemo/Rads, chemoradiation. 
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Figure 2.3. Overall survival (OS) in concurrent chemoradiation cohort 
compared to matched control cohort. 
  HR, hazard ratio; Chemo/Rads, chemoradiation. 
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demonstrating a combined pCR and pPR rate of 34% resulting in a significant 
association with better DFS and OS (hazard ratio (HR)=0.35 for recurrence and 
HR=4.27 for overall survival, both with p<0.01) when compared to non-
responders within the same treatment cohort. In that study, only the taxane was 
given neoadjuvantly, with the remainder of the chemotherapy regimen being 
given adjuvantly following a perioperative delay. Formenti’s study confirmed that 
patients able to achieve a pCR with concurrent chemoradiation obtain a 
significantly improved DFS and OS over non-responders treated the same way. It 
does not compare concurrent versus sequential chemotherapy and radiation as 
this trial does.  
 Trials of neoadjuvant chemoradiotherapy evaluating older regimens of 
chemotherapy without taxane have since also been published [30-33], most 
using 5-FU as the radiosensitizing agent, demonstrating feasibility and 
reasonable toxicity and pCR rates of 10-29% and an overall survival of 84%. 
These were mostly retrospective studies in highly selected patient cohorts. 
  Other trials evaluated neoadjuvant concurrent chemoradiotherapy as a 
rescue for LABC patients who progressed on first line neoadjuvant chemotherapy, 
using 5-FU as the radiosensitizer [34, 35] with reasonable pCR rates and 
resultant operability. Long-term outcomes were not reported. 
 Ours represents the first clinical trial evaluating full dose concurrent 
neoadjuvant chemotherapy including a radiosensitizing taxane as part of a 
modern chemotherapy regimen (FEC-D), delivered with locoregional radiation in 
LABC patients. Our findings support those of the Formenti group [29], where 
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pCR rates were significantly increased with concurrent delivery of radiation and 
taxane chemotherapy, and goes further to show a trend in improved DFS and OS 
at 3 years over standard sequential therapy. 
 This regimen was not without its toxicity, and while high rates (25%) of 
grade 3 dermatitis (moist desquamation of chest wall skin) might be considered 
clinically acceptable, the 25% rate of grade 3 or higher pneumonitis was 
concerning. All patients who presented with clinical pneumonitis had the 
diagnosis confirmed on CT scan and were treated with a 2-3 week tapering 
regimen of high dose corticosteroids. One patient suffered ARDS shortly after 
completion of preoperative therapy and died. None of the 30 patients proceeding 
to surgery required a delay in surgery due to pneumonitis. The pneumonitis 
experienced by the patients in this study behaved clinically like acute interstitial 
pneumonitis and not radiation pneumonitis in that the symptoms resolved acutely 
within weeks and did not lead to long-term impairment, however it is felt that the 
radiation likely exacerbated its presentation [36]. 
 Capillary leak and interstitial pneumonitis from taxane chemotherapy is 
well known, although pre-treatment with 8mg of dexamethasone, as was used in 
this trial, is felt to reduce this risk. The typical rate of pneumonitis (1-5% for q3 
weekly docetaxel) [37] increases when administered q-weekly, reportedly to 27%, 
which is comparable to our study [38]. Rates of pneumonitis are also elevated in 
patients with pre-existing lung disease [39]. On the other hand, with the q-weekly 
regimen, none of the patients suffered from other toxicity commonly associated 
with docetaxel, such as febrile neutropenia or peripheral neuropathy. None of the 
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study patients developed a postoperative wound infection or dehiscence, 
although one patient had a protracted seroma that required multiple aspirations.  
 This study was not without its limitations. As a single arm phase II trial, 
there was no randomization to a control arm to correct for unanticipated bias, and 
a matched design to a control cohort may have inadvertently introduced selection 
bias. Every effort was made to minimize this risk by having an independent 
statistician do the matching to our comprehensive patient population database by 
all variables thought to affect the outcomes of interest. It remains possible, 
however, that unanticipated confounders could have influenced the results.  
Although we found a difference of 15% in overall survival at 3 years, the study 
failed to reach statistical significance. This lack of statistical power is due to 
premature termination of the trial due to an unexpectedly high rate of 
pneumonitis, with one death from ARDS. 
The use of concurrent neoadjuvant chemoradiotherapy in LABC appears 
to significantly improve the pCR rate and result in a trend to improved overall 
survival. Given the poor outcome for LABC patients, any potential treatment 
regimen that could result in a 15% increase in overall survival should be 
aggressively pursued. Use of docetaxel appears to be associated with too high a 
rate of pneumonitis, therefore a future phase III multicentered randomized trial 
should be undertaken where the radiosensitizing benefit of taxanes can be 
exploited, using for example paclitaxel [29] concurrently with locoregional 
radiation as part of a full neoadjuvant chemotherapy regimen. 
 
	 67 
2.5 REFERENCES 
1. Canadian Cancer Society (2014) Canadian Cancer Society 
(www.cancer.ca). 
2. American Cancer Society (2014) American Cancer Society 
(www.cancer.org). 
3. National Institute of Health (2014) National Institute of Health 
(www.cancer.gov) 
4. Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, et al. 
(1999) Clinical course of breast cancer patients with complete pathologic primary 
tumor and axillary lymph node response to doxorubicin-based neoadjuvant 
chemotherapy. J Clin Oncol 17(2):460-9.  
5. Formenti SC, Dunnington G, Uzieli B, Lenz H, Keren-Rosenberg S, 
Silberman H, et al. (1997) Original p53 status predicts for pathological response 
in locally advanced breast cancer patients treated preoperatively with continuous 
infusion 5-fluorouracil and radiation therapy. Int J Radiat Oncol Biol Phys 
39(5):1059-68. 
6. Untch M, von Minckwitz G. Recent advances in systemic therapy: 
advances in neoadjuvant (primary) systemic therapy with cytotoxic agents. 
Breast Cancer Res 11(2):203.  
7. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, et al. 
(1998) Effect of preoperative chemotherapy on the outcome of women with 
operable breast cancer. J Clin Oncol16(8):2672-85.  
8. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux 
A, et al. (2008) Preoperative chemotherapy: updates of National Surgical 
Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 
26(5):778-85. 
9. Lerouge D, Touboul E, Lefranc JP, Genestie C, Moureau-Zabotto L, 
Blondon J (2004) Combined chemotherapy and preoperative irradiation for 
locally advanced noninflammatory breast cancer: updated results in a series of 
120 patients. Int J Radiat Oncol Biol Phys 59(4):1062-73. 
10. Shanta V, Swaminathan R, Rama R, Radhika R. (2008) Retrospective 
analysis of locally advanced noninflammatory breast cancer from Chennai, South 
India, 1990-1999. Int J Radiat Oncol Biol Phys. 70(1):51-8. 
11. Rouesse J, de la Lande B, Bertheault-Cvitkovic F, Serin D, Graic Y, 
Combe M, et al. (2006) A phase III randomized trial comparing adjuvant 
concomitant chemoradiotherapy versus standard adjuvant chemotherapy 
followed by radiotherapy in operable node-positive breast cancer: final results. Int 
J Radiat Oncol Biol Phys 64(4):1072-80.  
12. Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, et al. 
(2003) Preoperative twice-weekly paclitaxel with concurrent radiation therapy 
followed by surgery and postoperative doxorubicin-based chemotherapy in 
locally advanced breast cancer: a phase I/II trial. J Clin Oncol 21(5):864-70.  
13. Chakravarthy AB, Kelley MC, McLaren B, Truica CI, Billheimer D, Mayer 
IA, et al. (2006) Neoadjuvant concurrent paclitaxel and radiation in stage II/III 
breast cancer. Clin Cancer Res 12(5):1570-6.  
	 68 
14. Genet D, Lejeune C, Bonnier P, Aubard Y, Venat-Bouvet L, Adjadj DJ, et 
al. (2007) Concomitant intensive chemoradiotherapy induction in non-metastatic 
inflammatory breast cancer: long-term follow-up. Br J Cancer 97(7):883-7. 
15. Ren H, Wang Q, Yan Y, Li S, Huang B (2006) Preoperative 
Chemoradiotherapy for Inflammatory Breast Cancer 2006:130-3. 
16. Gaui MF, Amorim G, Arcuri RA, Pereira G, Moreira D, Djahjah C, et al. 
(2007) A phase II study of second-line neoadjuvant chemotherapy with 
capecitabine and radiation therapy for anthracycline-resistant locally advanced 
breast cancer. Am J Clin Oncol 30(1):78-81. 
17. Touboul E, Lefranc JP, Blondon J, Buffat L, Deniaud E, Belkacemi Y, et al. 
(1997) Primary chemotherapy and preoperative irradiation for patients with stage 
II larger than 3 cm or locally advanced non-inflammatory breast cancer. 
Radiotherapy and Oncology 42(3):219-29. 
18. Amat S (1999) Induction chemotherapy in operable breast cancer:  high 
pathological response rate induced by docetaxel. Proc Am Soc Clin Oncol 
18:79a. 
19. Ryberg M, Nielsen D, Skovsgaard T, Hansen J, Jensen BV, 
Dombernowsky P (1998) Epirubicin cardiotoxicity: an analysis of 469 patients 
with metastatic breast cancer. J Clin Oncol 16(11):3502-8. 
20. Kaklamani VG, Gradishar WJ. Epirubicin versus doxorubicin: which is the 
anthracycline of choice for the treatment of breast cancer? Clin Breast Cancer 4 
Suppl 1:S26-33.  
21. Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, et al. 
(2008) Phase 3 study comparing the use of docetaxel on an every-3-week versus 
weekly schedule in the treatment of metastatic breast cancer. Cancer 
112(7):1455-61. 
22. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, 
et al. (2004) A multicentre, randomised phase II study of weekly or 3-weekly 
docetaxel in patients with metastatic breast cancer. Ann Oncol 15(9):1358-65. 
23. Greene FL, American Joint Committee on Cancer., American Cancer 
Society (2002) AJCC cancer staging handbook : from the AJCC cancer staging 
manual. 6th ed. New York: Springer; xv, 469  
24. NationalCancerInstitute. Common Terminology Criteria for Adverse 
Events v3.0 (CTCAE) (2006) (www.ctep/cancergov/) 
25. Perez EA, Suman VJ, Davidson NE, Sledge GW, Kaufman PA, Hudis CA, 
et al. (2008) Cardiac safety analysis of doxorubicin and cyclophosphamide 
followed by paclitaxel with or without trastuzumab in the North Central Cancer 
Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26(8):1231-8.  
26. Rastogi P (2007) Five-year update of cardiac dysfunction on NSABP B-31, 
a randomized trial of sequential doxorubicin/cyclophosphamide (AC)-paclitaxel 
compared to AC-T with trastuzumab. Proc Am Soc Clin Oncol 25:6s. 
27. Mackey JR, Clemons M, Cote MA, Delgado D, Dent S, Paterson A, et al. 
(2008) Cardiac management during adjuvant trastuzumab therapy: 
recommendations of the Canadian Trastuzumab Working Group. Curr 
Oncol15(1):24-35.  
	 69 
28. Honkoop AH, van Diest PJ, de Jong JS, Linn SC, Giaccone G, Hoekman 
K, et al. (1998) Prognostic role of clinical, pathological and biological 
characteristics in patients with locally advanced breast cancer. Br J Cancer 
77(4):621-6.  
29. Adams S, Chakravarthy AB, Donach M, Spicer D, Lymberis S, Singh B, et 
al. (2010) Preoperative concurrent paclitaxel-radiation in locally advanced breast 
cancer: pathologic response correlates with five-year overall survival. Breast 
Cancer Res Treatment 124(3):723-32.  
30. Bollet MA, Belin L, Reyal F, Campana F, Dendale R, Kirova YM, et al. 
(2012) Preoperative radio-chemotherapy in early breast cancer patients: long-
term results of a phase II trial. Radiother Oncol 102(1):82-8. 
31. Alvarado-Miranda A, Arrieta O, Gamboa-Vignolle C, Saavedra-Perez D, 
Morales-Barrera R, Bargallo-Rocha E, et al. (2009) Concurrent chemo-
radiotherapy following neoadjuvant chemotherapy in locally advanced breast 
cancer. Radiat Oncol 4:24. 
32. Fisher CS, Ma CX, Gillanders WE, Aft RL, Eberlein TJ, Gao F, et al. 
(2012) Neoadjuvant chemotherapy is associated with improved survival 
compared with adjuvant chemotherapy in patients with triple-negative breast 
cancer only after complete pathologic response. Ann Surg Oncol 19(1):253-8. 
33. Nardone L, Valentini V, Marino L, De Santis MC, Terribile D, Franceschini 
G, et al. (2012) A feasibility study of neo-adjuvant low-dose fractionated 
radiotherapy with two different concurrent anthracycline-docetaxel schedules in 
stage IIA/B-IIIA breast cancer. Tumori 98(1):79-85. 
34. Bourgier C, Ghorbel I, Heymann S, Barhi M, Mazouni C, Al Ghuzlan AA, 
et al. (2012) Effect of preoperative rescue concomitant FUN/XUN-based chemo-
radiotherapy for neoadjuvant chemotherapy-refractory breast cancer. Radiother 
Oncol 103(2):151-4. 
35. Karasawa K, Matsumoto F, Ito S, Oba S, Furuya T, Hirowatari H, et al. 
(2012) Hyperfractionated radiotherapy with concurrent docetaxel for advanced 
head and neck cancer: a phase II study. Anticancer Res 32(9):4013-8. 
36. Chow TL, Louie AV, Palma DA, D'Souza DP, Perera F, Rodrigues GB, et 
al. (2014) Radiation-induced lung injury after concurrent neoadjuvant 
chemoradiotherapy for locally advanced breast cancer. Acta Oncol 53(5):697-
701. 
37. King TE, Jett JR (2014) Taxane-induced pulmonary toxicity. 
(www.uptodate.com/contents/taxane-induced-pulmonary-toxicity) 
38. Chen YM, Shih JF, Perng RP, Tsai CM, Whang-Peng J (2006) A 
randomized trial of different docetaxel schedules in non-small cell lung cancer 
patients who failed previous platinum-based chemotherapy. Chest. 129(4):1031-
8.  
39. Tamiya A, Naito T, Miura S, Morii S, Tsuya A, Nakamura Y, et al. (2012) 
Interstitial lung disease associated with docetaxel in patients with advanced non-
small cell lung cancer. Anticancer Res 32(3):1103-6.  
 
	 70 
 
 
 
 
 
 
 
 
 
CHAPTER 3 
 
Role of Plasma Osteopontin as a Biomarker in Locally Advanced Breast 
Cancer. 
 
 
 
 
 
 
A version of this chapter was published, with M Brackstone as a senior co-
author: Anborgh PH, Caria LBR, Chambers AF, Tuck AB, Stitt LW, Brackstone 
M.   Am J Transl Res 2015, vol. 7(4): 723 –732. Reproduced with permission. 
	 71 
CHAPTER 3: ROLE OF OSTEOPONTIN AS A BIOMARKER IN LOCALLY 
ADVANCED BREAST CANCER. 
 
3.1 INTRODUCTION 
Locally advanced breast cancer (LABC) is considered an aggressive and 
advanced stage of non-metastatic breast cancer, accounting for approximately 5-
15% of all breast cancer cases [1-3], with a five year overall survival rate of 30-
42% [3-6]. Current treatment for this form of cancer is multimodal, involving 
neoadjuvant chemotherapy, surgery and radiotherapy [7, 8]. Approximately 10%-
20% of patients achieve a clinical complete response (CR) and 50%-60% will 
achieve a partial response (PR) to neoadjuvant therapy. However, only one half 
to two-thirds of clinical CRs will be confirmed pathologically (pathological 
complete response, pCR, defined as no residual invasive breast cancer in the 
surgical specimen [1]). Response to neoadjuvant chemotherapy allows clinicians 
to identify patients who may have a good outcome, as pCR remains the best 
predictor for long-term survival [6, 9]. 
Osteopontin (OPN) is a secreted, integrin-binding phosphoprotein that is 
expressed by several normal tissues and cell types [10, 11]. OPN plays an 
important role in various aspects of malignancy, particularly those involved in 
tissue invasion and metastasis [10, 12-18], and OPN levels have been 
associated with aggressiveness in several cancer types, including breast cancer. 
We, as well as other groups, have shown by immunohistochemistry that 
elevated levels of OPN found in primary tumours may be correlated with a poor 
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patient prognosis and tumour stage [19-21].  OPN can also be detected in the 
blood of patients with various forms of cancer, including breast, prostate, colon, 
lung, liver and stomach cancer and can be measured using an ELISA (enzyme-
linked immunosorbent assay) [22-27]. Plasma OPN levels are found to be 
elevated in the majority of metastatic breast cancer patients and increased 
baseline levels of plasma OPN in metastatic breast cancer patients are 
associated with a worse prognosis and increased tumour burden [23, 25]. 
Additionally, in metastatic breast cancer patients monitored by serial OPN blood 
levels, survival decreases (despite treatment) as plasma OPN levels increase 
over time [23, 25].  Plasma OPN may thus have both a prognostic and a 
predictive role in metastatic breast cancer, making monitoring plasma OPN levels 
in metastatic breast cancer patients throughout treatment and over their disease 
course potentially useful to predict aggressive tumour behavior. In contrast, we 
recently reported data obtained for early breast cancer patients that failed to 
show prognostic value for baseline plasma levels in those patients, although we 
did find elevated plasma OPN in post-baseline samples from a subset of patients 
[26]. 
This study is, to our knowledge, the first study to measure plasma OPN 
serially in LABC patients. Serial measurement of plasma OPN levels over 
treatment may potentially provide information with respect to patient response to 
neoadjuvant therapy and long-term survival. The ability to more accurately 
monitor response to neoadjuvant therapy may lead to better management of 
these patients. 
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3.2 MATERIALS AND METHODS 
3.2.1 Patient Enrollment and Treatment Course 
Fifty-two female patients and one male patient diagnosed with LABC, 
being treated at the London Regional Cancer Program in London, Ontario, 
Canada, were enrolled during 2007-2011 into this study, which was approved by 
the Western University Health Sciences Research Ethics Board. All patients had 
a histologically confirmed clinical stage III breast cancer and were eligible for 
neoadjuvant therapy, excluding inflammatory breast cancer or patients with 
distant metastases.  Patients with any prior history of invasive cancer or prior 
chemotherapy or radiotherapy were excluded. All patients provided written 
informed consent to participate in this study. No eligible patients declined 
participation. Standard patient treatment included neoadjuvant chemotherapy, 
modified radical mastectomy and adjuvant regional radiation.  Patients received 
one of two standard neoadjuvant chemotherapy regimens: AC-T (Doxorubicin 
60mg/m2 and cyclophosphamide 500mg/m2 IV q3 weekly x 4 cycles followed by 
docetaxel 100mg/m2 IV q3 weekly x 4 cycles) or FEC-D (5-fluorouracil 500mg/m2, 
epirubicin 100mg/m2 and cyclophosphamide 500mg/m2 IV q3 weekly x 3 cycles 
followed by docetaxel 35 mg/m2 qweekly x 9 cycles). The patients receiving FEC-
D received their regional external beam conformal radiotherapy (45 Gy in 25 
fractions plus 5.4 Gy in 3 fractions or 9 Gy in 5 fractions depending on disease 
burden) concurrent with docetaxel therapy in the neoadjuvant setting versus 
identical radiotherapy in the adjuvant setting for AC-D patients. This was followed 
in all patients by modified radical mastectomy to remove the breast and axillary 
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lymph nodes, which were examined pathologically. All surviving patients were 
followed for at least 2.5 years. All patients, with the exception of the male patient 
who died unexpectedly of aspiration-induced respiratory arrest following 
chemotherapy cycle 2, completed the treatment course. Three female patients 
became metastatic during neoadjuvant therapy. Patient characteristics as well as 
tumour characteristics and subsequent occurrence of metastases during or after 
neoadjuvant therapy are listed in Table 3.1. All patients were followed 
prospectively and none were lost to follow-up. 
 
3.2.2 Plasma Sample Collection and OPN Analysis 
Blood samples for OPN measurement were collected in tubes with EDTA 
anticoagulant and processed as previously reported [22]. OPN was measured in 
plasma samples by ELISA (Human Osteopontin EIA Kit, catalogue #ADI-900-142, 
Enzo Life Sciences, Ann Arbor, MI) as previously described [27]. Samples were 
collected from all patients at baseline (just prior to the first cycle of 
chemotherapy) and again just prior to each subsequent chemotherapy cycle 
treatment or every three weeks throughout neoadjuvant treatment for patients 
receiving their docetaxel weekly. Plasma samples from a cohort of 90 healthy 
women without cancer were collected and measured for OPN as described 
previously [26].  
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Table 3.1. Patient and tumour characteristics, and site of metastasis. 
 
OPN 
Number 
Age at 
Baseline 
Gender Tstage Nstage ER PR HER2 Grade Site of Metastasis 
01 53 F T3 N1 Pos Pos Pos 2 0 
02 52 F T4a N0 Unk Unk Unk 1 0 
03 68 F T4b N1 Pos Pos Neg 1 0 
04 52 F NA NA Pos Pos Neg 3 0 
05 50 F T4b N1 Pos Neg Pos 3 Liver 
06 64 F T3 N1 Pos Neg Equiv 2 0 
07 59 F T4b N1 Neg Neg Pos 3 Lung 
08 47 F T4b N1 Pos Pos Neg 3 Liver 
09 56 F T2 N1 Neg Neg Pos 3 0 
10 44 F T3 N1 Neg Neg Pos 3 0 
11 42 F T4b N1 Pos Pos Neg 3 Lung/Liver/Bone 
12 76 M T4b NX Unk Unk Unk 2 Unk 
13 67 F T3 N0 Pos Pos Neg 1 0 
14 64 F T4b N1 Pos Pos Pos 1 Liver 
15 39 F T2 N1 Pos Pos Pos 2 Brain/Liver/Lung/Bone 
16 46 F T3 N0 Pos Pos Neg 2 0 
17 42 F T3 N1 Neg Neg Pos 3 Lung 
18 48 F T3 N1 Pos Pos Neg 1 0 
19 53 F T4b N0 Neg Neg Pos 3 0 
20 47 F T4b N1 Neg Neg Neg 3 0 
21 44 F T1c N2 Neg Neg Pos 3 0 
22 38 F T2 N0 Neg Neg Pos 3 0 
23 62 F T2 N1 Neg Neg Pos 3 Brain 
24 26 F T2 N1 Neg Neg Neg 3 0 
25 58 F T3 N2 Pos Pos Pos 3 0 
26 43 F T2 N1 Pos Pos Pos 2 0 
27 52 F T2 N2 Pos Pos Pos 2 0 
28 49 F T3 N2a Pos Pos Pos 2 0 
29 63 F T3 N1 Neg Neg Neg 3 0 
30 48 F T3 N1 Pos Pos Neg 2 0 
31 61 F T3 N1 Pos Pos Neg 3 0 
32 39 F T3 N1 Pos Pos Neg 2 Lung 
33 43 F T3 N0 Neg Neg Pos 2 0 
34 47 F T3 N0 Pos Pos Neg 2 0 
35 49 F T2 N0 Neg Neg Neg 3 Bone 
36 64 F T3 N2 Pos Neg Neg 2 Bone 
37 34 F T3 N3 Neg Neg Neg 3 0 
38 40 F T2 N1 Pos Pos Neg 1 0 
39 58 F T1 N3 Pos Pos Pos 3 0 
40 42 F T2 N0 Pos Pos Neg 2 0 
41 53 F T3 N0 Neg Neg Neg 3 0 
42 44 F T3 N1 Pos Pos Pos 2 0 
43 45 F T3 N0 Pos Neg Neg 2 0 
44 57 F T2 N0 Pos Neg Pos 3 0 
45 60 F T3 N0 Pos Pos Neg 2 Bone 
46 50 F T3 N2 Neg Neg Neg 3 Lung 
47 44 F T3 N1 Pos Pos Neg 1 0 
48 45 F T3 N1 Pos Pos Neg 2 0 
49 62 F T3 N2a Pos Neg Pos 3 0 
50 51 F T3 NX Pos Pos Pos 2 0 
51 58 F T2 N1 Pos Pos Pos 3 0 
52 31 F T2 N3 Pos Pos Pos 3 0 
53 62 F T2 N3 Pos Pos Neg 2 0 
 
ER, estrogen receptor; Equiv, equivocal; NA, not available; Neg, negative; Pos, 
positive; PR, progesterone receptor; Unk, unknown.  
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3.2.3. Pathological Assessment  
Surgical specimens were sent for final pathological assessment. Tumour 
response to neoadjuvant chemotherapy was sub-stratified as follows [28]: 
i) Complete pathological response (pCR) (No evidence of residual invasive 
tumour in breast or axilla) 
ii) Partial response (PR) (at least a 30% decrease in residual tumour volume)   
iii) No evidence of response (stable disease) (NR) 
iv) Progression of disease (PD) (at least a 20% increase in residual tumour 
volume). 
 
3.2.4 Statistical Analysis 
Repeated measures analysis of variance was used to compare OPN 
levels across cycles of treatment, with Tukey’s multiple comparisons test used to 
make pair-wise comparisons between cycles. The co-variates used included age, 
gender, T stage, N stage, ER, PR, HER2 and grade. Student’s t-test was used to 
compare data between healthy women and patients. The Kaplan-Meier 
technique was used to estimate survival, comparisons were made using the log-
rank statistic, and the calculation of hazards ratios and evaluation of the effect of 
baseline OPN as a continuous variable were done using Cox regression. The 
relationship between OPN levels and response to chemotherapy was evaluated 
using Fisher’s exact test. SAS 9.3 was used for all statistical analyses (SAS 
Institute Inc., Cary NC). 
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3.3 RESULTS 
Plasma OPN levels in ng/ml for each patient over the course of 
neoadjuvant chemotherapy are shown in Figure 3.1. Patient 12, who was the 
only male in the study, died following the second cycle of chemotherapy from 
what appeared to be treatment-related toxicity. A baseline OPN level of 
69.7ng/ml was measured and at cycle two, just prior to his death, OPN level was 
elevated to 141.3ng/ml. The two OPN values for this patient were not used for 
the following analyses. A second patient progressed during the first 2 cycles of 
chemotherapy and was, therefore, removed from the study and not included in 
the analysis; the third patient died from acute respiratory distress syndrome 
shortly after docetaxel/radiotherapy without surgery and was, therefore, also 
excluded from analysis. The remaining 50 patients were included for analysis. 
OPN values at baseline/cycle 1 were obtained for 50 patients. Mean OPN 
value was 70.3ng/ml at baseline/cycle 1, while median value was 63.6ng/ml 
(range 33.3 – 189.8ng/ml). We have previously measured plasma OPN levels of 
90 healthy women and found a mean value of 32.0ng/ml (median value 
26.3ng/ml (range 11.8-108.6ng/ml) [26]. This differs significantly from the mean 
values of LABC patient plasma OPN at baseline/cycle 1 (p<0.001) (Figure 3.2).  
OPN levels across 7 cycles of neoadjuvant treatment were compared for 
the 34 patients for whom we had a complete set (no missed blood draw at each 
chemotherapy cycle) using repeated measures analysis of variance. There was 
an increase in OPN levels seen during chemotherapy cycles that was significant 
overall (p<0.001).  Mean  patient  plasma OPN levels between successive cycles   
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Figure 3.1. Plasma OPN levels during neoadjuvant therapy with final 
response to treatment and survival for all 53 LABC patients. At every 
treatment cycle plasma samples were obtained and OPN was measured 
in triplicate by ELISA. Average OPN levels are shown in ng/ml. Final 
patient response is denoted as complete response (CR), partial response 
(PR), no response (NR) or progressive disease (PD). Patient numbers in 
black indicate patients who were alive 2.5 years post-surgery and red 
numbers indicate patients who died within that period. Patients are 
grouped first according to status (alive vs dead) and then according to 
increasing baseline OPN, except patients for which no baseline OPN was 
obtained in which case OPN at cycle 2 was used. Patient 12 is a male 
patient who died following 2 neoadjuvant cycles. The dotted lines indicate 
upper limit of OPN levels in a cohort of 90 healthy women (108.6ng/mL) 
and median value at baseline/cycle 1 (63.6ng/mL), respectively.  
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Figure 3.2. Plasma OPN levels at baseline/cycle 1 compared to OPN levels 
of 90 healthy women.  The boxes show OPN value between the 
25th and 75th percentiles, with whiskers showing ranges; the lines 
within the boxes mark the median values. OPN values from healthy 
women were as reported.  
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show no significant difference from baseline/cycle 1 through to cycle 5. 
Significant pairwise differences exist between the mean OPN levels of cycle 1 vs 
cycle 6 (p<0.001), and cycle 1 vs cycle 7 (p<0.001). Overall, all but three OPN 
values at baseline/cycle 1 as well as the majority of the LABC patient samples 
from cycles 2-8 have OPN values within the normal range (i.e. ≤108.6ng/ml) 
based on a prior study of 90 healthy women without cancer [26] (Figure 3.1). 
 
3.3.1 Association of OPN Values with Overall Survival  
To determine the association of OPN values with overall survival, patients 
were divided into 2 groups: OPN <63.6ng/ml versus OPN ≥63.6ng/ml, the 
median OPN value at baseline/cycle 1. By comparison, the majority (92%) of 
healthy women had OPN values <63.6ng/ml. The Kaplan-Meier survival curve 
indicates that patients with baseline/cycle 1 OPN <63.6ng/ml had a significantly 
improved overall survival than patients with baseline/cycle 1 OPN ≥63.6ng/ml 
(Figure 3.3). The log rank test showed that this difference was statistically 
significant (Chi-square=5.9; p=0.015; hazard ratio (HR) 3.3; 95% confidence 
interval (CI): 1.3 – 10.4). Cox regression analysis with OPN at baseline/cycle 1 
as a continuous variable produced similar result (Chi-square=10.4; p=0.001).  
 
3.3.2 Association of OPN Values with Response to Neoadjuvant Therapy  
The majority of the female LABC patients (62% or 32 out of 52) had a PR 
to neoadjuvant therapy; eleven patients (21%) had a CR, four patients (6%) had 
PD  and  four  individuals  (8%)  had  NR  to  treatment.  Plasma  OPN  levels  at   
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Figure 3.3. Association of plasma OPN levels at baseline with LABC 
patient survival. Kaplan-Meier survival curves were constructed 
after dividing the patients into two groups according to the median 
OPN value at baseline/cycle 1 (63.6ng/ml) (log-rank test, p=0.011).  
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baseline were compared with the final pathologic response to neoadjuvant 
chemotherapy. Mean OPN value at baseline/cycle 1 for patients with CR was 
60.3ng/ml, while for patients with PD or NR, mean OPN value was higher at 
75.1ng/ml (Figure 3.4) however this difference was not statistically significant 
(p=0.054; two-tailed). Six out of seven (86%) patients with PD or NR had OPN 
values ≥63.6ng/ml at baseline/cycle 1 (for patient 18 with PD, no baseline/cycle1 
value was obtained), while 4 out of 11 (19%) patients with CR or PR had OPN 
values ≥63.6ng/ml at baseline/cycle 1 (p=0.066).  
 
 
3.4 DISCUSSION 
Tumour response to neoadjuvant treatment is an important predictor of 
prognosis and overall survival for the LABC patient population. In this current 
study, measuring serial plasma OPN levels was evaluated as a novel method for 
monitoring tumour response to neoadjuvant chemotherapy of LABC patients. The 
majority (83%) of the patients treated in this study had pCR or PR, of which pCR 
is believed to be the most important current prognostic marker for survival. 
Our results show that during the course of neoadjuvant treatment, as the 
patients receive additional cycles of chemotherapy, a statistically significant 
increase is seen in OPN levels at later cycles (6, 7 and 8) compared to earlier 
cycles (1–5). Cytotoxic chemotherapies that are used for cancer treatment can 
stimulate the immune system. Up-regulation of OPN expression in immune cells 
allows  for  increased  macrophage  adhesion,  migration,  cytokine  release  and   
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Figure 3.4. OPN levels at baseline for complete responders and non-
responders to neoadjuvant treatment. Lines indicate median 
OPN value for eleven patients with pCR (55.5ng/ml) and median 
OPN value for seven patients with NR or PD (75.8ng/ml) (p=0.054). 
Dashed line indicates the median OPN value at baseline 
(63.6ng/ml) of the entire group of patients.  
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phagocytosis, all of which are important events of the immune and inflammatory 
response [29, 30]. Therefore, it is possible that the increased plasma OPN levels 
observed in patients over the course of neoadjuvant chemotherapy is from two 
different sources:  OPN expressed by immune cells as a component of the 
inflammatory response, and that secreted by the primary tumour itself [14, 19, 
26]. Further work is required in order to determine the exact source of plasma 
OPN detected during treatment.  
We have recently reported that, in a group of 90 healthy women, plasma 
OPN levels ranged from 11.8-108.6ng/ml [26]. Based on this, a level of 
108.6ng/ml has been used as the upper limit of normal in the present study and 
OPN levels above this value were considered elevated. We have previously 
shown that in a cohort of 70 patients with metastatic breast cancer, 70% had 
elevated levels of OPN [23] and patients with increased plasma OPN levels had 
significantly shorter survival times. In line with this, Bramwell et al. [25] reported 
that in a larger cohort of women with metastatic breast cancer, 66% had elevated 
baseline OPN levels that were inversely and significantly associated with survival.  
In addition, serial monitoring of OPN levels revealed that an increase of 
>250ng/ml at any time was the most prognostic variable for poor survival. This 
association of increasing OPN levels over time with poor prognosis supports the 
use of serial monitoring of OPN levels in order to help make treatment decisions 
by determining response. In contrast, in a cohort of postmenopausal women with 
early breast cancer, only 4 women out of 314 (1.2%) had elevated OPN 
(>108.6ng/ml) at baseline. That study found a mean baseline plasma OPN level 
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of 46ng/ml (range 22.6 – 290ng/ml), which did not differ statistically from normal 
levels [26] and found no evidence supporting a prognostic value of plasma OPN 
for that group of early breast cancer patients.  
While plasma OPN levels have thus been reported to be elevated in 
women with metastatic disease but not with early breast cancer, levels for 
patients with locally advanced disease had not been previously studied. This 
current study showed that most LABC patients have plasma OPN levels that are 
not elevated above what had been previously considered the ‘normal range’ at 
baseline. However, mean OPN levels for LABC patients at baseline/cycle 1 were 
significantly higher than mean OPN level for the group of 90 healthy women. 
When comparing baseline OPN levels to final pathologic response, 
patients who did not respond to treatment had a higher mean OPN level 
compared to the eleven patients who had pCR to treatment (p=0.054). The 
majority of non-responders also had OPN values ≥63.6ng/ml at baseline while 
the majority of responders had OPN values ≤63.6ng/ml at baseline (p=0.066). 
These differences, although not reaching statistical significance in this small 
number of patients, are clinically interesting as they may help identify which 
patients are likely to respond to neoadjuvant chemotherapy and are worthy of 
further study.  
Baseline OPN levels were significantly associated with pathological 
response to treatment (p=0.015).  Cox hazard ratio regression revealed that 
patients with OPN levels above 63.6ng/ml were significantly more likely to die of 
their disease (hazard ratio=0.3; 95% confidence interval 0.10-0.78; p=0.01), and 
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overall, baseline OPN level was significantly associated with survival (p=0.001). 
Therefore, OPN represents the first known predictive and prognostic plasma 
tumour biomarker for overall survival in both locally advanced and metastatic 
breast cancer patients. 
 In conclusion, LABC patients have a poor overall prognosis, due to their 
high risk of tumour recurrence and development of future metastases. The study 
reported here demonstrates a statistically significant difference in survival 
between patients using baseline plasma OPN level. Our results strongly support 
the need for prospective clinical trials to further validate the utility of measuring 
plasma OPN levels in LABC patients, and to determine its role in clinical 
decision-making regarding anticipated response to neoadjuvant chemotherapy.  
 
3.5 REFERENCES 
1. Giordano SH (2003) Update on locally advanced breast cancer. 
Oncologist 8(6):521-30. 
2. Chia S, Swain SM, Byrd DR, Mankoff DA (2008) Locally advanced and 
inflammatory breast cancer. J Clin Oncol 26(5):786-90.  
3. Newman LA (2009) Epidemiology of locally advanced breast cancer. 
Semin Radiat Oncol 19(4):195-203. 
4. Valero VV, Buzdar AU, Hortobagyi GN (1996) Locally Advanced Breast 
Cancer. Oncologist 1(1 & 2):8-17.  
5. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, et al. 
(2004) Cancer statistics, 2004. CA Cancer J Clin 54(1):8-29.  
6. Yalcin B (2013) Overview on locally advanced breast cancer: defining, 
epidemiology, and overview on neoadjuvant therapy. Exp Oncol 35(4):250-2.  
7. Kaufmann M, Hortobagyi GN, Goldhirsch A, Scholl S, Makris A, 
Valagussa P, et al. (2006) Recommendations from an international expert panel 
on the use of neoadjuvant (primary) systemic treatment of operable breast 
cancer: an update. J Clin Oncol 24(12):1940-9.  
8. Gralow JR, Burstein HJ, Wood W, Hortobagyi GN, Gianni L, von 
Minckwitz G, et al. (2008) Preoperative therapy in invasive breast cancer: 
pathologic assessment and systemic therapy issues in operable disease. J Clin 
Oncol 26(5):814-9.  
	 87 
9. Alm El-Din MA, Taghian AG (2009) Breast conservation therapy for 
patients with locally advanced breast cancer. Semin Radiat Oncol 19(4):229-35. 
10. Wai PY, Kuo PC (2004) The role of Osteopontin in tumor metastasis. J 
Surg Res 2004;121(2):228-41.  
11. Rangaswami H, Bulbule A, Kundu GC (2006) Osteopontin: role in cell 
signaling and cancer progression. Trends Cell Biol 16(2):79-87.  
12. Tuck AB, Chambers AF, Allan AL (2007) Osteopontin overexpression in 
breast cancer: knowledge gained and possible implications for clinical 
management. J Cell Biochem 102(4):859-68.  
13. Rittling SR, Chambers AF (2004) Role of osteopontin in tumour 
progression. Br J Cancer 90(10):1877-81.  
14. Anborgh PH, Mutrie JC, Tuck AB, Chambers AF (2010) Role of the 
metastasis-promoting protein osteopontin in the tumour microenvironment. J Cell 
Mol Med 14(8):2037-44. 
15. Allan AL, George R, Vantyghem SA, Lee MW, Hodgson NC, Engel CJ, et 
al. (2006) Role of the integrin-binding protein osteopontin in lymphatic metastasis 
of breast cancer. Am J Pathol 169(1):233-46.  
16. Tuck AB, Hota C, Chambers AF (2001) Osteopontin(OPN)-induced 
increase in human mammary epithelial cell invasiveness is urokinase (uPA)-
dependent. Breast Cancer Res Treatment 70(3):197-204.  
17. Furger KA, Allan AL, Wilson SM, Hota C, Vantyghem SA, Postenka CO, et 
al. (2003) Beta(3) integrin expression increases breast carcinoma cell 
responsiveness to the malignancy-enhancing effects of osteopontin. Mol Cancer 
Res 1(11):810-9.  
18. Xuan JW, Hota C, Shigeyama Y, D'Errico JA, Somerman MJ, Chambers 
AF (1995) Site-directed mutagenesis of the arginine-glycine-aspartic acid 
sequence in osteopontin destroys cell adhesion and migration functions. J Cell 
Biochem 57(4):680-90. 
19. Tuck AB, O'Malley FP, Singhal H, Harris JF, Tonkin KS, Kerkvliet N, et al. 
(1998) Osteopontin expression in a group of lymph node negative breast cancer 
patients. Int J Cancer 79(5):502-8.  
20. Rudland PS, Platt-Higgins A, El-Tanani M, De Silva Rudland S, 
Barraclough R, Winstanley JH, et al. (2002) Prognostic significance of the 
metastasis-associated protein osteopontin in human breast cancer. Cancer Res 
62(12):3417-27.  
21. Coppola D, Szabo M, Boulware D, Muraca P, Alsarraj M, Chambers AF, et 
al. (2004) Correlation of osteopontin protein expression and pathological stage 
across a wide variety of tumor histologies. Clin Cancer Res 10(1 Pt 1):184-90.  
22. Bautista DS, Saad Z, Chambers AF, Tonkin KS, O'Malley FP, Singhal H, 
et al.(1996) Quantification of osteopontin in human plasma with an ELISA: basal 
levels in pre- and postmenopausal women. Clin Biochem 29(3):231-9.  
23. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF, 
et al. (1997) Elevated plasma osteopontin in metastatic breast cancer associated 
with increased tumor burden and decreased survival. Clin Cancer Res 3(4):605-
11. 
	 88 
24. Hotte SJ, Winquist EW, Stitt L, Wilson SM, Chambers AF (2002) Plasma 
osteopontin: associations with survival and metastasis to bone in men with 
hormone-refractory prostate carcinoma. Cancer 95(3):506-12.  
25. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, et al. 
(2006) Serial plasma osteopontin levels have prognostic value in metastatic 
breast cancer. Clin Cancer Res 12(11 Pt 1):3337-43.  
26. Bramwell VH, Tuck AB, Chapman JA, Anborgh PH, Postenka CO, Al-
Katib W, et al. (2014) Assessment of osteopontin in early breast cancer: 
correlative study in a randomised clinical trial. Breast Cancer Res 16(1):R8.  
27. Anborgh PH, Wilson SM, Tuck AB, Winquist E, Schmidt N, Hart R, et al. 
(2009) New dual monoclonal ELISA for measuring plasma osteopontin as a 
biomarker associated with survival in prostate cancer: clinical validation and 
comparison of multiple ELISAs. Clin Chem 55(5):895-903.  
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, 
Rubinstein L, et al. (2000) New guidelines to evaluate the response to treatment 
in solid tumors. European Organization for Research and Treatment of Cancer, 
National Cancer Institute of the United States, National Cancer Institute of 
Canada. J Natl Cancer Inst 92(3):205-16.  
29. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Berman JS (2001)  
Osteopontin as a means to cope with environmental insults: regulation of 
inflammation, tissue remodeling, and cell survival. J Clin Invest 107(9):1055-61.  
30. Giachelli CM, Steitz S (2000) Osteopontin: a versatile regulator of 
inflammation and biomineralization. Matrix Biol 19(7):615-22.  
 
	 89 
 
 
 
 
 
 
 
 
 
CHAPTER 4 
 
Radiation-Induced Lung Injury after Concurrent Neoadjuvant 
Chemoradiotherapy for Locally Advanced Breast Cancer. 
 
 
 
 
 
 
A version of this chapter was published, with M Brackstone as a senior co-
author: Chow TL, Louie AV, Palma DA, D’Souza DP, Perera F, Rodrigues GB, 
Warner A, Chambers AF, Brackstone M. Acta Oncologica 2014, vol. 53(5): 697–
701. Reproduced with permission. 
	 90 
CHAPTER 4: RADIATION-INDUCED LUNG INJURY AFTER CONCURRENT 
NEOADJUVANT CHEMORADIOTHERAPY FOR LOCALLY 
ADVANCED BREAST CANCER. 
 
4.1 INTRODUCTION 
Outcomes for women with locally advanced breast cancer (LABC) remain 
suboptimal, with five-year survival of approximately 50%, despite aggressive 
treatment with a combination of chemotherapy, radiotherapy and surgery, all 
delivered sequentially [1, 2]. Achieving a complete pathological response (pCR) 
to neoadjuvant therapy (defined as no residual cells in the breast or axilla) is a 
major prognostic factor, as women with a pCR have a significantly longer overall 
survival (OS) and disease free survival (DFS) than women without a pCR [3-6]. 
However, rates of pCR are low: a large meta-analysis demonstrated that 17% of 
women, on average, achieve a pCR after neoadjuvant treatment [4]. 
 For other malignancies, such as head and neck cancers, lung cancer, and 
cervical cancer, concurrent chemoradiotherapy provides a survival advantage 
over sequential chemotherapy and radiation therapy [7-10]. Delivery of both 
modalities concurrently affords several potential advantages, including spatial co-
operation, temporal co-operation, non-cross resistance, and radiosensitization 
[11]. In an attempt to improve the pCR rate for LABC, a phase II trial was 
launched, evaluating the efficacy of a regimen consisting neoadjuvant docetaxel 
concurrent with locoregional radiotherapy. At the recommendation of the data 
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safety monitoring committee, the trial closed early due to a higher-than-
anticipated rate of symptomatic radiation pneumonitis (RP).  
 In breast cancer, rates of RP after radiotherapy are usually low, often <5%, 
with fatal RP being rare [12, 13]. In contrast, rates of RP after treatment of lung 
are higher, affecting up to 13-37% of patients [14, 15]. Although predictors of 
symptomatic RP and CT-based radiation-induced lung injury (RILI) (as measured 
by Hounsfield unit density changes) have been evaluated in lung cancer patients, 
and in breast cancer patients receiving radiotherapy alone [16-18], to our 
knowledge no similar data exists examining patients receiving concurrent 
chemoradiotherapy for breast cancer. Therefore, the goal of this study was to 
evaluate predictors of symptomatic RP and CT-based RILI in a unique cohort of 
breast cancer patients treated with concurrent neodajuvant chemoradiation 
therapy. 
 
4.2 MATERIALS AND METHODS 
4.2.1 Patient Description 
From August 2009 to June 2011, thirty-two patients with biopsy-confirmed 
T3/T4 and/or N2/N3 LABC were accrued for this University of Western Ontario 
Research Ethics Board approved protocol. Patients with prior malignancies, 
systemic treatment within the last 5 years, or prior radiotherapy to the head, neck, 
breast or thorax, were excluded. Patients with the diagnosis of inflammatory 
breast cancer were also omitted. 
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4.2.2 Treatment Details 
Neoadjuvant chemotherapy was a standard anthracycline-based regimen. 
It consisted of three cycles of intravenous 5-fluoruracil (500mg/m2), epirubicin 
(100mg/m2) and cyclophosphamide (500mg/m2) administered every three weeks 
(FEC). This was followed by a period of concurrent chemoradiotherapy. Weekly 
IV docetaxel (35mg/m2) was given over nine weeks, with daily external beam 
radiation therapy (intensity modulated radiation therapy or three-dimensional 
(3D)-conformal radiotherapy, calculated using a collapsed-cone algorithm for 
dose calculation) administered concurrently during the first six weeks. A dose of 
45Gy in 25 fractions was given over 5 weeks, and a boost dose of either 5.4Gy in 
3 fractions or 9Gy in 5 fractions was given during the sixth week if residual 
disease was present. Radiation treatment was delivered on megavoltage 
machines using 6MV energy or greater. Five weeks after the last dose of 
docetaxel, patients underwent a modified radical mastectomy (MRM). 
 
4.2.3 Image Registration and Lung Density Measurements 
This report examines symptomatic RP and CT-based RILI. Oncologic 
outcomes (pCR rates and survival) will be reported separately once the survival 
data matures. All trial patients were eligible for this sub-study of symptomatic RP 
and RILI. All 32 patients were scored for possible symptomatic RP using National 
Institute of Health Common Terminology Criteria for Adverse Events (CTCAE) 
v3.0 (CTCAE grade ≥2).  The trial mandated that each patient received at least 
three CT scans. The first was done prior to FEC chemotherapy, the second 
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before the start of concurrent docetaxel-radiotherapy and the third was 
completed before surgery. Any additional CT scans were at the discretion of the 
treating oncologists. To assess CT-based RILI, 27 out of 32 patients had at least 
one follow-up CT scan available and were evaluable for that endpoint. 
Radiotherapy treatment planning scans were overlaid onto their post-treatment 
CT scans in order to measure changes in lung density over time (Figure 4.1). 
The relationship between dose and lung density changes was assessed similarly 
to previous studies [17]. Briefly, isodose levels (5Gy, 10Gy, 20Gy, 30Gy, 40Gy) 
were converted into contours on the planning scan and were transferred from the 
planning CT scans onto follow up scans after coregistration of the scans (MIM 
Software 5.5, Ohio, USA). Deformable registration was attempted, but due to the 
substantial differences between pre-radiotherapy and post-radiotherapy scans 
which resulted in difficulty obtaining adequate registrations, non-deformable 
algorithms were  used  instead.  Contours  were  then  examined  and  manually  
adjusted  if necessary. To assess changes in lung density over time, (HU) 
density changes in each ‘dose band’ (5-10Gy, 10-20Gy, 20-30Gy, 30-40Gy, 
>40Gy) were generated and compared among scans. Contralateral lung 
receiving <5Gy was considered unirradiated and used as a control to correct for 
baseline differences between scans.  
 
4.2.4 Statistical Analysis 
Descriptive statistics were generated for baseline patient, tumour and 
treatment characteristics. Univariable logistic regression analysis was performed   
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Figure 4.1. Representative example of image registration with overlaid 
isodose lines: (A) >40Gy, (B) 30-40Gy, (C) 20-30Gy, (D) 10-20Gy, 
(E) 5-10Gy, (F) <5Gy. (a) Planning CT scan with contoured isodose 
lines (b) Post-treatment follow-up CT scan with the contours from 
the planning scan overlaid via rigid registration. 
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for each available factor to identify predictors of symptomatic RP. T-tests and 
ANOVAs (Analysis of Variance) were used to identify significant differences in 
density change stratified by various combinations of: (a) RP grade (≥2 versus <2), 
(b) radiation dose (5-10, 10-20, 20-30, 30-40 and >40Gy), and (c) time (0-3, 3-6, 
6-12 and >12 months). Linear mixed models were generated to examine 
relationships between radiological lung density changes (dependent variable), 
radiation dose (fixed effect), time (fixed effect), and other potential predictors 
(fixed effects). Statistical analysis was performed using SAS version 9.2 software 
(SAS Institute, Cary, NC, USA) with two-sided statistical testing at the 0.05 
significance level.  
 
4.3 RESULTS 
Baseline characteristics for the 31 evaluable patients are reported in Table 
4.1, and radiotherapy planning parameters are reported in Table 4.2. In total, 17 
(53%) patients developed symptomatic RP (CTCAE v3.0 grade ≥2). Eight 
developed grade 3 pneumonitis requiring supportive oxygen, and one died of 
acute respiratory distress syndrome (ARDS) associated with RP (grade 5 
toxicity). Univariable logistic regression of potential predictors of symptomatic RP 
is shown in Table 4.3. No treatment, patient, or tumour factors were significantly 
associated with symptomatic RP. Since all patients received concurrent 
chemotherapy, the effect of chemotherapy could not be assessed on logistic 
regression.  
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Table 4.1. Baseline tumour, patient and treatment characteristics of all 
patients (n=31). 
 
 
Characteristic 
 All Patients 
     (n=31) 
 
Age – median (mean, max) 
  
 49 (27, 64) 
 
T stage – n (%) 
T1 
T2 
T3 
T4 
 
 
   1 (3.2) 
   4 (12.9) 
 21 (67.7) 
   5 (16.1) 
 
N stage – n (%) 
N0 
N1 
N2 
N3 
NX 
 
 
   9 (29.0) 
 11 (35.5) 
   6 (19.4) 
   4 (12.9) 
   1 (3.2) 
 
Smoking History – n (%) 
  
 11 (35.5) 
 
Left Ventricular Ejection Fraction  
(LVEF) (%) – median (min, max) 
  
 64 (50, 77) 
 
HER2/Neu status – n (%) 
Negative 
Positive 
Equivocal 
 
 
  17 (54.8) 
    8 (25.8) 
    6 (19.4) 
 
Total docetaxel dose received (mg) – 
median (min, max) 
 
522 (360, 666) 
 
Received trastuzumab (Herceptin) – n (%) 
  
  11 (35.5) 
 
Radiation delivery – n (%) 
3D-CRT 
IMRT 
Tomotherapy 
 
 
 
  16 (51.6) 
  13 (41.9) 
    2 (6.5) 
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Table 4.2. Dosimetric parameters. 
 
 
Parameter 
  
Median (mean, max) 
 
Lung V5 (%) 
 
31.2 (25.5, 97.0) 
Lung V10 (%) 27.2 (20.9, 45.4) 
Lung V13 (%) 23.7 (19.4, 34.8) 
Lung V20 (%) 21.0 (10.5, 31.1) 
Lung V30 (%) 17.7 (7.628.8) 
Lung V40 (%) 11.7 (0.7, 24.1) 
Mean Lung Dose (Gy) 10.3 (8.1, 15.7) 
Heart V5 (%) 29.5 (3.6, 100) 
Heart V10 (%) 22.5 (0.03, 91.8) 
Heart V20 (%) 11.5 (0.0, 52.5) 
Heart V30 (%)   6.0 (0.0, 49.2) 
Heart V40 (%)   0.7 (0.0, 38.9) 
Mean Heart Dose (Gy)   8.7 (1.6, 26.9) 
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Table 4.3. Univariable logistic regression models examining the 
relationship between individual predictors of pneumonitis 
grade ≥2 (n=31). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
** overall analysis of effects (applicable to categorical variables only)  
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In total, 79 follow-up CT scans for 27 patients were co-registered with 
baseline CT scans and analyzed for RILI, with a median of three follow-up CT 
scans per patient (range 1-6). Following analysis of the post-treatment scans, 
linear mixed modelling showed both radiation dose and time post-treatment to be 
highly predictive of CT RILI (p<0.001 and p=0.021, respectively). Overall density 
changes at low dose levels (<10Gy) were minor, but a marked increase evident 
with increasing dose, with regions receiving ≥20Gy exhibiting density increases 
of 100 HU or more (Figure 4.2). For both 6-12 months and >12 months post-
treatment, significant differences in density change were observed across all 
dose bands (both p<0.001), with greater differences observed for higher dose 
bands compared to lower dose bands, respectively. This trend was also 
observed during the 3-6 month period, although was not found to be significant 
(p=0.058). 
Patients with symptomatic RP were observed to have higher rates of 
density  change across all  dose levels  (Figure 4.3),  with  significant  differences 
observed in the low-dose (5-10Gy, p=0.040) and high-dose regions (>40Gy, 
p=0.024). Patients who developed RP also had significantly larger CT density 
changes than patients without RP at both 6-12 months (p=0.002) and >12 
months (p = 0.013) post-treatments, suggesting a sustained effect transitioning to 
fibrosis.  
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Figure 4.2. Estimated means (± standard error) for CT lung density 
changes (in Hounsfield Units (HU)) over time (months), 
stratified by radiation dose (Gy). 
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Figure 4.3. Estimated means (± standard error) for CT lung density 
changes (HU) relative to radiation dose (Gy), stratified by 
pneumonitis grade ≥2 versus <2. 
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4.4 DISCUSSION 
In animal models, CT-based HU density changes after radiotherapy are 
strong surrogates of RILI, and correlate with histologic evidence of radiation 
injury, including the presence of inflammatory cells and infiltrative changes in the 
irradiated lung [19]. In this study of taxane-based concurrent chemoradiotherapy 
for LABC, more than half of patients developed symptomatic RP and one patient 
sustained a grade 5 toxicity. RILI was evident even in regions areas of lung 
receiving modest doses of radiotherapy, with a significant relationship evident 
between radiation dose, time post-treatment, and RILI.  
 The extent of CT-based RILI evident in this cohort appears to be higher 
than in patients who do not receive concurrent taxanes. In a cohort of 25 patients 
with stage III NSCLC where CT-based RILI was measured after cisplatin-based 
(non-taxane) chemotherapy with 60-66Gy of radiotherapy, there was no change 
in HU density within the first 3 months after treatment at any dose level. In that 
group, regions of lung receiving 40-50Gy did not show increases of more than 
100 HU at any time in follow-up [18]. Similar results were seen in a mixed cohort 
of 118 patients, including breast cancer, lymphoma, and lung cancer patients 
treated with a variety of fractionations: relative to the lowest dose levels (0-5Gy), 
areas receiving modest doses of radiotherapy (<40Gy), showed very little RILI at 
3-months, and relatively minor HU increases (<50 HU) with further follow-up. 
Although care must be taken in drawing conclusions from comparisons across 
studies, due to differences in baseline factors and data collection, these findings 
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suggest that the more profound, early HU increase seen herein (Figure 4.2) may 
be related to the radiosensitizing properties of concurrent taxanes.  
When given concurrently with radiotherapy, taxanes are potent 
radiosensitizers [20-23], a property that this phase II study attempted to exploit to 
improve the pCR rate. Locoregional radiation for breast cancer is usually well 
tolerated, with only <5% of patients experiencing symptomatic RP, which is 
typically transient [12]. In a recent randomized trial of locoregional vs. local 
radiotherapy after lumpectomy for node-positive breast cancer, the rate of RP in 
the arm receiving locoregional radiotherapy was 2.3% [13]. Although the final 
data on oncologic outcomes, including pCR rate and survival, will be reported 
once the data matures, this interim analysis suggests that concurrent taxane-
based chemoradiotherapy for breast cancer should be used with caution and 
only in the context of a controlled trial. The radiosensitizing properties of taxanes 
are recognized in the treatment of non-small cell lung cancer. For such patients, 
a recent individual patient data meta-analysis demonstrated that the use of 
taxane compared to non-taxane chemotherapy with radiotherapy was a 
significant predictor for developing pneumonitis (p<0.001) [14].  
Since taxanes have become incorporated into routine oncologic use for 
node-positive breast cancer, the challenge of maximizing their benefits while 
minimizing toxicity, namely pneumonitis, has become complex. The synergistic 
interaction of taxanes and radiotherapy has shown promise with regards to 
disease-free and overall survival of patients with node positive breast cancer [24, 
25], yet pneumonitis remains an important cause of morbidity. Limited studies 
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have been conducted for concurrent chemoradiotherapy to treat LABC, but a few 
small trials have shown promise and are the basis upon which we conducted our 
phase II trial [26, 27]. A retrospective review of 44 high-risk breast cancer 
patients demonstrated the feasibility of concurrent radiation delivered with either 
paclitaxel or docetaxel every three weeks [26]. Treatment was well tolerated with 
nine (20%) patients experiencing Grade 3 skin toxicity, with higher rates of 
toxicity associated with docetaxel, and no reports of pneumonitis. Another study 
was conducted on 44 LABC patients who received 30 mg/m2 paclitaxel twice 
weekly with concurrent radiation prior to surgery [27]. An improved pCR was 
achieved, with acceptable toxicity and no cases of RP. These differences in RP 
may be related to choice of taxane (docetaxel vs. paclitaxel), their dosing, or the 
frequency of administration, and further research is needed to determine the 
optimal, safe parameters.  
The findings of this study must be considered in the context of its 
strengths and limitations. The clinical data used herein was collected as part of a 
rigorous, phase II trial, but the analysis of CT-based RILI was an unplanned, 
retrospective analysis. The CT registration process is associated with some 
inherent imprecision [28], which we attempted to correct by manually inspecting 
and correcting isodose line contours. Some CT scans were done at the discretion 
of the treating oncologists, which may introduce unmeasured confounding factors. 
The small sample size resulted in limited power to detect predictors of RP, and 
the selected nature of the study population may affect the generalizability of our 
findings.  
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In conclusion, rates of RP after concurrent docetaxel-based 
chemoradiotherapy are higher than would be expected after breast radiotherapy. 
In this population, CT density changes of RILI occur earlier and appear to be 
more profound than in other studies measuring RILI after thoracic radiotherapy, 
suggesting a radiosensitizing effect of the docetaxel. Mature oncologic outcomes 
from this study are required to fully define the therapeutic ratio, but in the interim, 
concurrent taxane-based chemoradiotherapy should be used cautiously. Further 
study is needed to determine optimal, safe strategies for delivery of highly active 
chemotherapy with locoregional radiotherapy for patients with LABC. 
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CHAPTER 5: GENERAL DISCUSSION 
 
5.1 OVERVIEW OF RESULTS 
Locally advanced breast cancer (LABC) represents a challenging 
subgroup of advanced disease requiring more aggressive treatment than is 
currently being provided, given its low survival. Chapter 1 of this thesis 
represents an overall review of breast cancer and of the existing LABC treatment 
[1]. The current guidelines for LABC patients on for Cancer Care Ontario can be 
found in Appendix II [2]. Chapter 2 represents a clinical trial that was undertaken. 
Thirty-two LABC patients were treated with neoadjuvant FEC-weeklyD 
chemotherapy with concurrent locoregional radiation during docetaxel, reporting 
the clinical outcomes of this study. The full protocol for this clinical trial can be 
found in Appendix III. Chapter 3 represents a biological correlative study of the 
same clinical trial, evaluating plasma osteopontin (OPN) as a tumour biomarker 
and predictor of response to treatment or prognostic marker of survival [3]. 
Chapter 4 represents an evaluation of the radiation pneumonitis toxicity seen 
during this same clinical trial, which ultimately resulted in its premature 
termination [4]. In addition, other exploratory biological correlative substudies 
were undertaken, and the results are reported in Appendix IV. The findings of the 
studies reported in each chapter of this thesis are summarized separately below. 
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5.1.1 Neoadjuvant Chemoradiation Therapy in LABC 
Thirty-two LABC patients were treated with neoadjuvant FEC q3 weekly x 
3 cycles followed by weekly docetaxel x 9 cycles with locoregional radiation 
delivered during the first 6 of these weeks (45Gy in 25 fractions plus 5.4Gy in 3 
or 9Gy in 5 fractions). All patients underwent a modified radical mastectomy five 
weeks after completing treatment. These patients were matched 1:3 to a 
concurrent control cohort of LABC patients treated with the standard treatment 
sequence (neoadjuvant chemotherapy regimen AC-D or FEC-D) using 
propensity matching, where 27 patients were successfully matched to 81 control 
patients for age, stage and molecular subtype.  
 Patients treated with the study regimen using concurrent chemoradiation 
were significantly more likely to have a pathological complete response to 
treatment (i.e. no residual invasive breast cancer in the breast or lymph nodes). 
There was a trend towards a 15% improvement in overall and disease-free 
survival that failed to reach statistical significance to due premature termination 
of the study following one treatment-related death. 
 Based on the results of the clinical trial reported in this thesis, and given 
the poor clinical outcomes in LABC, the improvement in treatment response with 
concurrent chemoradiation by exploiting the radiosensitization of taxanes should 
be further explored. 
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5.1.2 Osteopontin as a Tumour Marker 
Osteopontin is a secreted, integrin-binding phosphoprotein found in 
several tissue types, including breast cancer. Plasma OPN levels have been 
demonstrated to be prognostic among metastatic breast cancer patients, where 
baseline levels at diagnosis were significantly elevated in comparison to normal 
healthy controls. There have been no studies to-date evaluating OPN levels 
among locally advanced, but not yet metastatic, breast cancer patients.  
OPN levels were measured in 32 patients with LABC treated every three 
weeks during neoadjuvant q3 weekly FEC chemotherapy followed by weekly 
docetaxel concurrent with locoregional external beam radiation (see Chapter 3). 
These patients were added to 20 LABC patients treated with neoadjuvant 
anthracycline and cyclophosphamide q3 weekly x 4 cycles followed by docetaxel 
q3 weekly x 4 cycles, where OPN levels were also collected every 3 weeks. OPN 
levels were measured using ELISA. The serial OPN levels seemed to 
demonstrate a slight trend toward increasing over treatment, which did not 
appear to be related to clinical response to treatment. Baseline pre-treatment 
OPN levels were studied and contrasted to clinical outcomes, to evaluate 
whether plasma OPN levels predicted treatment response. Our study 
demonstrated that, when the patient population was dichotomized based on the 
median value of 63ng/mL, baseline elevated OPN level significantly predicted for 
overall survival, and showed a trend to predicting pathological response to 
treatment [3].  
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Thus, OPN appears to be a predictive marker for neoadjuvant treatment 
response in LABC, as well as a known prognostic marker for metastatic breast 
cancer. These findings should be validated in a larger prospective clinical trial. 
 
5.1.3 Toxicity of the Neoadjuvant Chemoradiation Therapy 
Although chemosensitization by docetaxel resulted in an increased pCR 
and a trend toward improved disease-free and overall survival, it was not without 
an increase in toxicity (see Chapter 4). Eight of the 32 patients experienced 
grade 3 pneumonitis following docetaxel and radiation, most commonly 
presenting as shortness of breath at 1-2 weeks after the completion of radiation. 
One patient, who was a long-time smoker, was the only patient to require 
transient oxygen therapy. All were treated with a tapering regimen of high dose 
steroids (see study protocol, Appendix III), and in all but one of these cases, 
patients were clinically resolved by the time surgery was done 5 weeks later. The 
prior smoker remained with grade 1 shortness of breath for several months after 
surgery. One patient experienced acute respiratory distress syndrome after 
having been treated bilaterally with radiation using intensity-modulated radiation 
therapy for bilateral locally advanced breast cancer. As a result of this death, the 
study’s independent data safety monitoring committee recommended premature 
termination of the study.   
 Radiation dosage and time to radiation were found to be predictive of 
radiation-induced lung injury. Serial CT lung images of patients with pneumonitis 
were contrasted to the radiation planning CT images for the 27 of 32 patients 
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who had follow-up CT scans of the lungs after radiation. Lung tissue density was 
found to increase with increasing radiation dosage, time and degree of 
pneumonitis [4].    
   Radiation density was found to be higher than expected from radiation 
alone, and therefore it is possible that docetaxel itself resulted in chemical 
pneumonitis secondary to its known capillary leak syndrome risk. Prior studies 
evaluating the use of another taxane, paclitaxel, with concurrent radiation 
showed very low rates of clinical pneumonitis [5, 6]. If this concurrent 
radiosensitizing chemotherapy regimen is considered for future trials, it is 
recommended that paclitaxel, rather than docetaxel, be utilized in order to avoid 
this toxicity while retaining its beneficial effects on improvement of pCR. 
 
5.2 LIMITATIONS AND FUTURE DIRECTIONS 
The clinical trial reported in this thesis was a prospective single arm Phase 
II trial, and as such, it is prone to limitations common to all studies that are not 
randomized controlled. Despite every effort being made to independently match 
the patients to concurrently treated control patients by variables that could impact 
on pCR or survival, it remains possible that other patient, tumour or treatment 
factors were not adjusted between the two groups, and therefore impacted on the 
differences in pCR rates, disease-free and overall survival rates seen. This 
finding should therefore be validated in a prospective randomized controlled trial. 
More needs to be understood about the relationship between regional 
radiation therapy and resultant improved overall survival. An older but eloquent 
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simple study done by Wallgren and colleagues in 1978 [7] randomized patients 
with breast cancer to preoperative versus postoperative radiation. These patients 
all received the same radiation modality, all had modified radical mastectomies 
and did not receive any hormonal therapy or chemotherapy. Consequently, any 
impact on overall survival can be attributed to the random assignment of 
radiation timing. Patients who received preoperative radiation had a significantly 
improved survival compared with postoperatively treated patients. More recent 
work in the exploding field of immuno-oncology has suggested that radiation may 
prime immunogenic cell death, likely by a number of mechanisms related to 
antigenic T-cell activation [8]. Clearly, more research needs to be done, but 
further work should focus on exploration of the tumour antigen priming effects of 
radiation when delivered preoperatively in breast cancer patients. Future trials 
involving preoperative radiation should all include the collection of serial tumour 
samples, in order to evaluate this potential complex immunogenic effect of 
radiation.  
Given the toxicity seen with docetaxel, specifically resulting in pneumonitis 
rates higher than expected from radiation alone or from other taxanes, such as 
paclitaxel concurrent with radiation, future randomized trials should be 
considered with paclitaxel using the dosage and schedule evaluated by Dr. 
Formenti and colleagues [5]. It has only been studied in a sandwich regimen with 
neoadjuvant paclitaxel twice weekly with concurrent locoregional radiation 
followed by surgery followed by anthracycline-based chemotherapy. Therefore, a 
future trial should be undertaken to exploit chemosensitizing radiation impacts on 
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clinical response to treatment with a novel regimen using paclitaxel, such as 
anthracycline and cyclophosphamide q2-3 weekly x 4 cycles followed by twice 
weekly paclitaxel x 9 weeks with locoregional radiation during the first 6 of those 
weeks. Patients should be randomized to this novel regimen versus the same 
regimen delivered in the adjuvant setting. This could be followed by breast 
conserving surgery for patients experiencing a good response to treatment, or 
mastectomy for those with a less favourable response to treatment.  
At the time that this clinical trial was undertaken, there were significant 
shortages in cancer funding to hospitals, and chemotherapy chair time was at a 
premium. It was, therefore, not feasible to propose a clinical trial where patients 
who were currently receiving chemotherapy once every 3 weeks would instead 
be coming for chemotherapy twice a week. Since that time, weekly paclitaxel and 
weekly docetaxel regimens have become much more common. As a result, it is 
much less of a stretch to propose a twice-weekly regimen to patients who would 
otherwise be treated weekly during the taxane component of chemotherapy.  
 
 
5.3 CONCLUSION 
A phase II clinical trial was undertaken in LABC patients treated with a 
novel neoadjuvant chemotherapy regimen, where docetaxel was given weekly 
and concurrently with daily locoregional radiation. When compared to standard 
treatment, chemoradiation significantly improved pCR and appeared to show a 
trend in improved disease-free and overall survival. This needs to be exploited in 
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future randomized clinical trials using paclitaxel, to avoid an elevated risk of 
pneumonitis. Plasma OPN as a prognostic tumour biomarker can then also be 
validated in this future proposed trial. 
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APPENDIX II: LOCOREGIONAL THERAPY OF LOCALLY ADVANCED 
BREAST CANCER: GUIDELINE RECOMMENDATIONS 
 
 
II.1 INTRODUCTION 
This guideline addresses several questions related LABC as defined 
previously.  In early breast cancer, breast-conserving surgery (BCS) with 
adjuvant radiotherapy (RT) has been found equivalent to mastectomy (in patients 
meeting BCS selection criteria) for long-term outcomes and it is preferred by 
many patients for cosmetic and psychological reasons.  The applicability of BCS 
to LABC and the use and extent of RT after mastectomy is still a matter of debate.  
Historically, LABC has had poor outcomes.  Although neoadjuvant (preoperative, 
induction) therapy was first introduced in an attempt to improve tumour 
resectability and overall survival (OS) rate with early adjuvant treatment, 
improved OS was not realized [1-5].  However, other clinically important 
outcomes were observed, including disease downstaging and feasibility of breast 
conservation in select cases, which form the basis for continued use of this 
approach. Furthermore, neoadjuvant chemotherapy (NACT) also allows an in 
vivo assessment of chemosensitivity, potentially allowing a regimen change that 
would not otherwise be made with traditional postoperative adjuvant treatment. 
Finally, NACT provides a platform for important biomarker and correlative studies 
to enhance our understanding of this disease.  
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Although BCS becomes technically feasible in some patients with LABC 
with good response to NACT, there is uncertainty as to whether mastectomy or 
BCS is most appropriate.  Conversely, optimal treatment when LABC does not 
respond to initial NACT is unclear.  Sentinel lymph node biopsy (SLNB) is used in 
early breast cancer as an alternative to full axillary lymph node dissection (ALND).  
The role of SLNB compared with ALND in patients with LABC receiving NACT 
has not been established.  
NACT has expanded beyond classically unresectable LABC and it is being 
used more frequently for some smaller tumours, especially certain biologic 
subtypes (e.g., triple negative, HER2+). Although this document does not 
evaluate effectiveness of NACT, its expanded use means that clinical trials often 
cover a heterogeneous patient population (see Section III.1.2 Target Population). 
 
 
II.2 METHODS 
II.2.1 Guideline Development 
The evidence-based guideline series developed by Cancer Care Ontario’s 
(CCO’s) Program in Evidence-Based Care (PEBC) use the methods of the 
practice guidelines development cycle. The core methodology used to develop 
the evidentiary base for the present project was the systematic review. The 
resulting evidence underpins the recommendations developed by the working 
group and the Breast Cancer Disease Site Group (DSG). The systematic review 
and companion recommendations are intended to promote evidence-based 
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practice in Ontario. The full three-part evidence series can be found on the 
Cancer Care Ontario (CCO) Web site. 
 
 
II.2.2 Questions 
1. In female patients with locally advanced breast cancer with good response 
to neoadjuvant therapy, what is the role of breast-conserving surgery 
(BCS) compared with mastectomy? 
2. In female patients with LABC, 
a.  is radiotherapy indicated for those who had mastectomy? 
b. does locoregional irradiation result in higher survival and lower 
recurrence rates compared with breast/chest wall irradiation alone? 
c. is RT indicated for those achieving pathological complete response 
(pCR) to NACT? 
3. In female patients with locally advanced breast cancer who receive 
neoadjuvant chemotherapy is sentinel lymph node biopsy (SLNB) or 
axillary dissection the most appropriate axillary staging procedure?  Is 
SLNB indicated before neoadjuvant chemotherapy rather than at the time 
of surgery? 
4. How should female patients with locally advanced breast cancer who do 
not respond to initial neoadjuvant therapy be treated? 
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II.2.3 Target Population 
This guideline is pertinent to female patients with locally advanced breast 
cancer (LABC).  For purposes of this guideline, LABC includes Stages IIB and 
IIIABC and inflammatory cancer, as defined in the AJCC Cancer Staging Manual, 
6th edition [6].  Most studies in the evidentiary base (see Section 2) included 
heterogeneous populations spanning Stages IIB – IIIC and sometimes included 
inflammatory breast cancer.  Very few studies dealt only with Stage III or specific 
subgroups such as patients with T3N0 cancer.  As most of the major studies did 
not report results separately for patients with Stage IIB and Stage III cancers, the 
evidence did not support recommendations based on a narrower definition of 
LABC or subdivided by stage.  Although some people do not consider Stage IIB 
to be locally advanced, there is an increasing trend to treat less bulky disease 
(Stage IIB) in a similar manner, including neoadjuvant therapy; therefore, the 
recommendations may also be applicable to this group. 
 
II.2.3.1 Intended Users 
The intended users are surgeons and medical and radiation oncologists 
specializing in breast cancer. 
 
II.2.4 Literature Search 
The full search strategy and inclusion criteria are presented in the 
systematic review (Brackstone et al, 2014); only a brief summary is provided 
here. The literature in the medline and embase databases (1996 to December 11, 
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2013) and the Cochrane Library was searched for relevant studies. Searches of 
the Web sites of Canadian and international health organizations were also 
conducted to identify existing clinical practice guidelines, systematic reviews, and 
health technology assessments relevant to the guideline questions. All studies 
identified through the literature search were assessed against the selection 
criteria by a health research methodologist from the working group (GGF), with 
Cindy Walker–Dilks screening results from preliminary searches. Studies of 
uncertain eligibility were discussed with the other authors. 
The literature search was designed to retrieve systematic reviews, meta-
analyses, randomized control trials (RCTS), cohort studies, and clinical practice 
guidelines concerning locoregional therapy for LABC. Studies had to include at 
least 50 patients (except for question 4), have a prospective design, and provide 
a statistical comparison of the interventions of interest. Systematic reviews and 
meta-analyses had to include a description of the review methods (literature 
search, study selection, data extraction). 
Randomized controlled trials were included if they addressed stages IIB 
and IIIABC disease (including inflammatory breast cancer), as were RCTS that 
addressed stage II (unspecified) and stage IIA disease, provided that stage I plus 
stage IIA disease constituted fewer than half the cases or that subgroup results 
for either or both of stages IIB and III were available. Studies in which the title 
and abstract indicated only “early breast cancer” with no mention of stage or 
other indication that patients meeting our definition of LABC might form all or part 
of the population were excluded. An exception was made for RCTs located 
	 125 
based on another publication about LABC (review, guideline, or RCT): in such 
cases, the Methods and Results of the original RCT publication were reviewed to 
determine whether the study group actually met our definition of LABC despite a 
title and abstract indicating otherwise. Studies in which the cancer was described 
as metastatic were excluded unless metastasis only to regional lymph nodes was 
mentioned. Randomized controlled studies were the preferred publications. 
Cohort studies were considered in the initial screening, but were included only if 
the comparison groups were equivalent—for example, they had a similar tumour 
stage distribution. Cohort studies were excluded if the patients were assigned to 
treatment based on patient and disease factors instead of randomly, such that 
the prognoses in the groups (before treatment) were not equivalent. 
For question 2(b) about the extent of RT (whole breast or chest wall, or 
locoregional), studies were excluded if they focused on partial compared with 
whole-breast irradiation (for example, accelerated partial breast irradiation, 
brachytherapy, intensity-modulated radiation therapy) or on intraoperative 
techniques (for example, targeted intraoperative radiotherapy or intraoperative 
radiotherapy with electrons), or if they compared RT techniques (dose-density, 
boost, hypofractionation) or focused on simulation or treatment planning. 
 
II.2.5. Development of Recommendations 
The working group drafted recommendations based on the systematic 
review. Where evidence from RCTs was limited, recommendations were based 
on the authors’ professional experience, together with a consideration of current 
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practice and recommendations in other guidelines. Such limitations are clearly 
indicated in the key evidence and qualifying statements that follow each 
recommendation. 
 
II.2.6. Internal and External Review Process 
Before submission of the draft report for external review, the systematic 
review and practice guideline were reviewed by the members of the Breast 
Cancer DSG and the PEBC Report Approval Panel (RAP). The latter group 
consists of the PEBC director and two other members with expertise in clinical 
and methodology issues. The DSG and RAP members reviewed the draft 
systematic review and practice guideline and provided feedback, which was 
incorporated into the guideline. The revised draft document was then distributed 
for external review. External review included both targeted peer review (intended 
to obtain direct feedback from a small number of content experts) and 
professional consultation (intended to facilitate dissemination of the guideline to 
Ontario practitioners and to provide opportunity for additional feedback). Results 
of those two sources of feedback can be found in the full guideline report on the 
CCO website (Brackstone et al, 2014). 
 
 
II.3 RESULTS 
After removal of duplicate citations, the searches in Medline and embase 
resulted in 42,138 publications. After application of the inclusion and exclusion 
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criteria, 143 publications of trials, 18 clinical practice guidelines, and 27 
systematic reviews or meta-analyses remained. Most studies included a mix of 
cancer stages. The full systematic review (Brackstone et al. 2014) provides 
details of the methodologic characteristics and clinical outcomes of the included 
trials. 
No studies meeting the inclusion criteria were located for question 1 (BCS 
vs. mastectomy after good response to NACT). Several RCTs dealt with question 
2(a) (RT after mastectomy), with some studies including patients receiving 
anthracycline-based chemotherapy, but not taxanes. For question 2(b) (extent of 
RT), one prospective nonrandomized study [7] met the inclusion criteria. Three 
RCTs were relevant (two published only as abstracts), but they included both 
early cancer and LABC and therefore did not meet the threshold of 50% or more 
of the patients having stage IIB–III cancer. A large number of studies compared 
the technical feasibility of SLNB and ALND, but they did not compare long-term 
survival outcomes. Data for question 4 were also very limited. 
 
 
II.4. DOCUMENT REVIEW PROCESS 
II.4.1. Internal Review 
During the internal review by DSG members (other than those of the 
working group), 16 approved the document, 1 had strong concerns about the 
inclusion of stage IIB in the guideline and did not approve, and 1 abstained 
because the document was outside his area of expertise. Most of the comments 
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received were related to the definition of LABC. Although 1 reviewer preferred 
that stage IIB be removed from the definition of LABC, the working group decided 
that it was neither feasible nor desirable to redo the evidence summary, because 
most studies reported a heterogeneous patient group, and few dealt specifically 
with stage III cancers. As suggested by 1 reviewer, we incorporated a footnote 
describing the rationale and limitations of the LABC definition into the text 
describing the target population, because those aspects are essential to the 
document and address some of the other comments. 
There was concern that, in recommendation 1, modified radical 
mastectomy was said to be the standard of care for LABC (that is, for all patients 
with LABC) and that such treatment did not really apply to patients with stage IIB 
breast cancer. Although the working group did not feel it appropriate to list all 
situations in which bcs might be considered, recommendation 1 was modified to 
clarify that mastectomy does not apply to everyone and that the judgment of the 
surgeon—and patient preference—is required. A qualifying statement was also 
revised to clarify that evidence for BCS in LABC is weak overall, but that 
exceptions exist. 
As a result of 2 comments, we included a qualifying statement for 
recommendation 1 indicating that the type of surgery offered (for example, skin-
sparing mastectomy with immediate reconstruction) continues to evolve, but that 
such advancements are beyond the scope of the guideline. 
A comment about question 4 suggested that some patient groups (for 
example, estrogen receptor–positive, lobular histology) do not respond as well to 
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chemotherapy. The working group believes that recommendation 4(b) (consider 
second-line chemotherapy, hormonal therapy if appropriate, RT, or immediate 
surgery) is sufficient. A separate guideline on lobular cancer could be useful, but 
addressing that variant in the current guideline is not feasible. 
The RAP members had several suggestions that were addressed in the 
revised document. The key evidence and qualifying statements were edited to be 
less narrative and more succinct; the reader should review the evidence 
summary8 (literature review) for more details. The description of the study 
selection criteria was reworded to be clearer to the reader. The 
Recommendations and Key Evidence and Literature Search sections were both 
revised to ensure that studies for question 2(b) are clearly understood to have 
been conducted in a broad group of patients with stages I–III cancer and not 
specifically LABC. Those studies do not meet the inclusion criteria of 
approximately 50% or more LABC cases in either the full study or a reported 
subgroup analysis; however, two studies were reported only as abstracts and 
might include subgroup data relevant to LABC when fully reported. Adverse 
effects had been included in the recommendations during the development 
process; additional details for some questions were added to the Discussion 
section of the systematic review. 
 
II.4.2. External Review 
Responses were received from 7 targeted peer reviewers (2 surgical 
oncologists, 3 radiation oncologists, 2 medical oncologists) considered to be 
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clinical experts on the topic of the guideline. The documents and a brief 
questionnaire were also distributed to professions in our database with an 
interest in breast cancer. During the latter professional consultation, 28 
responses were received: 10 from medical oncologists, 4 from pathologists, 6 
from radiation oncologists, 5 from surgeons, and 3 from surgical oncologists. 
Most reviewers considered the guideline to be of high quality and said that they 
would make use of it in their practice. Most comments were related to choice of 
wording or unclear phrasing, and revisions were made accordingly. Some 
reviewers wanted further or more specific recommendations, but available RCT 
data would not allow for that. Other queries related to items outside the scope of 
the questions and the literature review. Detailed comments and responses from 
the authors are reported in the full evidence document8 
 
 
II.5 RECOMMENDATIONS 
II.5.1 Preamble 
Communication between physicians, surgeons, and pathologists is 
essential.  A multidisciplinary case conference is the recommended forum for 
discussion of cases. 
Any prior use of neoadjuvant therapy should be indicated when specimens 
are submitted for pathologic examination.  Clinical details often affect the 
pathologic examination and interpretation, whereas details of pathology reports 
will determine appropriate treatment. Prior therapy (including neoadjuvant 
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therapy) can change the nature of the specimen and what should be reported.  
The experience of the authors is that use of neoadjuvant treatment is frequently 
not indicated when submitting specimens.  
It is recommended that surgical clips marking the original (pretreatment) 
tumour location be inserted before administration of neoadjuvant therapy.  
Neoadjuvant therapy may result in change in the extent or distribution of tumour, 
or complete disappearance (clinically or pathologically complete response).  The 
consensus reached at the Canadian Consortium for Locally Advanced Breast 
Cancer (COLAB) in 2011 [8] was that clips should be inserted at the time of 
diagnosis to mark tumour location and this should be considered the standard of 
care.  Use of clips allows more accurate identification of the original tumour site 
(especially if there is complete response), resection of all (previously) cancerous 
tissue with adequate margins, pathologic diagnosis of the most appropriate area 
of specimens, and better accuracy of molecular analyses. 
 
II.5.2  Recommendation 1 
For most patients with LABC, modified radical mastectomy should be 
considered to be the standard of care. 
BCS may be considered for some patients with non-inflammatory LABC 
on a case-by-case basis when the surgeon deems the disease can be fully 
resected and there is strong patient preference for breast preservation. 
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II.5.2.1 Key Evidence 
No randomized controlled trials (RCTs) that directly compared BCS with 
mastectomy in patients with LABC were found in the literature review. 
Evidence in early breast cancer is that BCS plus radiation is equivalent to 
mastectomy alone [9, 10].  There is a continuum in breast cancer stage, as 
opposed to a sharp cut-off between early and locally advanced (see Target 
Population).  The Cancer Care Ontario/Program in Evidence-Based Care 
(CCO/PEBC) guideline [10] included all of Stage I and II, although the Early 
Breast Cancer Trialists’ Collaborative Group (EBCTCG) defined early as “breast 
cancer in which all clinically apparent disease can be removed surgically” [11].  
Therefore, at least some cancers defined as LABC in the current guideline (e.g., 
Stage IIB) are covered in the recommendations of these other guidelines.   
Guidelines by the American College of Radiology (ACR) [12], National 
Comprehensive Cancer Network (NCCN) [13], and the Consensus Conference 
on Neoadjuvant Chemotherapy in Carcinoma of the Breast [14] indicate BCS is 
appropriate for some patients with LABC after NACT. This may include small 
N2/N3 tumours with nodal response, or large (T3N0 or T3N1) tumours with good 
response.  NCCN recommends patients initially Stage IIIABC (except T3N1) with 
good response be treated with mastectomy or consider lumpectomy (plus ALND 
plus radiotherapy).  We endorse the criteria for BCS as outlined in the ACR [12] 
and Consensus Conference guidelines [14] and The International Expert Panel 
on Inflammatory Breast Cancer [15]. 
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II.5.2.2 Qualifying Statements 
Patients should be informed that for LABC as a whole the data are 
insufficient to recommend BCS as a rule; however, there may be some 
exceptions that can be considered on a case-by-case basis. 
The extent of surgery, including BCS, should be determined after full 
discussion between the patient and the treating oncologist, taking into 
consideration the patient’s values and the lack of direct evidence regarding the 
relative benefit of BCS versus mastectomy in this particular situation. 
When considering between mastectomy and BCS (for those meeting 
selection criteria), benefits and harms must be weighed.  BCS is considered to 
have generally better cosmetic effects, and for some female patients may have 
less impact on body image, self-esteem and sexuality than complete breast 
removal by mastectomy.  With BCS there is usually no need for additional 
reconstructive surgery and the operation may be less complex.  In some cases of 
BCS, there may be positive margins requiring re-excision.  In cases of recurrence 
after BCS, further surgery may be needed, and some patients may wish to 
eliminate this possibility by having mastectomy as initial treatment. 
Wide excision of the remaining tumour in the region of the original pre-
neoadjuvant treatment tumour bed plus RT is recommended for patients with 
LABC who strongly desire BCS.  
BCS is not advised in inflammatory breast cancer because the extent of 
tumour involvement cannot be reliably ascertained. 
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There is continuing evolution in the type of surgery offered (e.g., skin-
sparing mastectomy with immediate reconstruction), but these are beyond the 
scope of this guideline. 
 
II.5.3 Recommendation 2(a) 
Radiotherapy following mastectomy is recommended for patients with 
LABC.  
 
II.5.3.1 Key Evidence 
The EBCTCG meta-analyses [16] found radiotherapy (RT) reduced 
recurrence rates and increased survival rates in high-risk patients (15-year breast 
cancer mortality rate 44.6% vs 49.5%, p<0.00001; overall mortality rate 51.4% vs 
55.2%, p=0.0002).   
In patients with node-positive breast cancer who had mastectomy plus 
axillary clearance (ALND) there was improvement in 5-year local recurrence risk 
(5.8% vs 22.8%, p<0.00001), 15-year breast cancer mortality risk (54.7% vs 
60.1%, p=0.0002), and 15-year overall mortality rate (59.8% vs 64.2%, 
p=0.0009).  There were significantly increased survival rates in patients with 1-3 
positive nodes or ≥4 positive nodes, for all T groups, and for patients receiving 
systemic therapy.  
The benefit of RT in reducing breast cancer recurrence and mortality rates 
appears to be offset by adverse effects in older trials (primarily cardiovascular 
and lung adverse effects) especially in female patients with low risk of recurrence.  
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The ratio of breast cancer mortality rate to other mortality rates was strongly 
affected by nodal status, age, and decade of follow-up.  The absolute benefit still 
favoured RT overall, but not necessarily in subgroups with particularly low risk of 
recurrence.  More recent reviews found that the effectiveness of RT is increased 
and cardiopulmonary adverse effects are greatly reduced with modern RT 
planning and technique; therefore, the non-cancer mortality rate data in the 
EBCTCG meta-analyses may not be relevant to current practice. 
 
II.5.3.2 Qualifying Statements 
The use of three-dimensional (3D) treatment planning is important to 
minimize the dose to the lung and heart to ensure improvements in breast-
cancer-specific survival rates are not offset by non-breast cancer mortality rates.  
Treatments provided should conform to accepted standards with respect to 
tissue coverage and dose.  Techniques such as gated RT or active breath-hold 
are used in some centres to reduce cardiotoxicity, although these were not 
evaluated in this guideline series. 
Radiotherapy after BCS was not part of this review, however guidelines for 
early breast cancer recommend radiation following BCS [9, 10] and this is the 
current standard of care.  In the absence of RCTs to the contrary, it is logical that 
radiation be used following BCS for LABC as well.  Radiotherapy following BCS 
for LABC is the current standard of care.   
The EBCTCG meta-analysis found RT improved recurrence and survival 
rates in the subgroup of patients with systemic treatment, and improved 
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recurrence rates (but without significant improvement in survival rate) in patients 
without systemic treatment. RT significantly improved the local recurrence rate in 
patients receiving anthracycline-based chemotherapy but there was no effect on 
survival rate.  Several of the studies used older regimens such as 
cyclophosphamide + methotrexate + fluorouracil (CMF).  Whelan et al [17] also 
found RT reduced mortality in patients with node-positive breast cancer who 
received systemic treatment. No studies were included in the systematic review 
using taxane-based chemotherapy.  Newer chemotherapies and targeted 
therapies may reduce the absolute benefit of RT for some patients, although in 
the absence of RCTs, RT is still recommended. 
Patients should be informed that improvements in recurrence and 
disease-specific survival rates have not necessarily translated into advantages in 
OS, possibly related to radiation-induced adverse effects in older studies.  This 
may be especially relevant to patients with low risk of recurrence.  RT reduced 
the recurrence rates in all groups reported, but the absolute benefit in patients 
with very low risk of recurrence due to disease characteristics and systemic 
therapy may be small, and some may consider the incremental benefit of RT, 
although statistically significant, to be clinically unimportant. 
Lymphedema is more likely when surgery includes ALND or/and when RT 
includes the nodal areas. Decreased shoulder mobility, decreased strength, arm 
weakness, and paresthesia/hypesthesia have also been reported.  The 
Bundesministrium für Forshung und Technologie (BMFT; German Breast-Cancer 
Study Group) 03 study [18] found that 25% of RT patients had acute skin 
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reactions, and 28% had long-term skin alterations (1-2 years after RT).  
Radiation pneumonitis has been reported in approximately 4% of patients [19, 
20], although this increased to 23% (p=0.008) when RT and anthracycline 
chemotherapy were both used. In some older RT regimens there was a 
significant increase in contralateral breast cancer and non-cancer mortality rates, 
primarily from heart disease and lung cancer [16, 21].  Careful treatment planning 
is likely to reduce (but not eliminate) risks other than lymphedema and skin 
effects. 
The benefit of post-mastectomy radiotherapy (PMRT) in patients with 
node-negative LABC (T3-4, N0) is less clear because they have not been 
reported in isolation.  The fourth cycle of EBCTCG [16] revealed that patients 
with T3-4 cancer experienced a 5.7% reduction in mortality rate (70.1% vs 75.8%, 
p=0.20), whereas patients with node-negative cancer (primarily early cancer) had 
a 4.2% increase in mortality rate (42.4% vs 38.2%, p=0.0002).  Patients with 
T3N0 cancer remain a group with limited data and should be discussed 
individually with regards to risks and benefits. 
 
II.5.4 Recommendation 2(b) 
It is recommended that patients with LABC receive locoregional radiation 
encompassing the breast/chest wall and local node-bearing areas following 
breast-conserving surgery or mastectomy. 
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II.5.4.1 Key Evidence 
The recommendation for breast/chest wall irradiation is based on several 
RCTs as summarized in the EBCTCG meta-analyses [11, 16, 22-25] and is 
discussed in Question 2a.   
A prospective nonrandomized study [26] in high-risk patients with Stage II-
III breast cancer found improved disease-free survival (DFS) rates at median 77 
months follow-up (73% with internal mammary (IM) node RT vs 52% without, 
p=0.02), whereas OS was 78% vs 64%, p=0.08.  Subgroups at higher risk of 
recurrence may have greater benefit, as has been reported for patients with 
positive nodes.   
A meta-analysis of the role of RT to regional nodes included three trials 
(two abstracts and one full publication) in patients with early/LABC [27] and 
concluded that regional RT to IM and medial supraclavicular (MS) nodes 
improves DFS, OS, and distant metastasis-free survival (DMFS) in Stage I-III 
breast cancer.  This analysis did not meet our inclusion criteria because only 
approximately 36% of patients had LABC; therefore, the results need to be 
confirmed when the trials are fully published including subgroup data.  
The recommendation to include local node-bearing areas is consistent 
with current practice and other clinical practice guidelines.  The NCCN guideline 
[13] recommends that if IM lymph nodes are clinically or pathologically positive, 
RT should be administered to the IM nodes; otherwise, treatment to the IM nodes 
should be strongly considered in patients with node-positive and T3N0 cancer. 
NCCN also states that RT to the infraclavicular region and supraclavicular area is 
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recommended for patients with ≥4 positive nodes and should be strongly 
considered if 1-3 nodes are positive, and considered for patients with T3N0 
cancer (especially if inadequate axillary evaluation or extensive lymphovascular 
invasion).   
The American College of Radiology [28] recommends PMRT for T1-2N2+ 
and T3-4N+, usually including ipsilateral supraclavicular fossa for patients with 
positive nodes. There is more variation for IM nodes, but IM RT is considered for 
patients at risk of IM involvement such as those with medial or centrally located 
tumours and positive axillary lymph nodes.  PMRT treatment of T1-2N1 and 
T3NO is controversial and should be individualized.   
 
II.5.4.2 Qualifying Statements 
Locoregional treatment (compared with breast/chest wall alone) increases 
the risk for cardiovascular/pulmonary adverse effects.  The additional fields are 
more technically complex to administer.  The use of 3D treatment planning is 
important to minimize the dose to the lung and heart to ensure improvements in 
breast-cancer-specific survival are not offset by non-breast cancer mortality. 
The risk of long-term adverse effects from locoregional radiation should be 
weighed against the potential benefits in patients with lower-risk disease, 
particularly those with left-sided tumours. Ideally, such patients should be 
discussed in a multidisciplinary setting.  
In light of the incomplete data, any recommendations regarding the role of 
extended radiation in LABC are significantly limited.  Although some studies 
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attempted to isolate the role of irradiation to the IM nodes [29, 30], others 
included additional radiation to the MS nodes [31-33] or all locoregional nodes 
[34, 35].   
The additional benefit of regional nodal RT is small, but significant for the 
overall patient groups studied in RCTs (early cancers plus LABC combined). 
The incidence and/or severity of lymphedema is higher with locoregional 
RT.  Especially in patients with lower-risk disease, the risk of long-term adverse 
effects from locoregional radiation should be weighed against the potential 
benefit of reduced recurrence rates and increased survival rates.   
Patients with T3N0 cancer (verified to be N0 pre- and post-neoadjuvant 
therapy) remain a group with limited data and should be discussed individually 
with regards to risks and benefits.  An updated EBCTCG analysis on mastectomy 
patients [36] was published in March 2014 (after the literature review). A 
comparison of the effect of RT in female patients with node-negative cancer who 
had axillary sampling or ALND found RT significantly reduced recurrence only in 
those with axillary sampling.  Patients with ALND had significantly worse overall 
mortality with RT than without (RR=1.23, p=0.03), whereas in patients with 
axillary sampling RT had no significant effect (RR=1.00, p>0.1).  Although this 
does not separate the effect of locoregional from chest wall RT, it suggests that 
RT to the axilla is necessary when there is not full ALND. 
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II.5.5 Recommendation 2(c) 
It is recommended that postoperative radiotherapy remains the standard 
of care for patients with LABC who have pathologically complete response to 
neoadjuvant therapy. 
II.5.5.1 Qualifying Statements 
No prospective randomized studies were found in the literature review 
(see Section 2) that compared treatment with vs without RT in female patients 
with pathologically complete response (pCR) to neoadjuvant therapy.  The 
consensus of the authors is that postoperative RT should therefore remain the 
standard of care. 
When examining the evidence, it is important for the clinician to be aware 
of the various definitions for pCR that have been used in clinical studies. These 
range from no microscopic evidence of viable tumour cells, only residual necrotic 
or nonviable tumour cells, or only residual intraductal tumour cells in the resected 
specimen. The MD Anderson Cancer Center requires the added disappearance 
of axillary lymph node metastasis for a pCR. 
Randomized trials such as those planned by the Athena Breast Cancer 
Network [37, 38] and the NSABP B51/RTOG 1304 trial may provide data to re-
evaluate the recommendation for specific subgroups in the future. 
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II.5.6 Recommendation 3(a) 
It is recommended that axillary dissection remain the standard of care for 
axillary staging in LABC, with the judicious use of SLNB in patients who are 
advised of the limitations of current data. 
 
II.5.6.1 Key Evidence 
The median sentinel lymph node (SLN) identification rate (SLN ID rate) 
was 93% in patients with cN0 cancer and 85% in patients with clinically positive 
nodes. SLN ID rates depend on the experience of surgeons and the techniques 
used.   
The ACOSOG Z1071 trial [39, 40] conducted with patients with positive 
nodes (>85% LABC) is one of the largest and most recent studies.  It found a 
93% SLN ID rate for cN1 cancer and 89% for cN2 cancer.  The false negative 
(FN) rate is not dissimilar to the recommended FN rates for early breast cancer 
surgery [41].  
Although the studies indicate that SLNB is technically feasible in both 
early and locally advanced breast cancer, a small percentage of patients will be 
understaged using SLNB alone.  This risk needs to be weighed against the 
increased adverse effects of ALND.   
This recommendation is based on the authors’ valuing potentially 
increased survival rates with use of ALND over increased postoperative 
complications.  Given the results of the Z0011 and EBCTCG studies for early or 
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operable cancers, some patients may decide that for less advanced LABC (e.g.. 
Stages 2b-3a) the adverse effects of ALND are greater than the benefits.   
 
II.5.6.2 Qualifying Statements  
Although the SLNB technique in patients (mostly with LABC) receiving 
NACT is comparable to that in early breast cancer, the clinical implications of a 
FN SLNB is not known in these patients. 
The benefit of ALND is that more nodes are removed and examined, 
giving more accurate staging for some patients.  Provided that locoregional RT is 
to be administered in all patients, as recommended in Questions 2a and 2b, the 
staging may have no impact on treatment.  However, some patients may value 
the additional prognostic information. If a patient is not going to receive 
locoregional RT, then ALND is recommended. 
There may be a secondary treatment benefit of ALND in that involved 
nodes are removed and, therefore, will not metastasize further.  
More than 80% of female patients undergoing ALND have at least one 
postoperative complication in the arm and psychological distress is common [42].  
In the Z0011 trial [43, 44] ALND added to SLNB resulted in more wound 
infections, axillary seromas, paresthesias, and subjective reports of lymphedema 
than SLNB alone. 
The NCCN guideline [13] (not specifically on NACT) indicates “in the 
absence of definitive data demonstrating superior survival [with axillary lymph 
node staging], the performance of ALND may be considered optional in patients 
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who have particularly favourable tumours, patients for whom the selection of 
adjuvant systemic therapy is unlikely to be affected, for the elderly, or those with 
serious comorbid conditions”.  They recommend that cN0 plus SLN negative 
(including T3N0) need no further ALND.  However, the authors of the current 
guideline note that most patients with LABC are pathologically node positive 
before neoadjuvant therapy, even those considered clinically negative; therefore, 
a high portion may still be pathologically node positive after neoadjuvant therapy.  
None of the studies included inflammatory breast cancer; therefore, these 
findings cannot be extrapolated to that cohort of patients.   
 
II.5.7. Recommendation 3(b) 
Although SLNB before or after NACT is technically feasible, there is 
insufficient data to make any recommendation regarding the optimal timing of 
SLNB with respect to NACT.  Limited data suggests higher SLN ID rates and 
lower FN rates when SLNB is conducted before NACT; however, this must be 
balanced against the requirement for two operations if SLNB is not performed at 
the time of resection of the main tumour.   
 
 II.5.7.1 Key Evidence  
Only three of the studies in Table 6 of the evidence summary [45-47] 
compared timing of SLNB (before or after NACT) and one additional study 
(abstract only) performed SLNB before neoadjuvant therapy [48]. The rest of the 
studies performed SLNB and ALND after completion of NACT.  Before NACT the 
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SLN ID rate was 98-99%, whereas after NACT it was a median of 93% in 
patients with clinically node-negative cancer and 88% overall.  The studies also 
suggest FN rates are lower when SLNB is conducted before NACT.   
The SENTINA study [45] did not conduct ALND if the SLNB before NACT 
was negative so FN rates could not be determined for this subgroup.  Arm B of 
the SENTINA trial included patients initially cN0 with a positive SLN (pN1SN) 
before NACT and conducted a second SLNB plus ALND after NACT. SLN ID 
rate was 76% in the second SLNB and the FN rate based on the second SLNB 
was 61% compared with a SLN ID rate of 99% in patients with cN0 cancer when 
SLNB was performed before NACT.  This suggests that SLNB should not be 
performed both before and after NACT.   
 
II.5.7.2 Qualifying Statements 
It is often considered that adjuvant treatment should be based on the initial 
stage as determined before any treatment, although the extent of surgery 
depends on the size/extent of the tumour immediately before surgery (i.e., after 
any neoadjuvant treatment).  Some studies suggest NACT often eliminates 
cancer from the SLN but not all the other nodes.  For these reasons, there is 
theoretical justification for performing SLN biopsy before NACT.  The very limited 
data would support this, but is considered insufficient at this time to make a 
strong recommendation due to the trade-off required in risk and inconvenience of 
needing to perform two separate operations (one for SLNB and one to remove 
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the main tumour) compared with the normal procedure of removing the tumour 
and SLN (or ALND) in one operation. 
 
II.5.8 Recommendations 4(a) and 4(b) 
II.5.8.1 Recommendation 4(a) 
It is recommended that patients receiving neoadjuvant anthracycline-
based therapy whose tumours do not respond or where there is disease 
progression be expedited to the taxane portion of the anthracycline-taxane 
regimen.  
  
II.5.8.2 Recommendation 4(b) 
For patients who fail to respond or who progress on first-line NACT, there 
are several therapeutic options to consider including second-line chemotherapy, 
hormonal therapy (if appropriate), radiotherapy, or immediate surgery (if 
technically feasible).  Treatment should be individualized considering tumour 
characteristics, patient factors and preferences, and risk of adverse effects.  
Management of patients who do not respond to initial neoadjuvant therapy 
should be individualized through discussion at a multidisciplinary case 
conference. 
 
II.5.8.3 Key Evidence (Recommendations 4(a) and 4(b)) 
Anthracycline-taxane is a standard therapy, with the taxane administered 
either concurrently or consecutively.  The NSABP B-27 trial [49-51] found AC 
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followed by docetaxel gave significantly improved clinical and pathological 
response and lower rates of local recurrence compared with neoadjuvant AC 
alone.  Because most patients were not LABC and patients were not randomized 
based on response, the trial is not included in the evidence review of Section 2. 
The GeparTrio study [52] and a trial by Qi et al [53] evaluated early 
switching to second-line chemotherapy after nonresponse to two cycles of first-
line chemotherapy and demonstrated conflicting findings: the first demonstrated 
no improved response to treatment but better tolerability and the second 
demonstrated some improved response but worse adverse effects and treatment 
delays. There is therefore insufficient evidence to switch chemotherapy mid-
treatment.   
The recommendations are based on current practice and are consistent 
with the guidelines by NCCN [13], Health Canada [54], and the Consensus Panel 
for Neoadjuvant Chemotherapy [14].  
 
II.5.8.4 Qualifying Statements (Recommendation 4(b)) 
There is a body of literature including patients with locally advanced and 
metastatic disease (mostly single-arm case series, small pilot studies, or 
retrospective studies) that supports a variety of second-line single agent and 
multi-agent NACT and/or RT regimens to improve response (including 
pathologically complete response) and, thus, operability or survival.  Although the 
data are limited and not within the rigorous inclusion criteria of the literature 
review, Table 8 of Section 2 lists some of these studies as examples of regimens 
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in the medical literature that have been tried in this clinical scenario. These data 
are not systematically reviewed nor of quality sufficient to make a 
recommendation as to preferred regimens.  It is advised that oncologists 
individualize the choice of therapy based on the patient and risk of adverse 
effects. 
 
 
II.6 FUTURE RESEARCH 
Prospective RCTs designed for patients with LABC who fail to respond to 
NACT are needed so that more definitive treatment recommendations can be 
developed. 
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APPENDIX III. LABC CLINICAL TRIAL PROTOCOL 
 
III.1 PATIENT ELIGIBILITY 
III.1.1 Eligibility Criteria 
• Biopsy proven LABC, Locally advanced breast cancer. (operable or non-
operable) 
• Any T3/T4 or N2, N3 Clinical TNM stage breast cancer without metastases 
• Adequate renal function, as evidenced by a measured or calculated creatinine  
clearance ≥50 ml/minute. If calculated, the following formula must be used: 
Calculated creatinine clearance (ml/min)= 
(140-age) x weight (kg) x 1.04 
Cr (µmol/l) 
 
• Adequate hematologic reserves, as evidenced by an absolute neutrophil 
count ≥1.5 x 109/L, platelets ≥100 x 109/L  
• Adequate hepatic function as evidenced by a total bilirubin ≤1.5 x the 
upper limit of normal (ULN), and AST ≤2.5 x ULN. 
• ECOG Performance Status of 0, 1 or 2. 
• Patients should be able to comprehend the Letter of Information and be 
capable of giving informed consent.  
• Female age ≥18 years old 
• Negative serum pregnancy test  
• Adequate wall motion study results (LVEF ≥50%) 
	 156 
• Patients with other prior malignancies will be considered eligible if they are 
felt to be beyond risk of recurrence of the previous malignancy (generally 
>5 years after diagnosis, with no evidence of recurrence).   There are no 
restrictions on time from a basal cell or squamous cell carcinoma of the 
skin or a carcinoma in situ of the cervix 
• Adequate baseline pulmonary function studies must be confirmed prior to 
consent for radiation or radiation treatment planning. FEV1 should be 
equal to or greater than 1.0 litre. 
 
III.1.2 Ineligibility Criteria 
• Inflammatory cancer (as defined by clinical evidence of dermal-lymphatic 
tumour involvement.) 
• Patient refuses modified radical mastectomy 
• No patient may have received prior systemic treatment for disease within 
last 5 years, no prior radiotherapy given to head and neck, breast, or 
thoracic site. 
• Previous ipsilateral breast cancer diagnosis. 
• Pregnant or lactating females are ineligible.  
• Female patients of reproductive potential who decline to employ an 
adequate contraceptive method are ineligible.  
• Participation in any concomitant trials. 
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III.2 REGISTRATION PROCEDURES 
All eligible patients enrolled on the study will be entered into a patient 
registration log located at London Regional Cancer Program (LRCP).  This will 
provide a serial number for that patient which should be used on all 
documentations and correspondence.  
All registration will be carried out by LRCP and will be obtained by calling 
the LRCP Clinical Research Unit at 519-685-8623. At the time of calling, a 
completed eligibility and signed consent must be available.  There will be no 
exceptions to the eligibility/ineligibility criteria. 
 
 
III.3 OVERAL TREATMENT PLAN 
III.3.1 Concurrent Neoadjuvant Chemotherapy and Radiation (CNCR) 
III.3.1.1 Initial Chemotherapy 
CNCR treatment will begin within 6-8 weeks of their diagnosis of LABC 
(study enrollment) and will consist of 3 cycles of intravenous FEC chemotherapy 
(5-fluoruracil (500mg/m2), epirubicin (100mg/m2) and cyclophosphamide 
(500mg/m2)) q3 weekly. The FEC chemotherapy will be followed by additional 
chemotherapy using docetaxel, concurrent with radiation.  Adverse events from 
chemotherapy and radiation therapy as well as grading of any developed toxicity 
will be assessed by the oncologist as per National Cancer Institute. Any dose 
delays or dose reductions will be reported to the principal investigator, but dose 
reductions to 80% prescribed dose or one week dose delay will be acceptable for 
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this study.  Patient tolerability will be assessed every 3 patients, and any grade 4 
toxicities or treatment delays will be reviewed by an independent clinical review 
board and will be reported to the Health Sciences Research Ethics Board at the 
University of Western Ontario.   
  
III.3.1.2 Radiation Concurrent with Chemotherapy 
Docetaxel (35mg/m2) will be given IV weekly with radiation treatment daily 
during the first 6 weeks of docetaxel. Concurrent radiation therapy will start 
during the first day of week one of docetaxel chemotherapy.  Radiation therapy 
will consist of external beam therapy for a total dose of 45Gy in 25 fractions over 
5 weeks. A reduced volume boost of 5.4Gy in 3 fractions to 9Gy in 5 fractions will 
then be given to residual gross disease in the breast or regional lymph nodes 
during the sixth week. The patient is to be placed in the supine position on an 
angle board with straight spine and the ipsilateral arm raised and supported by 
an armrest and the chin extended with appropriate headrest.  All treatment 
planning will be performed on the Phillips Pinnacle workstation. All radiation 
treatment will be delivered on megavoltage machines using 6MV energy or 
greater with the following procedures/variables: 
Treatment Interruption: any treatment delay of less than one week, 
radiation should be completed to prescribed dose. Any treatment delay of greater 
than one week, radiation should be completed to prescribed dose at the 
discretion of the treating radiation oncologist. All treatment delay causes and the 
length of the delay shall be reported. 
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Dose and Fractionation: Phase I – the dose will be 45Gy in 25 daily 
fractions over 5 weeks. 95% of the PTVs should receive 95% of this dose. Dose 
variation within the breast should be no more than plus 7% and no less than 
minus 5 percent.  
Phase II – the boost dose will be 5.4Gy in 3 daily fractions to 9Gy in 5 
daily fractions over 1 week. If there is concern that the residual gross tumor 
volume is too extensive, the boost will be limited to 5.4Gy in 3 fractions over 1 
week. Any gross residual in the supraclavicular area will be limited to a boost of 
5.4Gy in 3 fractions. 
Prescription Point: For the tangents, this will usually be the point at a 
depth of two-thirds of the distance from the overlying skin contour to the posterior 
tangents at mid-separation. The normalization point is placed away from the 
underlying lung.  For the supraclavicular and axillary fields, the prescription point 
is at midplane. 
 
III.3.1.3 Surgery 
Chemotherapy with radiation will be followed by modified radical 
mastectomy 5 weeks after the last dose of docetaxel, which would give 8 weeks 
of radiation recovery preoperatively. The patient will receive a single dose of 
preoperative antibiotic 30 minutes prior to commencement of the surgery. The 
modified radical mastectomy will be performed in the standard fashion, resecting 
the breast parenchyma through an elliptical incision in order to allow for primary 
skin closure. Through the same wound, a complete level I and II axillary 
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dissection will be performed. A 19 Blake drain will be place beneath the skin flaps 
and secured through a stab incision with Prolene suturing, and the skin flaps will 
be reapproximated with buried subdermal 3-0 monocryl sutures and the 
epidermis closed with a running subcuticular 4-0 monocryl suture and the wound 
covered with steri-strip dressings. Homecare nursing will be arranged for daily 
wound assessment and drain care, which will be removed when the serous 
drainage falls below 30ml per day. 
 
III.3.1.4 Translational Research Components 
Plasma OPN – blood will be drawn for plasma osteopontin at the same 
time blood is drawn for CBC or biochemistry.  The blood will be labelled with the 
patient ID # and sent to the 4th floor laboratory at the LRCP for storage and 
analysis. 
Sesta MIBI SPECT/CT – each patient will have 3 CTs done.  The first CT 
will be performed just prior to the start of FEC chemotherapy.  Second CT will be 
done just prior to the start of the Docetaxel chemotherapy.  The third CT will be 
done just prior to surgery.  CT scans will be performed by the nuclear medicine 
department at LHSC. 
Core Needle Biopsy – at the time of your diagnostic biopsy procedure, you 
may have agreed to participate in a biopsy evaluation study and have signed a 
separate consent and letter of information. If you have participated in that study, 
the additional samples taken will also be used as the first set of tumour samples 
for this current study. If you have refused to participate in the biopsy evaluation 
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study, it does not affect your participation in this study. If you were NOT invited to 
participate in a research study at the time of your diagnostic biopsy procedure, 
you will be asked to undergo another ultrasound-guided biopsy procedure, where 
three extra pieces of tumour tissue will be taken. Taking extra pieces will not 
change the ability of doctors to diagnose or treat your cancer, and will not change 
the outcome of the treatment. It is important to be able to test whether the ability 
of the cancer cells to grow and spread changes over the duration of the 
treatment. This study involves having 3 sets of biopsies IN TOTAL to be used for 
the research study only – at the baseline as described above, at the half-way 
point of chemotherapy (after 9 weeks), and when you are having your surgery 
(after completing chemotherapy and radiation) (when you are already asleep for 
your surgery, to avoid any discomfort to you). Each biopsy will take 
approximately 3-5 minutes. These biopsies will be performed at St. Joseph’s 
Health Centre. 
Ex Vivo Tumour Invasion Model – the serial tumour biopsy samples will be 
collected fresh in phosphate-buffered saline and delivered to Dr. Costello’s 
laboratory, where these samples will be dissected into 1mm tumour plugs. One 
of these will be immediately stored in RNA Later and kept frozen at -80oC for 
later analysis. The remaining samples will be placed in individual culture wells 
and incubated in fresh bovine Type I collagen at 37oC for five days after each 
row of wells has been treated with the chemotherapies used in the trial according 
to CPS maximum allowable IV dosage (FEC and D). Half of the wells will be 
radiated at 0.8Gy once. At the completion of 5 days, optical spectroscopy will be 
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used to determine the maximal diameter of tumour cell invasion into the matrigel. 
Half of the tumour plugs in these wells will be formalin fixed and paraffin-
embedded, and the other half will be flash frozen at -80oC. This will be performed 
by Dr. Costello’s company titled Oncoscreen®. The laboratory will be completely 
blinded to patient identifiers or treatment response of any patient. 
RNALater Samples – the samples frozen in RNALater will be shipped 
frozen to Sudbury Ontario to be processed by RNA Diagnostics Inc. under the 
supervision of Dr. Amadeo Parissenti. The RNA integrity will be assessed and 
quantified. Samples will be de-identified so that the analysis will be completed 
prior to any information regarding patient identifiers or individual treatment 
response.  If sufficient RNA quality is identified in a given tumour sample, its DNA 
and RNA will be extracted. DNA copy counts of proteins felt to be involved in 
treatment resistance will be measured and full genomic RNA array analysis will 
be performed using micro-array technology. The remaining sample products will 
be kept for  potential micro-proteomic analysis if required to quantify tumour 
proteins felt to be involved in treatment resistance.  
Immunohistochemical Protein Expression Analysis: Samples which are 
paraffin-embedded will be analyzed using immunohistochemical (IHC) staining 
for the proteins involved in drug or treatment resistance or apoptosis. 
Laser Cytometric Analysis of Cancer Stem Cells – samples which are 
flash-frozen will be analyzed for cancer stem cell population counts per 0.4µm 
slide using immunofluorescence for markers of breast cancer stem cells including 
CD24, CD44 and ALDH and measured by computerized cell count analysis. 
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III.3.2 Chemotherapy Treatment 
The planned regimen is 3 cycles of FEC (5-fluorouracil 500mg/m2, 
epirubicin 100mg/m2 and cyclophosphamide 500mg/m2 intravenously) every 21 
days to be followed by concurrent daily radiation with once weekly docetaxel 
35mg/m2 IV for 6 weeks.  Upon completion of the concurrent treatment, subjects 
will continue on with weekly docetaxel for an additional 3 weeks.  In the study of 
concurrent radiation with bi-weekly paclitaxel, although all women were able to 
complete the 6-week course of chemoradiation, over 90% of subjects required 
more than the planned 2 weeks for skin recovery from completion of treatment to 
surgery. The additional chemotherapy will allow time for tissue healing 
preoperatively, as well as give a complete course of systemic treatment.  This will 
be followed by primary surgery 5 weeks after completion of chemotherapy. 
Women with Her2/neu positive breast cancer will receive neoadjuvant 
trastuzumab as per standard of care.  The trastuzumab will be initiated with 
docetaxel at the start of chemoradiation.  Although trastuzumab is associated 
with a small risk of cardiotoxicity, the updated results of adjuvant studies do not 
demonstrate any increased risk, even when trastuzumab is administered 
concurrently with radiation or taxanes. Monitoring for cardiac toxicity of 
trastuzumab will be done as per institutional standard at the London Regional 
Cancer Program with wall motion study performed every 3 months while on 
therapy. Dose modification will be made as per international and institutional 
guidelines for Trastuzumab-associated cardiac dysfunction.  Trastuzumab will be 
continued for a total duration of 1 year as per standard of care. 
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Women with estrogen receptor positive breast cancer will receive 
endocrine therapy according to their menopausal status.   This will be initiated 
after completion of their systemic chemotherapy. 
 
III.3.2.1 Administration of Chemotherapy 
G-CSF not routinely given, but could be given as per LRCP standard. 
Timetable of administration of FEC is as follows: 
• standard prophylaxis with antinausea and antiemetics 
• 0min – start hydration using 500ml/hr 0.9% NaCl for a total of 500ml 
• 15min – Fluorouracil 500,mg/m2 IV push then Epirubicin 100mg/m2 IV 
push by chemo suite nurse over 5-10min 
• 20min – Cyclophosphamide 500mg/m2 IV infusion, full dose over 40min 
• 60min – flush with 0.9% NaCl and disconnect the patient 
 
Docetaxel will be given weekly for 9 weeks. Her2/neu positive breast 
cancer will receive trastuzumab with docetaxel at the start of chemoradiation and 
the protocol is as follows: 
• week 1 – start trastuzumab, over 90min, 1hr observation 
• week 4 – start trastuzumab, over 60min, 30min observation 
• week 7 – start trastuzumab, over 30min, 30min observation 
• week 11 – start trastuzumab, over 30min, no observation 
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On the evening prior to chemotherapy, dexamethasone (8mg tablet) will be taken 
by the patient. Docetaxel administration during week 1 and week 2 will be as 
follows: 
• 0min – start hydration using 500ml/hr 0.9% NaCl for a total of 500ml 
• patient receives another 8mg dexamethasone from chemo suite nurse 
• 15min – docetaxel 35mg/m2 in 250 ml of 0.9% NaCl infused as:  
o ¼ rate for first 15 minutes, then BP check by nurse 
o ½ rate for next 15 minutes, then BP check by nurse 
o ¾ rate for next 15 minutes, then BP check by nurse 
o full rate for remaining 60 minutes, then BP check by nurse 
Patient is then taken to radiation suite to receive daily regional breast 
radiation (IMRT) for first 2 weeks. On the evening of chemotherapy, 
dexamethasone (8 mg tablet) is taken by the patient. 
During week 3 to 9 (if patient tolerates the docetaxel without significant 
hypotension), dexamethasone (8mg tablet) is taken by the patient on the evening 
prior to chemotherapy; docetaxel administration will be as follows: 
• 0min – start hydration using 500ml/hr 0.9% NaCl for a total of 500ml 
• patient receives another 8mg dexamethasone from chemo suite nurse 
• 15min – docetaxel 35mg/m2 in 250 ml of 0.9% NaCl infused at full rate for 
60 minutes, then BP checked by nurse. 
Patient is then taken to radiation suite to receive daily regional breast 
radiation (IMRT) for first 2 weeks. On the evening of chemotherapy, 
dexamethasone (8mg tablet) is taken by the patient. During all infusions of 
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docetaxel, patient is wearing ice mitts and ice slippers to minimize toxicity to nail 
beds. 
In the event of toxicity, the doses of FEC and docetaxel will be adjusted 
according to the guidelines shown in the dose delays/modifications table (Table 
III.1).  If an adverse event is not covered in this table, doses may be reduced or 
held at the discretion of the investigator for the subject’s safety.  Dose 
adjustments for hematologic toxicity are based on the blood counts obtained in 
preparation for the day of treatment. 
No dose reductions will be made for any hypersensitivity reactions. All 
patients receiving docetaxel will also receive dexamethasone (8mg PO) night 
prior, 1hour prior and immediately prior to docetaxel administration. If, despite 
pre-treatment, the patient experiences a hypersensitivity reaction, treatment 
should be as indicated in Table III.2. 
 
III.3.2.2 Side Effects – FEC Chemotherapy 
These side effects, occur in 25%-50% of patients taking the chemotherapy 
used in this study: 
• Nausea, vomiting, fatigue 
• Lowered white blood cell count (may lead to infection), lowered red blood 
cell count (may lead to anemia, tiredness, shortness of breath) 
• Irregular or permanent stoppage of menstrual cycles, inability to get 
pregnant 
• Complete hair loss  
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Table III.1 Rules for dose and schedule adjustments in LABC patients. 
 
FEC x 3 cycles (wk 1-9) 
 Grade Treatment Modification 
Myelosuppression: 
 
Asymptomatic NP 
 
 
 
 
Febrile NP 
 
 
 
Asymptomatic TCP 
 
 
<1.5 x 109/L 
 
 
 
 
<1.5 x 109/L 
Temp ≥ 38.5ºCor  
38.3ºC at least 1hr apart 
 
Platelets ≤75x 109/L 
 
 
Defer 1 week  
If defer >1wk:dose-reduce all agents 
of FEC by 20% subsequently 
 
Dose reduce all agents of FEC by 
20% subsequently 
 
 
 
Hold FEC until platelets  
>75x 109/L. 
 
All other toxicities 
(except alopecia) 
 
Grade 3/4 
 
Hold until resolve to ≤ Grade 1 
 
Weekly docetaxel with concurrent radiation (wk 10-15) 
 
Myelosuppression: 
 
Asymptomatic NP 
 
 
 
 
Febrile NP 
 
 
 
Asymptomatic TCP 
 
 
 
<1.5 x 109/L 
 
 
 
 
<1.5 x 109/L 
Temp ≥ 38.5ºCor  
38.3ºC at least 1hr apart 
 
Platelets ≤75x 109/L 
 
 
 
Defer 1 week  
If defer >1wk:dose-reduce by 20% 
subsequently 
 
 
Dose reduce by 20% subsequently 
 
 
 
Hold FEC until platelets 
>75x 109/L. 
 
Fluid Retention: 
 
 
 
 
Grade 1-2 
 
 
Grade 3  
 
No adjustment mandated; diuretics 
discretionary. 
 
Diuretics mandatory. If life-
threatening despite optimal medical 
management: OFF PROTOCOL 
 
Hypersensitivity 
Reactions: 
  
No dose adjustment. 
Anaphylaxis: OFF PROTOCOL 
 
Hepatic Dysfunction: 
 
 
Total Bili      AST          AlkPhos 
Normal     >1.5xULN   >2.5xULN 
 
Normal     2.5-5xULN         -- 
 
 
Dose Reduce 
       25% 
 
       25% 
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Normal           >5xULN           -- 
 
26-43µmol/L       --                 -- 
 
 >43µmol/L         --                 -- 
       50% 
 
       50% 
        
       75% 
 
Skin Reactions: 
 
 
Acute Gr 1-2 
 
Gr ≥3 
 
No modifications 
 
See section on Radiation Toxicity  
 
All other toxicities 
(except alopecia) 
 
Grade 3/4 
 
Hold until resolve to ≤Grade 1 
 
Weekly docetaxel (wks 16-18) 
 
Myelosuppression: 
 
Asymptomatic NP 
 
 
 
Febrile NP 
 
 
 
Asymptomatic TCP 
 
 
 
<1.5 x 109/L 
 
 
 
<1.5 x 109/L 
Temp ≥ 38.5ºCor  
38.3ºC at least 1hr apart 
 
Platelets ≤75x 109/L 
 
 
 
Defer 1 week begin G-CSF (if 
assessable) if deferred >1wk then 
dose reduce by 20% subsequently 
 
Defer 1 week begin G-CSF (if 
assessable) if deferred >1wk then 
dose reduce 20% subsequently 
 
Hold until platelets >75x 109/L 
 
Fluid Retention: 
 
 
 
 
Grade 1-2 
 
 
Grade 3  
 
No adjustment mandated; diuretics 
discretionary. 
 
Diuretics mandatory. If life-
threatening despite optimal medical 
management: OFF PROTOCOL 
 
Hypersensitivity 
Reactions: 
  
No dose adjustment. 
Anaphylaxis: OFF PROTOCOL 
 
Hepatic Dysfunction: 
 
 
Total Bili      AST          AlkPhos 
Normal     >1.5xULN   >2.5xULN 
 
Normal     2.5-5xULN         -- 
 
Normal    >5xULN              -- 
 
26-43µmol/L       --                 -- 
 
 >43µmol/L         --                 -- 
 
Dose Reduce 
       25% 
 
       25% 
 
       50% 
 
       50% 
        
       75% 
 
Skin Reactions: 
 
 
Acute Gr 1-2 
 
Gr ≥3 
 
No modifications 
 
See section on Radiation Toxicity  
 
All other toxicities 
(except alopecia) 
 
Grade 3/4 
 
Hold until resolve to ≤Grade 1 
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Table III.2 Management of hypersensitivity reaction in LABC patients 
enrolled in the clinical trial. 
 
Mild symptoms: 
Localized cutaneous 
reactions such as mild 
pruritus, flushing, rash 
 
Consider decreasing the rate of infusion until recovery 
from symptoms, stay at bedside and monitor patient. 
Then, complete docetaxel infusion in the initial planned 
rate. 
 
Moderate symptoms: 
Any symptom that is not 
listed above (mild 
symptoms) or below 
(severe symptoms) 
such as generalized 
pruritus, flushing, rash, 
dyspnea, hypotension 
with systolic blood 
pressure >80mmHg. 
 
1. Stop docetaxel infusion 
2. Given diphenhydramine 50mg iv with or without  
Hydrocortisone 100mg IV; monitor patient until 
resolution of symptoms 
3. Resume docetaxel infusion after recovery of 
symptoms; depending on the physician's assessment 
of the patient, docetaxel infusion should be resumed at 
a slower rate, then increased incrementally to the 
initial planned rate, (e.g. Infusion at an 8hr rate for 
5min, then at a 4hr rate for 5min, then at a 2hr rate for 
5min, then finally, resume at the 1hr infusion rate) 
4. Depending on the intensity of the reaction observed, 
additional oral or iv premedication with an 
antihistamine should also be given for the next cycle 
of treatment, and the rate of infusion should be 
decreased initially and then increased back to the 
recommended 1hr infusion, (e.g. infuse at an 8hr rate 
for 5min, then at a 4hr rate for 5min, then at a 2hr rate 
for 5 min, and finally, administer at the 1hr infusion 
rate). 
 
Severe symptoms: 
Any reaction such as 
bronchospasm, 
generalized urticaria, 
systolic blood pressure 
≤80mmHg, angioedema 
 
Stop docetaxel infusion. 
Give diphenhydramine 50mg iv with or without 
hydrocortisone 100mg iv and/or epinephrine as 
needed with physician order: monitor patient until 
resolution of symptoms. 
The same treatment guidelines outlined under 
moderate symptoms (ie. 3rd and 4th point) should be 
followed. If severe reaction recurs despite additional 
premedication, the patient will go off protocol 
treatment. 
 
Anaphylaxis 
(Grade 4 reaction) 
 
OFF PROTOCOL TREATMENT 
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• Temporary red-coloured urine following chemotherapy (not blood) 
• Time away from work 
• Hot flashes (in premenopausal women) 
 
These side effects occur in 10-24% of patients taking the chemotherapy in this 
study: 
• Sores in mouth and/or throat, infection 
• Taste changes 
• Skin and nail changes, including discolouration and peeling 
• Pain at the site where chemotherapy is administered 
 
These side effects occur in 3-9% of patients taking the chemotherapy in this 
study: 
• Diarrhea, constipation, loss of appetite 
• Low platelet count, leading to increased bruising or bleeding 
• Headache, abdominal pain, skin rash/itching, muscle pain, eye irritation 
• Darkening of the soles of the feet or palms of hands 
• Thickening of the walls of the veins used for chemotherapy 
• Blood in the urine 
• Fever 
• Fever with a low white blood cell count 
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Rare but serious side effects that occur in less than 3% of patients taking the 
chemotherapy used in this study include: 
• Decreased ability of the heart to pump blood. If severe, you could have 
shortness of breath and other symptoms of heart failure. (If mild, you may 
not have any symptoms.) 
• Skin damage (due to leakage of the drug) 
• Acute leukemia (cancer of the blood cells) 
• Lung damage 
• Lowered red blood cell count severe enough to require red blood cell 
transfusion; lowered platelet count severe enough to require a platelet 
transfusion 
• Severe infection 
• Blood clots 
• Changes in blood test results that indicate possible liver injury 
• Allergic reaction including itching, hives,rash, flushing, hypersensitivity, 
shortness of breath, wheezing, chest tightness, fever, chills, muscle 
stiffening, severe breathing problems 
 
III.3.2.3 Side Effects – Docetaxel (Taxotere) 
These side effects occur in 25% -50% of patients receiving docetaxel: 
• Hair loss, nausea, vomiting, taste changes 
• Weakness/loss of strength, fatigue 
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• Hot flashes (in premenopausal women), Irregular or permanent stoppage 
of menstrual cycles (periods), inability to become pregnant 
• Skin and nail changes, including discoloration and peeling 
• Lowered white blood cell count (may lead to infection), lowered red blood 
cell count (may lead to anemia, tiredness, shortness of breath) 
• Time away from work 
 
These side effects occur in 10-24% of patients receiving docetaxel: 
• Diarrhea, constipation, loss of appetite 
• Mouth sores, infection 
• Pain in muscles, bones, or joints 
• Headache 
• Fluid retention (bloating or swelling) 
• Numbness, tingling, prickling, and burning in the hands and feet 
 
These side effects occur in 3-9% of patients receiving docetaxel: 
• Ulcers in the stomach or bowels 
• Darkening of the soles of the feet or palms of the hands 
• Peeling of the skin (including hands and feet)  
• Lowered number of platelets (which may lead to increased bruising or 
bleeding) 
• Eye irritation, blurred vision 
• Dizziness 
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• Changes (high or low) in blood pressure 
• Hardening of the walls of the veins used for chemotherapy 
• Reversible changes in blood test results that show possible liver injury 
Symptomatic lung damage generally occurs in fewer than 3 percent of 
patients secondary to docetaxel alone.  Symptomatic lung damage from 
locoregional radiation alone for breast cancer occurs in 5 percent or fewer 
patients, with severe shortness of breath restricting activities of daily living (grade 
3 or greater) occurring in a subset of patients. The combination of docetaxel and 
locoregional radiation for breast cancer may increase the frequency and severity 
of symptomatic lung damage.  
 
These side effects occur in less than 3% of patients receiving docetaxel: 
• Liver failure 
• Gastrointestinal problems (such as bleeding, blockage, or perforation 
[opening of a hole] in the stomach or bowel) 
• Lowered red blood cell count severe enough to require red blood cell 
transfusion 
• Skin and tissue damage in the area surrounding the catheter where the 
chemotherapy drugs are injected 
• Acute leukemia (cancer of the blood cells) 
• Blood clots that may be life-threatening 
• Heart damage, lung damage 
• Severe infection 
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• Inflammation of the pancreas causing abdominal pain 
• Allergic reaction including itching, hives, skin rash, flushing, shortness of 
breath, wheezing, chest tightness, fever, chills, severe shivering, sinus 
congestion, or swelling of face, especially eyelids 
• A group of symptoms which may include a blister-like rash that may be 
severe; fever; inflamed eyes; redness, swelling and painful sores on lips 
and in mouth (If this occurs, you may need to be hospitalized and have IV 
fluids and medicines.)  
 
III.3.3 Radiation Therapy 
Concurrent radiation therapy will start during the first day of docetaxel.  
Radiation therapy will consist of external beam therapy for a total dose of 45Gy in 
25 fractions over 5 weeks. A reduced volume boost of 5.4Gy in 3 fractions to 9Gy 
in 5 fractions will be given to residual gross disease in the breast  and/or regional 
lymph nodes. Gross disease in the high axilla or supraclavicular area will be 
limited to 5.4Gy in 3 fractions maximum boost. If treatment is delivered using 
IMRT, gross disease will be limited to 5.4Gy concomitant boost  (total dose 
50.4Gy in 28 fractions to gross disease and 45Gy in 28 fractions to uninvolved 
breast, axilla, IMC, and supraclavicular volumes). 
 
III.3.3.1 Patient Position and Immobilization 
         Patient is to be placed in the supine position on an angle board with straight 
spine and the ipsilateral arm raised and supported by an armrest and the chin 
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extended with appropriate head rest.  Patient is to be instructed to breathe quietly 
in order to minimize respiratory motion during scanning and treatment. A 
radiopaque breast wire will be placed around the ipsilateral clinical breast mound.  
 
III.3.3.2 Scanning Protocol 
         Serial CT is to be collected utilizing Philips Brilliance large bore CT scanner 
(or equivalent technology).  Three-millimetre thick slices at 3 mm intervals will be 
scanned from the level of the lower jaw to L1 (in order to encompass the whole 
lung volume).  For the single isocenter technique, the junction between the 
breast portals and the regional nodal portals is placed at the level of the inferior 
and medial ipsilateral clavicle. The junction line is marked by tattoos. Intravenous 
contrast is optional but may help with the delineation of gross residual tumor and 
the regional blood vessels. 
 
III.3.3.3 Treatment Planning 
All treatment planning will be performed on the Phillips Pinnacle 
workstation.  In general one of the following three treatment techniques will be 
used: 
a) Single isocenter technique: The single isocenter is located at the level 
of inferior border of the medial head of clavicle. The affected breast and 
ipsilateral internal mammary chain are treated using medial and lateral deep 
tangents with half beam blocking of the superior borders to create a non-
divergent match with the supraclavicular and axillary fields. The tangents can be 
	 176 
non-opposed, if necessary, to create a non-divergent deep/ posterior border 
which can reduce underlying lung in the high dose volume. Both medial and 
lateral shielding should be checked to verify maximum sparing of normal tissues 
and also adequate coverage of any gross disease. The ipsilateral axillary and 
supraclavicular nodes are treated with anterior and posterior oblique fields with 
half beam blocking of the inferior borders to create a non-divergent match with 
the deep tangents. The medial field borders should fall along the medial border of 
the ipsilateral sternomastoid muscle with gantry rotation to avoid the spinal cord 
(usually 8 to 12 degrees gantry rotation to the contra lateral side for the anterior 
supraclavicular - axillary field). The gantry angle for the posterior supraclavicular-
axillary field can be rotated such that the medial border creates a non-divergent 
match with the medial border of the anterior supraclavicular-axillary field. The 
superior border of the supraclavicular fields is usually at the level of the upper 
thyroid cartilage. The ipsilateral larynx, acromio-clavicular joint, and the upper 
one half to two-thirds of the humeral head should be shielded. If the ipsilateral 
lung volume receiving 20Gy exceeds 40 percent and /or if total lung volume 
receiving 20Gy exceeds 25 percent, the following alternative treatment 
techniques should be considered. 
b) Intensity modulated radiation (IMRT) for the involved breast with half 
beam blocking of the superior borders to match the supraclavicular-axillary fields 
described above. This option is especially useful when the supraclavicular-
axillary fields do not encompass much lung but the deep tangents would include 
too much lung. Usually, four or five field step and shot IMRT will reduce dose to 
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lung compared to the preceding technique but more detailed contouring will be 
necessary. Guidelines for treatment planning are in the treatment planning 
module. For this approach, the supraclavicular-axillary fields will receive 45Gy in 
25 fractions over five weeks. The uninvolved breast and lower axilla within the 
IMRT volume will receive 45Gy in 28 fractions (no BED correction) over five and 
a half weeks while gross disease will receive 50.4Gy in 28 fractions over five and 
a half weeks (concomitant boost). If feasible, the uninvolved breast and lower 
axilla and gross disease will be treated, using IMRT, to a dose of 45Gy in 25 
fractions. A reduced volume boost of 5.4Gy in 3 fractions using 3-D conformal 
radiation or IMRT boost is allowed.  
c) IMRT for the entire volume, including the ipsilateral breast, axilla, 
supraclavicualr area, and internal mammary chain. This approach is useful when 
both deep tangents and supraclavicular-axillary fields encompass too much lung. 
Treatment planning requires detailed contouring of normal structures as well as 
target volumes. The ipsilateral breast, the right and left lungs, the heart, the 
larynx and trachea as an organ at risk (OAR) should all be contoured. The target 
volumes will also be contoured as defined below.  
The uninvolved breast, IMC, axilla, and supraclavicular area will receive 
45Gy in 28 fractions. Gross disease will be treated to 50.4Gy in 28 fractions  
 
III.3.3.4 Treatment Delivery 
           All radiation treatment will be delivered on megavoltage machines using 
6MV energy or greater.  Calibration of all radiation treatment machines will be 
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under the supervision of the Department of Radiation Physics at the London 
Regional Cancer Program. 
 
III.3.3.5 Critical Structure Dose Constraints 
 Maximum spinal cord dose shall be 45Gy. In the lung, maximum 30% of 
total normal lung volume is to receive less than or equal to 20Gy. While V20Gy to 
total lung under 30 percent is acceptable, V20Gy under 20 to 25 percent is 
preferred. In the heart, maximum dose to 25% of the heart volume will be less 
than or equal to 25Gy. For the ipsilateral humeral head, maximum dose to 50% 
will be less than or equal to 30Gy. 
 
III.3.3.6 Treatment Interruption 
Any treatment delay of less than one week, radiation should be completed 
to prescribed dose. Any treatment delay of greater than one week, radiation 
should be completed to prescribed dose at the discretion of the treating radiation 
oncologist. All treatment delay causes and the length of the delay shall be 
reported. Any treatment delay of greater than two weeks will result in the patient 
being discontinued from protocol. 
 
III.3.3.7 Deviations in Radiation Protocol 
Prescription Dose: Minor – between 6-10 % difference between protocol 
and prescription dose; major – greater than 10 % difference between protocol  
and prescription dose. 
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Dose Uniformity: Minor – either (-10% to -5%) or (+7% to +10%) variation 
in dose target volume homogeneity; major – dose variation to target greater than 
± 10%. 
Volume: Minor – margins are less than specified or fields excessively 
large; major – transecting tumour of lymph node bearing areas. 
 
III.3.3.8 Radiation Planning 
Target volumes are as follows: 
• Ipsilateral Breast: This is defined as the clinical breast volume harbouring 
malignancy plus any gross clinical tumor extension beyond the ipsilateral 
breast. During treatment planning, it should be marked with a radiopaque 
wire around its periphery. The breast will be the volume bounded by the 
radio-opaque wire, excluding the chest wall and the overlying 5mm of skin. 
•  PTVBREAST: This is the expansion of the BREAST plus 7mm. 
• PTVEVALBREAST: This is the PTVBREAST as defined above minus 
overlying 5mm of skin. 
• GTVPRIMARY: –This is the volume of gross disease in the breast at 
defined at the time of CT simulation and any other available diagnostic 
information including clinical exam. 
• CTVprimary: - GTVPRIMARY plus 1.5cm margin in all directions but 
limited to the anterior aspect of the pectoralis major muscle (if no muscle 
invasion) and to 5 mm or more deep to the skin contour of the breast (if no 
direct skin extension). The deep border of the CTV primary should include 
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the muscle to rib interface if there is pectoralis muscle involvement; the 
superficial border should include the skin surface if there is skin 
involvement. 
• PTVprimary – CTVprimary plus 1cm. 
• PTVevalprimary – PTVprimary constrained to within 5 mm of overlying 
skin, if no skin involvement, or to the skin surface if skin involvement. The 
deep boundary will be the rib to lung interface. 
• GTVNODESBOOST – these are nodes considered to be grossly involved 
in the ipsilateral supraclavicular and axillary area and measuring 7mm or 
more in short axis at the time of planning CT scan. Pretreatment CT scan 
showing the same nodes to be larger can be used to identify significant 
nodes. 
• CTVnodesBOOST – This is the GTVNODESBOOST plus 1cm in all 
directions but limited to the nearest surface of the adjacent muscles 
(pectoralis major or minor, serratus, lattisimus, sternomastoid) and to 5mm 
or more deep to the overlying skin. It should also lie within the CTVAXSC. 
The superficial border should include the skin surface if there is skin 
involvement. 
• PTVNODESBOOST – this is CTVnodesBOOST expanded by 7 to 10mm 
(use 7mm except in large patients). 
• PTVEVALNODESBOOST – this is PTVNODESBOOST minus the 
overlying 5mm of skin and minus any underlying lung.  
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• CTVIMC – this is the contour of the ipsilateral IMC vessels expanded 
medially to touch the ipsilateral border of the sternum at the level of the 
first, second, and third intercostal spaces. Any visible lymph nodes at 
these 3 levels should be contoured and expanded by 7mm. The CTVIMC 
should include the visible nodes plus the 7mm expansion. 
• PTVIMC – this is the CTVIMC expanded by 7mm. 
• PTVEVALIMC – this is the PTVIMC minus underlying lung and heart. 
• CTVAXSC: This volume encompasses the axillary and supraclavicular 
lymph nodes at risk. The inferior level is usually at the level of the fifth rib 
in the mid-axillary line or at least 1cm below any grossly visible lower 
axillary lymph nodes. The lateral border is at least 1cm lateral to any 
visible lymph nodes in the low to mid axilla (level 1 and 2 nodes) and 
usually lies within a line drawn from the lateral edge of pectoralis major 
and the lateral edge of the latissimus muscle. At the level of the high axilla 
(level 3 nodes), the lateral border is medial to the coracoid. At the level of 
the supraclavicular area, the lateral border is at the mid-clavicular line. 
The medial border, anterior, and posterior borders of the axilla are formed 
by the nearest surfaces of the adjacent muscles (pectoralis, serratus, 
lattissimus). The supraclavicular fossa is bounded medially by the lateral 
margin of the sternomastiod muscle. Inferiorly, contouring may continue 
deep to the medial clavicle where the subclavian crosses the lung apex at 
the level of the first rib posteriorly to join the internal jugular. Care should 
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be taken to avoid extending the volume medially towards the thyroid and 
the larynx, unless there is gross supraclavicular adenopathy. 
• PTVNODES – this is CTVAXSC and CTVIMC expanded by 7mm. 
• PTVEVALNODES – this is PTVNODES minus 5mm of overlying skin and 
minus lung and heart. 
 
Beam arrangement will be as follows: Phase I – the target volume is the 
ipsilateral breast plus tumour extension, the ipsilateral supraclavicular and 
axillary regions, the PTV primary, and the PTV nodal. Phase II – the target 
volume is any gross residual disease remaining at the time of CT simulation. 
Repeat CT simulation may be required if there has been more than a 2cm 
shrinkage in the surface contour secondary to tumor shrinkage. If feasible, gross 
residual tumor in the breast and or regional nodes can be boosted with direct 
electrons and clinical setup. For gross tumor more than 5cm deep to overlying 
skin, reduced volume boosts using multiple photon fields may be necessary 
(parallel pair in axilla, reduced tangents in breast, or 3 or 4 field techniques could 
be used).  
Dose and Fractionation will be as follows: Phase I – the dose will be 45Gy 
in 25 daily fractions over 5 weeks. Ninety-five percent of the PTVEVALs should 
receive 95% of this dose. Dose variation within the breast should be no more 
than +7% and no less than -5%.  Phase II – the boost dose will be 9Gy in 5 daily 
fractions over 1 week. If there is concern that the residual gross tumor volume is 
too extensive, the boost will be limited to 5.4Gy in 3 fractions over 1 week. Any 
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gross residual in the supraclavicular or high axillary area will be limited to a boost 
of 5.4Gy in 3 fractions Patients receiving concomitant boost with IMRT will 
receive 45Gy in 28 fractions to uninvolved areas and 50.4Gy in 28 fractions to 
grossly involved primary tumor and nodes.  
 Beam modifiers, such as shielding, multi-leaf collimators, wedges and 
compensators are allowed. 
Prescription point: for the tangents, this will usually be the point at a depth 
of two-thirds of the distance from the overlying skin contour to the posterior 
tangents at mid-separation. The normalization point is placed away from the 
underlying lung. For the supraclavicular and axillary fields, the prescription point 
is at midplane. 
Bolus (0.5cm thickness) will be placed to cover and gross skin extension 
of tumor or skin ulceration as   well as any inflammatory skin involvement (note: 
patients with inflammatory breast cancer are not part of this protocol). Bolus 
should extend 1 to 2cm beyond the visible skin involvement. 
 
III.3.3.9 Radiation Toxicities 
 These include the following: 
• Radiation pneumonitis: symptomatic pneumonitis from radiation alone 
occurs in 1 to 5 percent of patients and can range in severity from a dry 
cough to severe shortness of breath requiring medical management 
(including admission to hospital, use of oxygen, steroids, and inhalers) but 
is almost always self-limited. The combination of chemotherapy and 
	 184 
radiation for breast cancer may increase the frequency and severity of 
symptomatic lung injury from treatment. The clinical course of such lung 
injury has not been well documented and there is the potential risk of 
permanent shortness breath secondary to treatment. Treatment for 
symptomatic acute pneumonitis is typically oral corticosteroids. Initiate 
prednisone at 50mg orally for one to two weeks.  Reduce the dosage by 
fifty percent every 3 to 5 days based on patient symptomatic improvement. 
A more gradual taper of steroids may be appropriate for some patients. 
The majority of patients with pneumonitis recover. Progressive symptoms 
requiring oxygen or hospitalization are uncommon. 
• Brachial plexopathy: this complication occurs in one percent or less of 
patients at doses of 50 to 54Gy in 2Gy or 1.8Gy fractions, respectively. 
Transient plexopathy can occur within the first few months post radiation 
but later plexopathy can be permanent.  
• Rib fractures: this occurs in 2 percent or less of patients 
• Lymphedema: upper limb edema of any degree can occur in 10 to 20 
percent of patients but moderate to severe lymphedema occurs in 5 
percent or less of patients. Lymphedema can be permanent. 
• Cardiac toxicity: the risk of fatal MI from radiotherapy is estimated at 1 
percent or less. Acute pericarditis is also uncommon (less than 1 percent).  
• Second malignancies: there are reports of increase in lung cancer post   
radiotherapy for breast cancer. Skin cancers and rare sarcomas rarely 
occur post radiotherapy. 
	 185 
• Wound dehiscence requiring surgery: the rate of this complication is 
expected to be less than 5%. 
 
Any of the above toxicities graded by NCIC/CTC v3.0 at grade 4 will be 
assessed by the PI, radiation oncologist and medical oncologist together to 
determine whether to stop radiation or docetaxel. There is concern that acute 
skin toxicity will be increased by the combination of chemotherapy and radiation 
but it is expected that most patients will complete the full regimen. It is common 
with locoregional radiation alone for patients to develop patches of moist 
desquamation in areas of skin folds like the axilla, infra-mammary crease, and 
medial neck. These acute skin reactions alone will not require treatment 
modification. General acute radiation skin toxicity management guidelines and 
treatment modifications during radiation are as follows: 
(a) Grade 3 or greater (moist desquamation other than skin folds) acute skin 
reaction affecting more than 25 percent of the breast surface (excluding 
areas of direct skin involvement by tumor) or more than 25 percent of the 
supraclavicular skin surface: Hold both radiation and docetaxel up to one 
week until healing visible and then re-start docetaxel and radiation with no 
dose modifications. 
(b) Grade 3 or greater acute skin reaction of onset earlier than fraction 16 of 
radiation (start of week 4): Hold both radiation and docetaxel up to one 
week until healing visible and then re-start docetaxel and radiation with no 
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dose modifications. Consider the possibility of acute cellulitis and manage 
with antibiotics as well, if index of suspicion high. 
(c) Grade 3 or greater acute skin reaction as in 1 or 2 above but requiring 
more than one week but less than 2 weeks to show signs of healing: Re-
start radiation alone and discontinue docetaxel.  
(d) Grade 3 or greater acute skin reaction as in 1 or 2 above but with no 
healing within 2 weeks treatment break: Discontinue both docetaxel and 
radiation.  
 
Management of grade 3 or greater acute skin reaction includes flamazine 
applied topically 2 to 3 times a day (polysporin triple could be considered in 
patients allergic to flamazine). If superimposed acute cellulitis is suspected, 
antibiotic management for cellulitis can be initiated as well. Grade 4 radiation skin 
toxicity will be treated symptomatically in keeping with best clinical practice as 
already decided by the breast multi-disciplinary team regarding this protocol. 
Early experiences with the first ten patients going through this treatment 
protocol have raised concern about increased incidence and severity of radiation 
pneumonitis. Toxicity on this protocol is being monitored by an independent data 
safety monitoring committee.  Clinical shortness of breath secondary to radiation 
typical develops after radiation treatment is completed and usually one to four 
months post radiation. Among the first ten patients, clinical shortness of breath 
developed within the first few weeks after radiation and docetaxel. Shortness of 
breath was grade 3 in 3 of ten 10 patients and, in 2 of the 3 patients, was felt to 
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be definitely treatment related. In all 3 patients shortness of breath responded 
quickly to steroids and all 3 went on to definitive surgery without any delay.  Only 
1 of the 3 women has residual shortness of breath grade 2.  This patient had a 
significant history of smoking and continued to smoke throughout treatment. 
Complete pathologic response occurred in 5 of the first 10 patients, well above 
the 20% reported in the literature for chemotherapy alone.  The breast 
multidisciplinary team decided that an acceptable incidence of grade 3 
pneumonitis that does not improve to grade 1 or less within 8 weeks from the end 
of radiation or prior to surgery date as per protocol is five percent or lower.   As 
well grade 3 or greater shortness of breath attributed to treatment that does not 
improve to grade 1 or less within 8 weeks from the end of radiation or prior to 
surgery date as per protocol is five percent or lower. 
Pneumonitis assessment and management are as follows: 
(a) all patients should have baseline pulmonary function studies;  
(b) clinical considerations in evaluating a patient with shortness of breath during 
or after docetaxel and radiation include pulmonary, emboli, infection, cardiac 
dysfunction, and treatment related pneumonitis; 
(c) in addition to clinical assessment, patients reporting worsening shortness of 
breath at any time during radiation should have a complete blood count with 
differential and a chest x-ray. Respirology referral is appropriate if the patient has 
fever, neutropenia less than 1.0, or is not responding to medical treatment of 
pneumonitis; 
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(d) patients reporting grade 3 shortness of breath during or after completing 
radiation should have a CT scan of the thorax. Repeat CT scans of the thorax will 
be done as clinically indicated in patients who initially presented with grade 3 or 
greater shortness of breath felt to represent treatment related pneumonitis. It is 
recommended that CT thorax be obtained at 3 to 6 months post docetaxel and 
radiation in patients who initially present with grade 3 or greater pneumonitis, 
especially if there is residual shortness of breath; 
(e) medical management of docetaxel and radiation related pneumonitis: 
• Medical management is individualized. 
• Grade less than or equal to 2 shortness of breath: follow up only is 
appropriate.  
• Grade 3 or greater shortness of breath: Initiate prednisone at 50mg 
orally daily for one to two weeks.  Reduce the dosage by fifty 
percent every 3 to 5 days based on patient symptomatic 
improvement. A more gradual taper of steroids may be appropriate 
for some patients. If the patient is not responding to treatment, 
respirology consultation is appropriate. Pentoxifylline 400mg orally 
three times a day could be considered in patients who are still quite 
symptomatic despite steroids for more than two weeks. 
Pentoxifylline has been tested in a double blind, randomized clinical 
trial versus placebo but was given throughout radiation. 
(f) stopping rules for treatment related pneumonitis: a data safety monitoring 
committee review will be held if the number of patients with incidence of grade 3 
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pneumonitis (attributed to treatment) does not improve to grade 1 or less within 8 
weeks from the end of radiation or prior to surgery date as per protocol;   
exceeds 2 of the first ten patients, 3 of the first twenty patients, 4 of the first 30 
patients, or 5 of the first 40 patients (Table III.3). Toxicity profiles, risks and 
benefits, and the study protocol will be reviewed by the data safety monitoring 
committee. Protocol modifications will be discussed and reviewed by the breast 
multidisciplinary team. The revised study protocol will be approved by the data 
safety monitoring committee and the ethics review board before continuing. 
 
 
III.4 MEASUREMENT OF EFFECT 
 For the purposes of this study, patients should be evaluated every 3 
weeks during active treatment by caliper or ruler measurement.  Where feasible, 
the caliper measurement is to be done by the same investigator. 
Response and progression will be evaluated in this study using the new 
international criteria proposed by the Response Evaluation Criteria in Solid 
Tumors (RECIST) Committee. Changes in only the largest diameter 
(unidimensional measurement) of the tumor lesions are used in the RECIST 
criteria. Note:  Lesions are either measurable or non-measurable using the 
criteria provided below. The term “evaluable” in reference to measurability will not 
be used because it does not provide additional meaning or accuracy. 
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Table III.3. Stopping rules for treatment-related pneumonitis in the 
experimental treatment protocol in LABC patients. 
 
 
 
N 
Largest acceptable value First non-acceptable value 
# Cases (%) Exact 95% CI # Cases (%) Exact 95% CI 
 
10 
 
2 (20%) 
 
2.5% - 55.6% 
 
3 (30.0%) 
 
6.7% - 65.3% 
 
20 
 
3 (15.0%) 
 
3.2% - 37.9% 
 
4 (20.0%) 
 
5.7% - 43.7% 
 
30 
 
4 (13.3%) 
 
3.8% - 30.7% 
 
5 (16.7%) 
 
5.6% - 34.7% 
 
40 
 
5 (12.5%) 
 
4.2% - 26.8% 
 
6 (15.0%) 
 
5.7% - 29.8% 
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III.4.1 Definitions 
III.4.1.1 Measurable Disease 
Measurable lesions are defined as those that can be accurately measured 
in at least one dimension (longest diameter to be recorded) as ≥20mm with 
conventional techniques (CT, MRI, x-ray) or as ≥10mm with spiral CT scan.  All 
tumor measurements must be recorded in millimeters (or decimal fractions of 
centimeters). 
 
III.4.1.2 Non-Measurable Disease 
All other lesions (or sites of disease), including small lesions (longest 
diameter <20mm with conventional techniques or <10mm using spiral CT scan), 
are considered non-measurable disease.  Bone lesions, leptomeningeal disease, 
ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonis, inflammatory 
breast disease, abdominal masses (not followed by CT or MRI), and cystic 
lesions are all non-measurable. 
 
III.4.1.3 Target Lesions 
All measurable lesions up to a maximum of five lesions per organ and 10 
lesions in total, representative of all involved organs, should be identified as 
target lesions and recorded and measured at baseline.  Target lesions should be 
selected on the basis of their size (lesions with the longest diameter) and their 
suitability for accurate repeated measurements (either by imaging techniques or 
clinically).  A sum of the longest diameter (LD) for all target lesions will be 
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calculated and reported as the baseline sum LD. The baseline sum LD will be 
used as reference by which to characterize the objective tumor response. 
 
III.4.1.4 Non-Target Lesions 
All other lesions (or sites of disease) should be identified as non-target 
lesions and should also be recorded at baseline.  Non-target lesions include 
measurable lesions that exceed the maximum numbers per organ or total of all 
involved organs as well as non-measurable lesions. Measurements of these 
lesions are not required, but the presence or absence of each should be noted 
throughout follow-up. 
 
 
III.4.2 Guidelines for Evaluation of Measurable Disease 
All measurements should be taken and recorded in metric notation using a 
ruler or calipers.  All baseline evaluations should be performed as closely as 
possible to the beginning of treatment and never more than 4 weeks before the 
beginning of the treatment. Tumor lesions that are situated in a previously 
irradiated area must not be the only site of measurable disease. 
The same method of assessment and the same technique should be used 
to characterize each identified and reported lesion at baseline and during follow-
up. Imaging-based evaluation is preferred to evaluation by clinical examination 
when both methods have been used to assess the antitumor effect of a treatment. 
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III.4.2.1 Clinical Lesions 
  Clinical lesions will only be considered measurable when they are 
superficial (e.g., skin nodules and palpable lymph nodes).  In the case of skin 
lesions, documentation by colour photography, including a ruler to estimate the 
size of the lesion, is recommended.  
 
III.4.2.2 Chest X-ray 
Lesions on chest x-ray are acceptable as measurable lesions when they 
are clearly defined and surrounded by aerated lung.  However, CT is preferable. 
 
III.4.2.3 Conventional CT and MRI 
These techniques should be performed with cuts of 10mm or less in slice 
thickness contiguously.  Spiral CT should be performed using a 5mm contiguous 
reconstruction algorithm.  This applies to tumors of the chest, abdomen, and 
pelvis.  Head and neck tumors and those of extremities usually require specific 
protocols. 
 
III.4.2.4 Ultrasound (US) 
When the primary endpoint of the study is objective response evaluation, 
US should not be used to measure tumor lesions.  It is, however, a possible 
alternative to clinical measurements of superficial palpable lymph nodes, 
subcutaneous lesions, and thyroid nodules.  US might also be useful to confirm 
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the complete disappearance of superficial lesions usually assessed by clinical 
examination. 
 
III.4.2.5 Endoscopy and Laparoscopy 
The utilization of these techniques for objective tumor evaluation has not 
yet been fully and widely validated.  Their uses in this specific context require 
sophisticated equipment and a high level of expertise that may only be available 
in some centers.  Therefore, the utilization of such techniques for objective tumor 
response should be restricted to validation purposes in reference centers. 
However, such techniques may be useful to confirm complete pathological 
response when biopsies are obtained. 
 
III.4.2.6 Tumour Markers 
Tumor markers alone cannot be used to assess response.  If markers are 
initially above the upper normal limit, they must normalize for a patient to be 
considered in complete clinical response. Specific additional criteria for 
standardized usage of prostate-specific antigen (PSA) and CA-125 response in 
support of clinical trials are being developed. 
 
III.4.2.7 Cytology and Histology 
These techniques can be used to differentiate between partial responses 
(PR) and complete responses (CR) in rare cases (e.g., residual lesions in tumor 
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types, such as germ cell tumors, where known residual benign tumors can 
remain). 
The cytological confirmation of the neoplastic origin of any effusion that 
appears or worsens during treatment when the measurable tumor has met 
criteria for response or stable disease is mandatory to differentiate between 
response or stable disease (an effusion may be a side effect of the treatment) 
and progressive disease. 
 
III.4.3 Response Criteria 
III.4.3.1 Evaluation of Target Lesions 
The definitions are as follows: 
• Complete Response (CR): Disappearance of all target lesions; 
• Partial Response (PR): At least a 30% decrease in the sum of the longest 
diameter (LD) of target lesions, taking as reference the baseline sum LD; 
• Progressive Disease (PD):  At least a 20% increase in the sum of the LD 
of target lesions, taking as reference the smallest sum LD recorded since 
the treatment started or the appearance of one or more new lesions; 
• Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor 
sufficient increase to qualify for PD, taking as reference the smallest sum 
LD since the treatment started. 
 
III.4.3.2 Evaluation of Non-Target Lesions 
The definitions are as follows: 
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• Complete Response (CR):  Disappearance of all non-target lesions and 
normalization of tumor marker level; 
• Incomplete Response/Stable Disease (SD): Persistence of one or more 
non-target lesion(s) and/or maintenance of tumor marker level above the 
normal limits; 
• Progressive Disease (PD): Appearance of one or more new lesions and/or 
unequivocal progression of existing non-target lesions. 
Although a clear progression of “non-target” lesions only is exceptional, in 
such circumstances the opinion of the treating physician should prevail, and the 
progression status should be confirmed at a later time by the review panel (or 
study chair). Note: If tumor markers are initially above the upper normal limit, 
they must normalize for a patient to be considered in complete clinical response. 
 
III.4.3.3 Evaluation of Best Overall Clinical Response 
The best overall response is the best response recorded from the start of 
the treatment until disease progression/recurrence (taking as reference for 
progressive disease the smallest measurements recorded since the treatment 
started) (Table III.4). Patients with a global deterioration of health status requiring 
discontinuation of treatment without objective evidence of disease progression at 
that time should be classified as having “symptomatic deterioration.”  Every effort 
should be made to document the objective progression, even after 
discontinuation of treatment. 
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Table III.4. Evaluation of best clinical response in LABC patients 
undergoing clinical trial experimental protocol. 
 
 
Target Lesions 
 
Non-Target Lesions 
 
New Lesions 
 
Overall Response 
 
CR 
 
CR 
 
No 
 
CR 
 
CR 
 
Incomplete 
response/SD 
 
No 
 
PR 
 
PR 
 
Non-PD 
 
No 
 
PR 
 
SD 
 
Non-PD 
 
No 
 
SD 
 
PD 
 
Any 
 
Yes or No 
 
PD 
 
Any 
 
PD 
 
Yes or No 
 
PD 
 
Any 
 
Any 
 
Yes 
 
PD 
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III.4.4 Confirmatory Measurement of Pathological Response 
The final assessment of tumour response will be made by one and the 
same independent pathologist (confirmed by an unbiased secondary assessment 
by a second pathologist) based on the pathological assessment of the entire 
surgical specimen, according to current standards accepted by the Canadian 
Association of Pathologists, examining the entire specimen and taking 
representative blocks of tissue for analysis. Pathological response will be 
subcategorized as follows: 
pCR – pathological complete response (no residual invasive breast cancer 
in the breast tissue); 
pSPR – pathological significant partial response (<10 foci of microscopic 
invasive tumour within breast); 
pPR – pathological partial response (<30% of original invasive breast 
tumour volume remaining); 
SD – stable disease (30-80% of original invasive breast tumour volume 
remaining); 
NR – no response (81-120% of original invasive breast tumour volume 
remaining); 
DP – disease progression (>120% of original invasive breast tumour 
volume remaining).  
The baseline diagnostic breast MRI will be used to calculate the pre-
treatment tumour volume, as a surrogate measure for true pathological in vivo 
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tumour volume, given that it remains our most sensitive means of estimating in 
vivo breast tumour volume. 
 
III.4.4.1 Duration of Overall Response 
The duration of overall response is measured from the time measurement 
criteria are met for CR or PR (whichever is first recorded) until the first date that 
recurrent or progressive disease is objectively documented (taking as reference 
for progressive disease the smallest measurements recorded since the treatment 
started). 
The duration of overall CR is measured from the time measurement 
criteria are first met for CR until the first date that recurrent disease is objectively 
documented. 
 
III.4.4.2 Duration of Stable Disease 
Stable disease is measured from the start of the treatment until the criteria 
for progression are met, taking as reference the smallest measurements 
recorded since the treatment started.  
 
III.4.4.3 Progression-Free Survival 
Progression free survival is defined as the duration of time from start of 
treatment to progression (as defined above), death or last contact, or last tumor 
assessment before the start of further antitumor therapy. 
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III.4.5 Adverse Event Reporting 
The safety committee will consist of, at a minimum, the principal 
investigator, a statistician, the data manager, and one independent physician.  
They will meet annually and as required. 
Toxicities occurring as a result of treatment should be reported to the 
principal investigator and the Data Collection Centre at the Clinical Research Unit 
of the London Regional Cancer Program in the manner described below.  In 
addition, the IRB/REB will be notified in keeping with good clinical practice 
guidelines. 
 The investigator is responsible for the detection and documentation of 
events meeting the definition of an adverse event (AE) or serious adverse event 
(SAE) as provided in this section of the protocol.  In order to fulfill international 
safety reporting obligations, the investigator should include in his or her 
assessment any SAEs resulting from study participation (e.g., complications 
resulting from the taking of a blood sample). 
 
III.4.5.1 Definition of an AE 
An AE is any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily have a causal relationship with this treatment. An AE can, therefore, 
be any unfavourable and unintended sign (that could include a clinically 
significant abnormal laboratory finding), symptom, or disease temporarily 
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associated with the use of a medicinal product, whether or not considered related 
to the medicinal product. 
An AE does include a/an: 
• exacerbation of a pre-existing illness. 
• increase in frequency or intensity of a pre-existing episodic event or 
condition. 
• condition detected or diagnosed after study drug administration even 
though it may have been present prior to the start of the study. 
• continuous persistent disease or symptoms present at baseline (including 
cancer signs and symptoms if more severe than expected) that worsen following 
the start of the study. 
 
An AE does not include a/an: 
• medical or surgical procedure (e.g., surgery, endoscopy, tooth extraction, 
transfusion); the condition that leads to the procedure is an AE. 
• pre-existing disease or conditions present or detected at the start of the 
study that do not worsen. 
• situations where an untoward medical occurrence has not occurred (e.g. 
hospitalizations for cosmetic elective surgery, social and/or convenience 
admissions). 
• the disease or disorder being studied or sign or symptom associated with 
the disease or disorder unless more severe than expected for the subject’s 
condition (e.g. subjects with advanced stages of cancer are expected to 
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experience progression of disease including increased tumor size, new sites of 
disease, malignant pleural effusion, malignant ascites, and death due to cancer). 
• overdose of either study drug or concurrent medication without any signs 
or symptoms. 
  
 
III.4.5.2 Definition of an SAE 
An SAE is any adverse event occurring at any dose that results in any of 
the following outcomes: 
• death 
• a life-threatening adverse event. 
• inpatient hospitalization or prolongation of existing hospitalization. 
• a disability/incapacity. 
• a congenital anomaly in the offspring of a subject who received study drug. 
• important medical events that may not result in death, be life-threatening, 
or require hospitalization may be considered a serious adverse event when, 
based upon appropriate medical judgment, they may jeopardize the patient or 
subject and may require medical or surgical intervention to prevent one of the 
outcomes listed in this definition.  Examples of such medical events include 
allergic bronchospasm requiring intensive treatment in an emergency room or at 
home, or convulsions that do not result in inpatient hospitalization, or the 
development of drug dependency or drug abuse. 
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Clarifications: 
• “Occurring at any dose” does not imply that the subject is receiving study 
drug. 
• Life-threatening means that the subject was, in the view of the investigator, 
at immediate risk of death from the event as it occurred.  This definition does not 
include an event that, had it occurred in a more severe form, might have caused 
death. 
• Hospitalization for elective treatment of a pre-existing condition that did 
not worsen during the study is not considered an SAE. 
• Complications that occur during hospitalization are AEs.  If a complication 
prolongs hospitalization, the event is an SAE. “Inpatient” hospitalization means 
the subject has been formally admitted to a hospital for medical reasons.  This 
may or may not be overnight.  It does not include presentation a casualty or 
emergency room. 
• With regard to criteria above, medical and scientific judgment should be 
used when deciding whether prompt reporting is appropriate in this situation. 
 
Events or Outcomes Not Qualifying as SAEs: Any sign, symptom, 
diagnosis, illness, and/or clinical laboratory abnormality that can be linked to the 
disease under study or disease progression and is not possibly attributable to 
study drug, are not reported as SAEs even though such event or outcome may 
meet the definition of SAE. 
• Events that are exempt from reporting as serious adverse events include: 
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• Events emerging during the study that are part of the natural progression 
of the underlying cancer (including disease-related deaths) unless more severe 
than expected or not possibly attributable to study drug. For example, 
hospitalization for the evaluation or treatment of signs and symptoms of disease 
progression that are not possibly attributable to study drug will not be reported as 
an SAE.  
• SAE that occur more than 28 days after the final dose of study drug that 
are judged by the investigator to be unrelated to prior treatment with study drug. 
 
III.4.5.3 Lack of Efficacy as an AE or SAE 
“Lack of efficacy” (e.g., disease progression as documented by increased 
tumor size, increased number of lesions, new sites of disease, malignant pleural 
effusions, malignant ascites and death due to cancer) per se will not be reported 
as an AE.  The signs and symptoms or clinical sequelae resulting from lack of 
efficacy should be reported if they fulfill the AE or SAE definition (including 
clarifications). 
 
III.4.5.4 Clinical Laboratory Abnormalities and Other Abnormal Assessments as 
AEs and SAEs 
A laboratory abnormality per se will not be recorded as an AE or SAE 
unless it is serious (See definition of an SAE), represents the primary reason for 
treatment or study discontinuation, or is associated with a clinical diagnosis. 
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Sequelae of laboratory abnormalities (e.g., sepsis or fever in subjects with 
neutropenia) will be recorded on the Serious Adverse Event page. 
Findings from disease assessments (e.g., CT scans, MRI scans, X-rays, 
bone scans, physical examinations or medical photographs) will not be recorded 
as AEs or SAEs. Clinically significant abnormal findings or assessments (e.g., 
vital signs, electrocardiograms, physical examinations excluding disease 
assessments) that are detected after study drug administration or that are 
present at baseline and worsen following the start of the study are included as 
AEs and SAEs. 
The investigator should exercise his or her medical and scientific judgment 
in deciding whether an abnormal finding or assessment is clinically significant. 
 
III.4.5.5 Method, Frequency, and Time Period for Detecting AEs and SAEs 
All adverse events and serious adverse events (except as noted above), 
regardless of causality, that may occur anytime from the time of administration of 
the first dose of any study drug until mastectomy will be recorded on the CRF.  
Any delayed, continuing or New Toxicities related to study treatment must be 
recorded until 6 months after mastectomy. 
 
III.4.5.6 Documenting SAEs 
A separate set of SAE Report form pages should be used for each SAE.  
However, if at the time of initial reporting, multiple SAEs are present that are 
temporally and/or clinically related, they may be reported on the same SAE form. 
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The investigator should attempt to establish a diagnosis of the event 
based on signs, symptoms, and/or other clinical information.  In such cases, the 
diagnosis should be documented as the AE and/or SAE and not the individual 
signs/symptoms. If a clinically significant abnormal laboratory finding or other 
abnormal assessment meets the definition of an SAE, then an SAE form must be 
completed.  A diagnosis, if known, or clinical signs and symptoms if diagnosis is 
unknown, rather than the clinically significant abnormal laboratory finding, should 
be completed on SAE form.  If no diagnosis is known and clinical signs and 
symptoms are not present, then the abnormal finding should be recorded.  The 
laboratory data should either be recorded on the SAE form with the reference 
range and baseline value(s) or copies of the laboratory reports and reference 
ranges should be sent with the SAE form pages.  The SAE form should be 
completed as thoroughly as possible and signed by the investigator or his/her 
designee before transmittal to the Data Collection Centre.  It is very important 
that the investigator provide his/her assessment of causality to study drug at the 
time of the initial SAE report. 
 
III.4.5.7 Follow-Up of SAEs 
All SAEs must be followed until resolution, until the condition stabilizes, 
until the event is otherwise explained, or the subject is lost to follow-up.  The 
investigator is responsible to ensure that follow-up includes any supplemental 
investigations as may be indicated to elucidate as completely as practical the 
nature and/or causality of the SAE. This may include additional laboratory tests 
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or investigations, histopathological examinations, or consultation with other 
health care professionals.  New or updated information should be recorded on 
the originally completed SAE form with all changes signed and dated by the 
investigator. 
 
III.4.5.8 Prompt Reporting of SAEs 
SAEs must be reported promptly as described Table III.5, once the 
investigator determines that the event meets the protocol definition of an SAE. 
 
III.4.5.9 Regulatory Reporting Requirements 
The investigator must promptly report all SAEs to the Data Collection 
Centre. We have a legal responsibility to notify both the local regulatory authority 
and other regulatory agencies about the safety of a drug under clinical 
investigation.  Prompt notification of SAEs by the investigator to the appropriate 
project contact for SAE receipt is essential so that legal obligations and ethical 
responsibilities towards the safety of other subjects are met. 
The investigator, or responsible person according to local requirements, 
must comply with the applicable local regulatory requirements related to the 
reporting of SAEs to regulatory authorities and the IRB/IEC. 
If new safety information (e.g., revised Clinical Investigator’s Brochure) 
becomes available, the principal investigator is required to promptly notify her 
local IRB or IEC. 
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Table III.5. Time frames for submitting significant adverse event (SAE) 
reports. 
 
 
 Initial SAE Reports Additional Information 
on a Previously 
Reported SAE 
 
Type of SAE 
 
Time 
Frame 
 
Documents 
 
Time 
Frame 
 
Documents 
 
Death, result of an AE 
or reasonable 
possibility 
 
24/48 
hrsa 
 
SAE form 
 
48 hrs 
 
Updated 
SAE form 
 
Death, not result of an 
AE and not a 
reasonable possibility 
 
48 hrs 
 
SAE form 
 
48 hrs 
 
Updated 
SAE form 
 
Life-threatening event, 
regardless of 
relationship to study 
drug 
 
24/48 
hrsb 
 
SAE form 
 
48 hrs 
 
Updated 
SAE form 
 
Other SAEs 
 
48 hrs 
 
SAE form 
 
48 hrs 
 
Updated 
SAE form 
 
 
 
 
a Initial notification should be sent within 24 hours of the investigator 
learning of the death.  Fully completed documents (SAE form) should be 
sent within 48 hours. 
 
b Initial notification should be sent  within 24 hours of the investigator 
learning of the life-threatening event.  Fully completed documents (SAE 
CRF pages) should be sent to within 48 hours. 
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III.4.5.10 Post-Study AEs and SAEs 
Investigators are not obligated to actively seek AEs or SAEs in former 
study participants.  However, if the investigator learns of any SAE at any time 
after a subject has been discharged from the study, and such event(s) is(are) 
reasonably related to the study drug, the investigator should promptly notify the 
Data Collection Centre. 
 
III.4.6 Subject Discontinuation/Withdrawal 
Patients may discontinue protocol treatment for one or more of the 
following reasons/criteria: 
§ Unacceptable toxicity as defined in Section III.3.2.2 and III.3.2.3. 
§  Intercurrent illness which, in the opinion of the investigator, would seriously 
impair the successful completion of the protocol regimen. (If protocol 
treatment is stopped for his reason, every effort should be made to offer 
standard therapy or similar if and when it is possible to resume treatment). 
§ Tumour progression as defined using RECIST criteria in section III.4. 
§ Request by the patient (In this case the patient must be informed that he/she 
may be forfeiting substantial clinical benefit and even, potentially cure, and a 
standard alternative should be offered). 
§ If, in the judgement of the responsible investigator, the protocol is no longer in 
the best interests of the patient. A suitable alternative should be discussed 
with the patient. 
§ Other reasons, which should be explicitly recorded. 
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Every effort should be made to follow up all patients.  Patients whom are 
prematurely discontinue from protocol therapy, should have blood for plasma 
osteopontin and survival completed according to study calendar.  If protocol 
therapy is stopped prematurely, treatment is at the discretion of the investigator. 
 
III.4.7. Statistical Considerations 
 Sample size: a 95% confidence interval about a proportion p  is calculated 
using the formula: 
                          nppp /)1(96.1 −±  
  For 52 patients and an anticipated response rate of 52% a 95% 
confidence interval will have bounds no greater than ±14%. 
 
Statistical analysis: the pathological complete response rate will be 
calculated and a 95% confidence interval will be constructed.  The response rate 
will be compared to patients who received the same regimen but without 
radiation using a chi-square test. 
Kaplan-Meier estimates of overall survival and the disease free interval 
will be made and comparisons made with subjects on the same regimen but 
without  radiation using log-rank tests. 
The relationship between 99Tm sestaMIBI imaging at each of the three 
time points prior to surgery and response will be evaluated using logistic 
regression.  ROC curves may be used to further evaluate the usefulness of this 
imaging technique as a marker for tumour response.  Similarly, cellular 
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response/sensitivity to CNCR using the ex vivo 3D human tumour will be 
evaluated as a marker for tumour response. 
Toxicities and adverse events will be described.  Ninety-five percent 
confidence intervals about the percentages experiencing toxicities and adverse 
events will be calculated. 
 
III.4.8 Ethical, Regulatory and Administrative Issues 
III.4.8.1 Retention of Patient Records and Study Files 
An Investigator shall retain records defined as essential under GCP 
guidelines for a period of 2 years following the date of marketing application is 
approved for the drug for the indication for which it is being investigated; or, if no 
application is to be filed or if the application is not approved for such indication, 
until 2 years after the investigation is discontinued. 
 
III.4.8.2 REB Approval 
It is necessary to obtain local ethics approval of the protocol, letter of 
information and consent form. Annual re-approval is required as long as patients 
continue to be followed on the trial.  
 
III.4.8.3 Amendments 
An amendment to a protocol is a change significant enough to require 
review/approval by local REBs (and, if applicable, by the TTD of the HPB).  
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Protocol amendments will be circulated in standard format with clear instructions 
regarding REB review. 
 
III.4.8.4 Informed Consent 
The REB of an institution must approve the consent form document which 
will be used at that centre prior to its local activation; changes to the consent 
form in the course of the study will also required REB notification/approval. 
The following elements must appear in the consent form: a description of 
the purpose of the study (indicating, if appropriate, that the drug is 
investigational); potential side effects; potential benefits; study design; voluntary 
participation; and confidentiality. It is essential that the consent form contain a 
clear statement which gives permission for information to be sent to and source 
medical records to be reviewed by the other agencies as necessary. 
 
III.4.8.5 Consent Process/Patient Eligibility 
Patients who cannot give informed consent (i.e. mentally incompetent 
patients, or those physically incapacitated such as comatose patients) are not to 
be recruited into the study. Patients competent but physically unable to sign the 
consent form may have the document signed by their nearest relative or legal 
guardian. Each patient will be provided with a full explanation of the study before 
consent is requested. 
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III.4.9 Publications 
Results of this trial will be submitted for publication in a peer review journal. 
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APPENDIX IV. EVALUATION OF THE RESPONSE OF LOCALLY ADVANCED 
BREAST CANCER TO A NOVEL NEOADJUVANT 
CHEMORADIATION THERAPY PROTOCOL:  
BIOLOGICAL STUDIES. 
 
IV.1 INTRODUCTION 
Locally advanced breast cancer (LABC) represents 10-15% of all new 
breast cancers, with a 5-year survival of 50% using standard treatment that 
includes neoadjuvant chemotherapy, surgery and adjuvant radiation [1]. LABC is 
traditionally defined as stage IIB (T3N0) and Stage IIIA/B from the TNM 
classification [2]. Clinically, these tumours are greater than 5 cm in size and/or 
extend beyond the breast tissue into the surrounding skin or muscle, with/without 
matted axillary lymph nodes (N2), internal mammary nodes (N2) or ipsilateral 
supraclavicular lymph node involvement (N3).  
However, a small subset of women who receive neoadjuvant 
chemotherapy and achieve a pathologic complete response (pCR), (defined as 
no microscopic residual invasive breast cancer following neo-adjuvant treatment) 
have a vastly improved 5 year disease free survival rate of 87% [3] and 5-year 
overall survival rates of 89% [3] and 90% [4]. As such, pCR rates have become a 
surrogate measure for favourable long-term outcomes in trials involving 
neoadjuvant treatment [5], particularly since in vivo assessment is the only 
method by which a response can be measured. 
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Pathological complete response (pCR) at surgery is the best current 
surrogate for overall survival [5], therefore this was the primary end-point of this 
single-arm prospective Phase II trial. RNA Integrity Number (RIN), previously 
demonstrated to predict treatment response to neoadjuvant chemotherapy in 
NCIC MA-22 trial, has been validated as a predictive marker of pCR [6]. 
In order to improve survival from breast cancer, novel cytotoxic agents 
have been tested following, or concurrently with, anthracycline chemotherapy, 
notably taxanes [7, 8]. Docetaxel is a microtubule-stabilizing agent that induces 
cell-cycle arrest at mitosis and apoptosis [9, 10]. Based on its activity in the 
metastatic setting, docetaxel has been tested in randomized trials in early stage 
breast cancer, and demonstrated superior survival when added to anthracycline-
based regimens compared to these regimens alone. FEC-D (fluorouracil 
500mg/m2 IV, epirubicin 100mg/m2, cyclophosphamide 500mg/m2 IV every 3 
weeks x 3 cycles, followed by docetaxel 100mg/m2 IV every 3 weeks x3) remains 
a commonly employed regimen in the adjuvant post-operative setting [11-15]. In 
spite of the improved outcomes associated with the addition of taxanes to 
neoadjuvant chemotherapy regimens, the gains in achieving pCR have been 
modest. The most striking pCR rates have been in Her2+ breast cancers with the 
use of neoadjuvant trastuzumab (Herceptin), where pCR rates may exceed 50-
60%, however this is only true for a minority of patients [16]. 
It is well known that no two cancers are alike in their response to 
chemotherapy [6, 17]. Cancers of the same subtype, grade, stage and 
immunohistochemistry often respond quite differently to the same chemotherapy 
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regimen, very likely due to differences in tumour phenotype and genotype [18]. 
Despite this well-documented heterogeneity in response to chemotherapy, 
chemotherapy selection decisions continue to be based on large adjuvant 
randomized clinical trials, which have a “one for all” approach to chemotherapy 
drug selection. Since chemotherapy for breast cancer is usually delivered in the 
adjuvant setting, there is no clinical opportunity to assess in vivo response (or 
resistance) to the selected regimen. The tumour is deemed to have been 
resistant only when disease recurs, usually as distant metastases, which are no 
longer curable. Therefore it would be a significant clinical asset to develop early 
measures of chemotherapy sensitivity for any individual proposed regimen, 
allowing clinicians to tailor therapies effective for each individual patient 
(‘individualized medicine’). RNA integrity (RIN) has been demonstrated to be a 
good predictor of response to neoadjuvant chemotherapy as evidenced through 
the NCIC MA-20 clinical trial (Parissenti, Guo et al, 2015), and is therefore felt to 
be a potential individualized method of testing a tumour’s likelihood of responding 
well to chemotherapy early in treatment, rather than waiting until after the 
completion of a potentially ineffective cytotoxic regimen. RIN represents a 
quantification score of the degree of fragmentation of ribosomal RNA (rRNA), a 
process that occurs during degradation. Quantifying the rRNA integrity allows for 
a measure of how much degradation has occurred, and is a useful tool for 
scientists to gauge the reliability of the data they have obtained in RNA studies. 
The scale is from 1 (complete degradation) to 10 (completely intact RNA) [19].  
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Anatomic imaging tools, such as ultrasound and MRI, are capable of 
measuring size of the tumour; however, these modalities may not be as able to 
detect changes in amount of viable tumour a result of response to treatment 
(viable tumour in the specimen being replaced by stromal or fibrotic tissue). 
SPECT-CT imaging using 99mTc-bound to MIBI substrate is a functional nuclear 
medicine test that can show functional changes in the tumour as a response to 
treatment [20-22]. This substrate, injected intravenously, is avidly taken into 
tumour cells, showing a bright tumour on the initial 10min image. The substrate, 
however, actively effluxes through drug efflux transmembrane protein pumps, 
such as ABC transmembrane glycoprotein pumps (i.e. P-glycoprotein (Pgp), 
breast cancer resistance protein (BCRP) or multidrug resistance protein (MDP)) 
[23, 24]. These are the same drug efflux proteins felt to contribute, in part, to 
resistance to chemotherapy-induced cytotoxicity by actively effluxing the 
chemotherapeutic agent. Therefore, cancer cells able to efflux MIBI efficiently 
should be also able to efflux chemotherapy. As a result, if efflux pumps are 
working, rapid washout of MIBI substrate should be apparent, specifically in 
tumours with presumed chemotherapy resistance. It has been demonstrated that 
SPECT-CT imaging may be a useful test to predict sensitivity to chemotherapy in 
LABC [25, 26], but its sensitivity has not been evaluated in response to clinical 
outcomes among LABC patients, and has not been studied in the setting of serial 
evaluations during active treatment. We sought to evaluate whether SPECT-CT 
imaging could be used at baseline to predict sensitivity to chemotherapy when 
compared to pCR, the surrogate for survival. Secondarily, we sought to explore 
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whether there might be any interesting relationship between pre- mid- and post-
treatment MIBI SPECT-CT imaging in terms of whether chemo-resistance could 
be seen to be developing over treatment in patients who then were found to be 
clinically resistant to treatment. 
The OncoScreen® chemosensitivity assay is based on a 3D gel assay 
that was developed to examine the effects of radiation on the invasiveness of 
brain cancer cells (Dr. Penny Costello, personal communication). It provides a 
tissue-like environment for testing of tumour growth, invasion and response to 
chemotherapeutic agents ex vivo that more closely models the clinical situation 
of examining tumour growth in the context of breast cancer treatment protocols. 
Typically, tumours are surgically resected, followed by adjuvant therapy (which 
can include chemotherapy), radiation and other biological and hormonal 
therapies. In this scenario, there would likely be no primary tumour to contend 
with, only migrating cells seeking to establish themselves as new tumours. Thus, 
assessing sensitivity to drugs in a migration/invasion assay may be the best 
predictor of an individual tumour’s chemotherapy response at this stage of 
treatment.  
Most in vitro culture experiments, such as invasion assays, utilize 2-
dimensional monolayer cultures exposed to a variety of agents [27], 3-
dimensional spheroids [28, 29], or cultured cells plated in a 3-dimensional 
overlay culture on matrices in order to explore tumour response to various 
conditions [30, 31]; co-cultured cells in matrix and/or in transwells may be used to 
evaluate tissue interactions [32]. Three-dimensional cultures have been reported 
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in the literature as a tool for exploring tumour invasiveness within the stromal 
microenvironment in vitro [33]. Others have also used this model to determine 
breast cancer response to chemotherapeutic agents, such as rapamycin [34]. 
There have been three reported publications using the 3-dimensional 
human breast cancer invasion assay similar to the OncoScreen® 
chemosensitivity assay as method of screening for individual sensitivity to 
chemotherapies [35-37]. As a result, this method was felt to represent an ex vivo 
model, which could use tumour samples obtained by needle biopsy to predict 
individual chemotherapeutic sensitivities prior to treatment delivery. 
Given the poor prognosis of LABC, we proposed the use of an adjuvant 
regimen in the neoadjuvant setting, using the taxane (docetaxel) concurrently 
with radiation for radiosensitization. As an addition to a clinical trial (Chapter 2), 
three separate sub-studies were undertaken to assess the response of LABC 
tumours to treatment: RNA Integrity Assay (RIN), serial single photon emission 
computed tomography (SPECT-CT) imaging (sestaMIBI), and serial ex vivo 
studies of biopsied tumours (3D gel invasion assay) assessing the tumour 
invasiveness in response to chemotherapy. 
 
IV.2. METHODS 
IV.2.1 Patients and Therapeutic Regimen 
Thirty-two patients with stage III non-metastatic LABC were enrolled at a 
single institution between 2009 and 2011 (see Chapter 2). They were treated 
with neo-adjuvant 5-fluorouracil, epirubicin and cyclophosphamide q3 weekly for 
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4 cycles followed by weekly docetaxel (35mg/m2) concurrently with regional 
radiation (45Gy with 9Gy boost in 25 & 5 fractions) for the first 6 of 9 weeks. 
Patients underwent serial tumour biopsy for biological substudies (14-gauge 
tumour core biopsy) pre-, mid- and post-treatment and the biopsy specimen was 
stored in refrigerated phosphate buffered saline for transportation to the 
laboratory. One mm3 section was then taken from the biopsies, immersed in 
RNAlaterTM, and stored frozen at -80°C. At the completion of the third post-
treatment biopsy procedure, the patient then underwent a modified radical 
mastectomy. 
 
IV.2.2  RNA Integrity Assay 
IV.2.2.1 RNA Isolation from Tumour Core Biopsies 
RNA was isolated from image-guided tumour core biopsies of the patients 
pre-, mid-, and post-treatment using Qiagen RNAeasy® Mini kits, as per 
manufacturer’s instructions. Briefly, The biopsies were homogenized and the 
lysate was then passaged at least 5 times through a 20-gauge needle (0.9mm 
diameter) fitted to an RNase-free syringe. The sample was centrifuged at high 
speed in a refrigerated microfuge at 4oC for 3 minutes, with transfer of the 
supernatant to a new tube. One volume (500µl) of 70% ethanol was then added 
to the supernatant and the sample mixed well by repeated pipetting. A maximum 
of 700µl of the sample, including any precipitate, were added to an RNeasy® mini 
column and placed in a 2ml collection tube. The column was washed twice in 
RPE buffer and dried by centrifugation as per the manufacturer’s protocol. The 
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RNA was then eluted from the column in 30µl of RNase-free water and the eluate 
reapplied and eluted from the column to increase the yield and concentration of 
the RNA obtained. 
 
IV.2.2.2 Assessment of RNA Quality 
The obtained RNA samples were applied to RNA 6000 Nano LapchipsTM 
(Agilent Biotechnologies, Inc.) and subjected to capillary electrophoresis using an 
Agilent® 2100 Bioanalyzer.  The protocol followed was identical to that described 
in the company’s technical brochure for the Agilent® 2100 Bioanalyzer. The 
amount and quality (RIN value) of RNA from each core biopsy was then 
determined by the Bioanalyzer.   
 
IV.2.3 Serial SPECT-CT Imaging 
IV.2.3.1 Sesta-MIBI Scans 
99mTc-labelled sesta-MIBI scintimammography was performed on the 
LABC patients enrolled in the study (see IV.2.1) at the following time points: at 
the time of clinical diagnosis of LABC, in the middle of neoadjuvant 
chemoradiation therapy with FEC-D (after FEC chemotherapy was completed 
and prior to initiation of weekly docetaxel/radiation), and at 5 weeks post-
treatment (immediately prior to surgery). 
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IV.2.3.2 Sesta-MIBI Injection, Scanning Protocol and Analysis 
Patients underwent MIBI imaging (GE Infinia GP3 Hawkeye 4 SPECT/CT 
scanner) using the prone lateral imaging technique, which allows visualization of 
the breast tumour without contamination by the overlaying structures [38, 39]. 
99mTc-labelled sesta-MIBI (Lantheous, Montreal QC) was injected via gauge 20 
catheter placed in the patient’s arm contralateral to the breast tumour lesion. 
Patients underwent IV injection of 750MBq (20mCi) 99mTc-labelled sesta-MIBI, 
followed by 30ml saline flush. Prone lateral imaging was performed 10min after 
injection, and then at 3 hours post-injection. Images of the anterior, left lateral 
and right lateral positions were acquired for each patient, using a high-resolution, 
low-energy, parallel hole collimator, 512x512 matrix, no zoom, 15% energy 
window centered at 140keV. 
To measure MIBI washout [22, 40], a second MIBI scan was performed 3 
hours post-injection. Care was taken to reproduce breast positioning compared 
to early image; timing of both early and late scans relative to tracer injection was 
carefully noted. 
MIBI images were analyzed on XELERIS station (GE) using a method 
routinely used at our centre. Briefly, circular region of interest (ROI) was placed 
over the tumour on axial slice, which represented a maximum count from the 
tumour. Background (Bkg) counts were obtained from the same ROI/area from 
the opposite breast. The same process was repeated on early and delayed 
images. Count number was corrected for decay to obtain accurate calculations. 
Wash-out calculation was performed using the following formula: 
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𝑤𝑎𝑠ℎ𝑜𝑢𝑡 = 100% 𝑥  𝑒𝑎𝑟𝑙𝑦 𝑡𝑢𝑚𝑜𝑢𝑟𝑏𝑘𝑔 −  𝑑𝑒𝑙𝑎𝑦𝑒𝑑  𝑡𝑢𝑚𝑜𝑢𝑟𝑏𝑘𝑔 /𝑒𝑎𝑟𝑙𝑦 𝑡𝑢𝑚𝑜𝑢𝑟𝑏𝑘𝑔  
 
Lesion-to-normal breast (L:N) ratios were used to analyze MIBI uptake. 
Changes in MIBI uptake with therapy were expressed as the percentage of 
baseline L:N ratio and were compared with different categories of response to 
therapy. If the efflux was more than 30% of the baseline, the tumour was 
classified as chemotherapy resistant (R); conversely, equal to, or less than 30% 
washout led to tumour classification as chemotherapy sensitive (S) [40]. 
Statistical analysis was performed using SAS statistical software, with 
significance level set to p<0.05. 
 
IV.2.4 Ex vivo Tumour Studies 
IV.2.4.1 Protocol Rationale and Patient Recruitment 
The OncoScreen® chemosensitivity assay was selected to test whether a 
3D human tumour culture tool could be used to individually predict patient 
responsiveness to neoadjuvant chemotherapy. Patients were recruited as 
described in Section IV.2.1 and Chapter 2. Tissue samples were obtained from 
32 adult females between the ages of 35 and 88, diagnosed with invasive 
mammary carcinoma and undergoing a neoadjuvant clinical trial of FEC 
chemotherapy followed by weekly docetaxel concurrent with locoregional 
radiation prior to modified radical mastectomy (see Chapter 2). Samples were at 
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baseline (i.e. prior to all chemotherapy), mid-way through FEC regimen (but prior 
to radiation), and following docetaxel and radiation, just prior to surgery. 
 
IV.2.4.2 Tumour Tissue Sample Handling 
Tissue samples were received directly from the diagnostic imaging 
department where image guided biopsy samples were taken, and placed in a 
sterile phosphate-buffered saline solution at 4oC, within minutes of acquisition. 
The sample was transported to the laboratory where it was placed into a 
dissecting dish with a small amount of sterile buffer solution to cover the tissue. 
Using a scalpel and forceps, the tissue was cut into 1-3mm pieces, dissecting 
away any normal or non-viable material. The pieces were then washed with 
sterile saline to remove any remaining blood and debris. 
 
IV.2.4.3 Tumour Invasion Assay 
The tumour invasion of the biopsied tumour pieces was assayed using a 
collagen gel system. Briefly, a single piece of tissue was placed into the center of 
each well of a 48-well plate containing 0.25ml matrix mixture, ensuring the 
placement of each tissue fragment as close to the center of the well as possible. 
The gel was then permitted to set at room temperature, or at 37oC non-CO2 
incubator. Each well was overlaid with 0.25ml tissue culture media containing 
20% serum to achieve a final volume of 0.5ml per well. Collagen type I gel 
(Vitrogen 100, Cohesion Technologies, Palo Alto, CA) was added to the matrix 
buffer at a concentration of 1mg/ml and mixed, adjusting the pH to 7.4.    
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To assess tumour invasion in response to treatment of breast cancer cells 
with standard breast cancer chemotherapies, 48-well plates were again seeded 
with fresh tissue from patients in six replicates. Tissues were either left untreated 
(control) or treated with the following individual chemotherapeutic agents: FEC 
(5-fluorouracil (5-FU), epirubicin (epi), cyclophosphamide (cyclo)) or docetaxel 
(doc). The recommended intravenous therapeutic dosage for patients was used 
and reconstituted into 0.5ml total, and added to each well (5-FU 10µg/ml; epi 
4µg/ml; cyclo 20µg/ml and doc 3µg/ml). Plates were maintained at 37oC with 5% 
CO2 for 5 days, monitoring cell movement and invasion on days 1, 3 and 5. A 
screen was only deemed valid if there was cell movement or outgrowth from the 
main tumour sample in at least two of the six replicate wells. This was done on 
two separate 48-well plates per patient: one plate was irradiated (0.8Gy using 
60Cobalt γ-radiation) while the second plate was not, in order to mimic ex vivo the 
treatment being received with concurrent chemoradiation in vivo (R-control, R-
FEC, R-Doc). 
 
IV.3 RESULTS 
IV.3.1 Clinical Responses and Toxicities of FEC-D Neoadjuvant 
Chemoradiotherapy 
While 30 of the 32 patients (94%) completed the treatment protocol 
described above, patients did experience significant toxicities. Twenty-seven 
patients (84%) had grade 3 or greater toxicities, including grade 3 resolving 
pneumonitis (6 patients), grade 3 dermatitis (6 patients) and one treatment-
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related death.  Eight of these patients (23%) exhibited a pathologic complete 
response (pCR) to treatment (Table 2.3), which is approximately twice the 
Ontario pCR rate for locally advanced breast cancer (10%, unpublished data) 
and significantly higher than the 14% pCR rate seen in 81 matched controls (see 
Chapter 2). Moreover, at three years median follow-up, the relapse-free survival 
rate was 100% in the pCR cohort and 65% among partial responders (PRs).  
This suggests that the regimen, while exhibiting strong toxicity, appears to 
enhance the pCR and shows a trend toward a 15% improvement in disease-free 
and overall survival in locally advanced breast cancer patients.   
Tumours that exhibited pCRs were distributed almost equally amongst the 
basal (2 of 5 tumours = 40%), Her2 (3 of 3 tumours = 100%), and luminal B (3 of 
6 tumours = 50%) subtypes. No pCRs were found among the 11 patients with 
luminal A tumours (0%). While the numbers are small, the data suggests that 
FEC-D regimen with concurrent radiation appeared able to induce pCRs across a 
variety of breast cancer subtypes, except for the luminal A subtype. This 
supports existing data in the literature that pCR is a good surrogate for survival 
with the exception of luminal A subtype [41]. 
 
IV.3.2 Changes in Tumour RNA Content in Response to FEC-D 
Neoadjuvant Chemoradiotherapy 
We then assessed whether, similar to the NCIC-CTG-MA.22 clinical trial, 
changes in tumour RNA quality or quantity could be observed during or in 
response to treatment and whether low RNA quality was associated with a strong 
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clinical response the completion of treatment (i.e. pCR). Figure IV.1 illustrates the 
RNA concentration values for all patient biopsies isolated prior to treatment, in 
the middle of treatment, and post-treatment. The plot shows that there was some 
significant variability in the quantity of RNA isolated from the biopsies throughout 
treatment, including pre-treatment biopsies. This suggests possible variations in 
the preservation of RNA in the collected biopsies and time-dependent 
degradation at the time of tissue processing. In addition, the data suggests little 
difference in RNA content between pre-treatment biopsies and biopsies collected 
after FEC chemotherapy (mean tumour RNA concentration of 50.0±15.1 and 
50.0±11.9ng/µl, respectively). In contrast, the mean tumour RNA concentration 
fell significantly after the completion of the FEC-D regimen with concurrent 
radiation (10.6±2.1ng/µl, p<0.05). These findings suggest that the FEC 
chemotherapy alone is insufficient to induce reductions in tumour RNA content, 
but upon treatment with concurrent radiation therapy and docetaxel, tumour RNA 
content falls dramatically. Despite this treatment effect, no significant differences 
in tumour RNA content were observed amongst patients that exhibited a 
pathologic complete response post-treatment (pCR), patients that exhibited a 
partial response to treatment (PR), and patients with stable or progressive 
disease (SD or PD) post-treatment (Figure IV.2). 
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Figure IV.1. Changes in tumour RNA concentration during treatment of 
locally advanced breast cancer. There was a significant decrease 
in tumour RNA content in response to treatment with docetaxel 
followed by radiation therapy (* signifies p<0.05). 
 FEC, fluorouracil-epirubicin-cyclophosphamide; D-RT, docetaxel 
concurrent with radiation therapy. 
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Figure IV.2. Changes in tumour RNA content (A) pre-treatment, (B) during 
treatment and (C) post-treatment of locally advanced breast 
cancer. No changes in tumour RNA content were observed 
amongst patients exhibiting pCR, PR or NR (both SD and PD). 
 pCR, pathological complete response; PR, partial response; NR, no 
response; PD, progressive disease; SD, stable disease. 
pCR        PR    NR 
pCR        PR    NR 
pCR        PR    NR 
	 237 
IV.3.3 Changes in Tumour RIN Values in Response to FEC-D 
Neoadjuvant Chemoradiotherapy 
To assess changes in tumour RNA content during FEC-D chemotherapy with 
concurrent radiation treatment, all samples that were noted as “insufficient signal” 
for mathematical analysis were omitted. As shown in Figure IV.3A, in the three 
samples post-FEC chemotherapy but before docetaxel/radiation treatment (which 
achieved a pCR at the end of treatment), 2 out of 3 samples demonstrated RIN 
values indicative of high RNA integrity or minimal RNA degradation (RIN >7). 
Only one patient sample had a very low RIN value suggestive of significant loss 
of RNA integrity (RIN value = n/a or 0).  In the samples from non-responding 
patients (patients who did not achieve pCR post-treatment), no effect of FEC 
treatment could be discriminated using RIN.  These results suggest that FEC 
treatment may have an effect on RNA disruption, but this effect did not appear to 
be associated with a pCR post-treatment, since only 1 out of 3 adequate samples 
demonstrated this effect. 
When tumour RNA integrity was assessed, after both the FEC 
chemotherapy and docetaxel/radiation treatment, only two samples from patients 
that achieved a pCR post-treatment had sufficient RNA for mathematical analysis 
(Figure IV.3B), presumably because there was no viable tumour left in the biopsy 
sample from which to extract RNA, and/or that what was thought to be tumour by 
image guidance actually represented only stromal fibrosis rather than residual 
tumour. For these two samples, both had RIN values of n/a or zero, indicative of 
very  strong  loss  of  RNA  integrity.  These  two  responders  to  treatment  were  
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Figure IV.3. Changes in tumour RNA integrity in response to treatment of 
locally advanced breast cancer: (A) mid-treatment and (B) 
post-treatment. Following FEC (but prior to docetaxel) and 
radiation, the responders (patients achieving pCR) had a varied 
RIN level similar to non-responders (patients NOT achieving pCR), 
while after concurrent chemoradiation, all responders had low RIN 
levels, consistent with a treatment-related effect on RNA integrity.  
RIN, RNA integrity number  
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strongly distinct from non-responders based on RNA concentration and RIN 
values.  The low RIN values are indicative of loss of normal RNA.  In the non-
responders, a wide range of RIN values are noted which is indicative of a 
spectrum of change in tumour RNA from highly fragmented to highly intact.  
These results suggest that loss of RNA integrity occurred with radiation and 
docetaxel resulting in decreased RIN values and a loss in RNA concentration. 
This loss of RNA integrity correlated with a strong response to treatment (pCR). 
 
IV.3.4 Sesta-MIBI Serial SPECT-CT Imaging of LABC Tumours in Response 
to FEC-D Neoadjuvant Chemoradiation Treatment 
Of 32 patients included in the study, 2 patients failed to complete the full 
MIBI protocol; these were then excluded from the study. Of the remaining 30 
patients, tumours of 25 patients (83%) were found to be chemotherapy sensitive 
at baseline, 28 during mid-treatment (93%), and 22 out of 22 post-treatment 
(100%) (Figure IV.4). Chemotherapy sensitivity is presumed when a washout 
index of less than 30% is seen. With a low washout index, the cell's inability to 
efflux the cytotoxic chemotherapy is expected to result in damage to the cell in 
accordance with the molecular mechanism of cell death specific to whichever 
chemotherapy is delivered. Of those patients who achieved a pCR response to 
neoadjuvant chemoradiotherapy, pCR sensitivity was 8 out of 8 (100%). The 
sensitivity of the MIBI SPECT-CT imaging in the PR/SD cohort of patients was 17 
out of 22 (77%) (difference of 23%) (Figure IV.5), which was not statistically 
significantly significant (p=0.287).   
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Figure IV.4. The tumour sensitivity to concurrent neoadjuvant chemo-
radiation, as demonstrated by SPECT-CT imaging of sesta-
MIBI washout. At baseline, 83% of patients demonstrated 
sensitivity to chemotherapy; at mid-treatment, 93% of patients were 
sensitive, and post-treatment, 100% sensitivity was achieved. 
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Figure IV.5. The tumour sensitivity (mean ± 95% exact confidence interval) 
to concurrent neoadjuvant chemo-radiation, as a function of 
pCR. Among the 8 patients who achieved a complete pathological 
response, low washout index (and, therefore, chemosensitivity) was 
seen in all 8/8 (100%) patients. In the remaining 22 patients who 
demonstrated a partial response or stable disease to 
chemotherapy, 17/22 (77.3%) patients demonstrated 
chemosensitivity by washout index (p=0.287, Fisher exact test).  
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IV.3.5 Ex vivo Tumour Studies 
The number of tumour samples demonstrating growth (invasive cells seen 
beyond the tumour sample invading into the surrounding Matrigel®) was 
significantly impacted by the in vivo treatment. At baseline, prior to chemotherapy, 
100% of the 32 patients had tumours that exhibited growth using this invasion 
assay. After FEC chemotherapy, 17/32 (53%) of tumour samples exhibited 
growth. Following combined docetaxel and radiation, 7/23 (30%) of tumour 
samples demonstrated growth using this ex vivo model. Therefore, the ex vivo 
model appears to be most effective as an invasion assay when the baseline 
untreated patient tumour samples are used. The pre-treatment, mid-treatment 
and post-treatment mean tumour growth (as a percentage of control to account 
for intra-tumoural heterogeneity) was calculated for tumour samples cultured with 
FEC chemotherapy, DOC (docetaxel), R-FEC (FEC chemotherapy while also 
radiated at 0.8Gy to mimic radiosensitizing chemotherapy) and R-DOC 
(docetaxel chemotherapy while also radiated at 0.8Gy)  (Figure IV.6).  There was 
wide variety of responses both within patient wells and between patients treated 
with the same chemotherapy regimens, resulting in large standard error bars. As 
a result, these results do not demonstrate a clear reduction in growth with any 
particular chemotherapeutic agent, even when tumour growth is personalized 
(calculated as a proportion of the same tumour sample cultured alone, as a 
control). The only visual difference is seen in the radiated docetaxel samples, 
where the mid- and post-treated  samples  appear to show  less  tumour  growth  
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Figure IV.6. The tumour sensitivity to concurrent neoadjuvant chemo-
radiation, as demonstrated by the in vivo 3D gel invasion 
assay. Tumour growth sizes were obtained from core biopsies pre-
treatment, mid-treatment and post-treatment. While not statistically 
significant, docetaxel appeared to exhibit a radiosensitizing trend. 
  PRE, pre-treatment; MID, mid-treatment; POST, post-treatment. 
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than the pre-treated samples, perhaps demonstrating a radiosensitizing trend 
with the use of docetaxel not seen with chemotherapeutic agents alone. 
Using the baseline pre-treatment samples of tumours exposed to FEC, 
DOC, R-FEC and R-DOC, the patients who achieved a pCR in response to the 
neoadjuvant regimen were compared to the non-pCR patients treated the same 
way (Figure IV.7). Of the patients that had achieved pCR, docetaxel alone 
resulted in 43% of baseline tumour growth, while addition of radiation further 
reduced the tumour growth to 34% of baseline. The radiated tumour samples 
appear to differ in the pCR cohort from the non-pCR cohort. The tumour samples 
radiated while exposed to FEC appear to have a higher growth in the pCR cohort, 
which is difficult to explain. In the pCR patient cohort, the tumour growth was 
much lower when exposed to concurrent docetaxel and radiation (R-DOC) than 
in the non-pCR cohort (p=0.046). 
 The tumour growth seen in baseline untreated tumour samples exposed to 
FEC, DOC, R-FEC and R-DOC were statistically analyzed using Wilcoxon Rank 
Sums two-sided test to determine whether baseline growth predicted for death or 
recurrence of disease. The baseline DOC growth ex vivo appeared to best 
predict for recurrence or death (p=0.039), while the others did not (FEC p=0.71; 
R-FEC p=0.14; R-DOC p=0.29).  
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Figure IV.7. The tumour sensitivity to concurrent neoadjuvant chemo-
radiation, as a function of pCR, in the in vivo 3D gel invasion 
assay. Tumour growth sizes were obtained from core biopsies. 
Docetaxel  with radiation appeared to exhibit a radiosensitizing 
trend in patients exhibiting pCR response (p=0.046). 
 *p<0.05 from non-pCR group 
 FEC, fluorouracil-epirubicin-cyclophospamide; DOC, docetaxel; R-
FEC, radiation with FEC; R-DOC, radiation with DOC. 
  
*	
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IV.4 DISCUSSION AND CONCLUSIONS 
This study was the first to use a full chemotherapy regimen with radiation 
in the neo-adjuvant setting for LABC. Although this regimen was not without 
toxicity, concurrent chemo-radiation significantly improved the surrogate marker 
for survival in this high-risk group, resulting in a much-improved outcome, even at 
short-term follow-up. 
Of the tumour samples that provided sufficient RNA for analysis, RIN 
values appear to predict treatment response, particularly to taxane-based 
chemotherapy regimens. RNA concentration was lowest in tumour samples after 
concurrent chemoradiation with docetaxel. It may be that the radiosensitizing 
effects of docetaxel amplifies the genomic damage induced by external beam 
radiation, mimicking the improvement in clinical outcomes as a result of this 
combined therapy. Unfortunately, RNA testing revealed that many samples had 
undergone RNA degradation, likely as a result of prolonged transport time in PBS 
prior to being placed in RNA preservative. In order to fully evaluate the impact of 
RNA integrity as a predictive test for both neoadjuvant chemotherapy and 
radiation, these tests should be repeated prospectively, with samples being 
placed directly from the biopsy needle into RNA preservative.  
The sesta-MIBI SPECT-CT imaging study demonstrated that, among the 
pCR cohort, this test had 100% sensitivity in predicting patient sensitivity to 
chemoradiation treatment. However, because the sensitivity for partial 
responders and non-responders was still high at 77%, this test does not 
discriminate sufficiently whether patients will respond to systemic treatment to be 
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a clinically useful test. The serial use of sesta-MIBI SPECT-CT imaging appears 
to show an increasing sensitivity to treatment over time. This is probably due to 
the possibility that a maintained efflux of MIBI substrate resulting in a low 
washout index over time in patients receiving chemotherapy and/or radiation may 
no longer be indicative of drug efflux capacity in tumour cells, since the post-
treatment sensitivity to chemotherapy was 100%, and yet only a quarter of these 
patients achieved a pCR in response to chemotherapy. Perhaps it becomes 
difficult to determine where to measure washout of MIBI substrate when there is 
a treatment change in the imaged tumour, resulting in a falsely low washout 
index as treatment progresses. Further evaluation of this functional imaging 
modality would be helpful in elucidating the mechanisms around substrate and 
drug washout as measured serially in breast tumours receiving neoadjuvant 
treatment. 
 The 3D ex vivo OncoScreen® chemosensitivity assay model showed a 
wide variety of growth rates in response to the regimens given to these patients 
when assessed serially during treatment. As a result, there does not seem to be 
any visible trend in tumour growth over time, other than an apparent reduction in 
tumour growth in samples treated with docetaxel while concurrently radiated, 
perhaps demonstrating a radiosensitizing phenomenon. Further studies are 
required to elucidate this. The most interesting finding was that tumour growth 
appeared significantly inhibited by concurrent radiation and docetaxel in the 
patients who achieved a pCR compared to those who did not. Again, these are 
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preliminary findings, but do suggest that more studies should be done to exploit 
the radiosensitizing effects of taxane chemotherapies in breast cancer patients. 
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